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Preface
Cystic fibrosis (CF) is one of the most common fatal inherited diseases. The 
discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) 
gene 30 years ago set the cornerstone for unravelling the pathogenesis of CF lung 
disease, continuous development of disease-modifying agents, and the inception of 
mutation-specific therapies, which are now becoming available for a subgroup 
of patients.
This book provides an update on aspects of CF lung disease. Frost et al. describe 
the use of novel culture-independent techniques such as next-generation 
sequencing to analyse the lung microbiome, allowing us to further understand 
the diversity, complexity, and effects of acute exacerbations, and the use of 
antibiotics on bacterial communities. The understanding of the CF microbiome 
presents new opportunities for disease management in CF and has the potential 
to explore the impact of CFTR modulators. Abdelbary also provides an overview 
of the microbiology in CF including the impact of bacterial colonisation, fungi and 
respiratory viruses.
The overview of CFTR modulators and gene therapy provides understanding 
of personalized therapeutic options with a focus on an individual’s specific 
mutations. Rang et al. provide a succinct summary of these exciting treatment 
modalities in CF and how these treatment modalities for forever alter the care of 
these patients.
Szczesniak et al. discuss the use of CF registries that have the potential to improve 
on CF clinical management effectiveness and the development of treatment 
policies, although missing and confounding data can be huge challenges in the 
evolution of these policies.
Around 40 percent of patients with CF have some form of liver abnormalities. In 
recent years, an increase in CF-related liver disease (CFLD) has been noted. This is 
most likely related to patients with CF who are being screened more stringently for 
liver disease starting from a young age. Wiecek et al. provide an overview of the risk 
factors, clinical symptoms, diagnostic methods and treatment of liver changes in 
the course of CF.
In light of COVID-19, many health-governing bodies are turning to remote 
consultations in order to minimise the risk of infection for staff and patients. 
Fogazzi et al. describe the use of video education to improve the adherence of 
airway clearance and inhaled therapies. This is an important stress test depicting 
the usefulness of technology in this specific patient cohort.
Finally, Vagg et al. describe the design and development of a patient passport 
mHealth application for adults with CF. This application allows patients access 
to their own data. It will be of benefit when travelling abroad and between CF 
centres. This technology also has the potential to improve the quality and safety 
of care.
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The Pulmonary Microbiome in 
Cystic Fibrosis
Freddy J. Frost, Dilip Nazareth and Dennis Wat
Abstract
The chronic colonisation of the lower airways by bacterial pathogens is the 
leading cause of morbidity and mortality in patients with cystic fibrosis (CF). The 
use of novel culture-independent techniques such as next-generation sequencing 
(NGS) to analyse the lungs has allowed us to further understand the diversity, the 
complexity, the effects of acute exacerbations and the use of antibiotics on the 
bacterial communities. The understanding of the CF microbiome to airway disease 
remains a fascinating area of research; it presents new opportunities for disease 
management in CF and has the potential to explore the effects of cystic fibrosis 
transmembrane conductance regulator (CFTR) modulators. It also allows further 
appreciation regarding the roles played by anaerobic organisms within the CF 
airways. It is also of interest that a number of studies have demonstrated that the 
fluctuations of microbiome are not necessarily associated with the patient’s clinical 
status. Despite the available evidence, there remain many challenges that must be 
overcome if microbiome profiling is going to influence future clinical practice. The 
effects of fungus and the emergence of nontuberculous mycobacteria in CF are also 
briefly discussed in this chapter.
Keywords: cystic fibrosis, microbiome, CFTR modulators, nontuberculous 
mycobacteria, Aspergillus
1. Introduction
Traditional culture techniques rely on growing bacteria on media in laboratory 
conditions often optimised for growth of specific organisms so that they can then 
subsequently be identified. In the last 20 years, novel techniques utilising next-
generation sequencing (NGS) to identify bacteria have become available, enabling 
detection and description of bacterial communities without the need for conven-
tional culture. These technologies have allowed a greater understanding of bacterial 
communities throughout the human body and have revealed functional roles in 
both health and disease.
A healthy human gut, for example, is home to a highly diverse community of 
bacteria, termed as microbiome, which has symbiotic functions including metab-
olism of otherwise indigestible compounds and defence against opportunistic 
pathogens [1, 2]. Furthermore, bacteria in the gut influence the stimulation and 
development of the innate mucosal immune system [3]. In addition to the roles 
in health, there has been significant interest in the relationship between micro-
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bacteria, termed as microbiome, which has symbiotic functions including metab-
olism of otherwise indigestible compounds and defence against opportunistic 
pathogens [1, 2]. Furthermore, bacteria in the gut influence the stimulation and 
development of the innate mucosal immune system [3]. In addition to the roles 
in health, there has been significant interest in the relationship between micro-
biomes and diseases such as obesity, inflammatory bowel disease and diabetes 
mellitus [4–6].
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Studies utilising culture-independent techniques to analyse the lungs have iden-
tified the presence of bacterial communities that are much more complex than the 
previously appreciated. The lungs were long considered to be an inherently sterile 
environment, in part due to the fact that conventional culture techniques often 
yielded negative results during health and it was only during disease that pathogens 
were detected. However, the advent of culture-independent techniques has demon-
strated that multiple organisms comprise a community, termed the ‘microbiome’, 
in the lungs of patients, both healthy and diseased [7–9]. In this chapter, we discuss 
the techniques employed in 16S rRNA sequencing and the evidence these tech-
niques have generated so far in relation to cystic fibrosis.
2. 16S rRNA gene sequencing
The 16S rRNA gene codes for a ribosomal subunit present in nearly all bacteria. 
The gene itself is approximately 1.5 kb long and consists of conserved regions, 
similar in nearly all microorganisms, and nine variable regions labelled, V1–V9, 
which are practically specific to each microorganism [10]. The identification of a 
specific DNA sequence that corresponds to the known variable region of 16S rRNA 
gene can allow discrimination of the presence and relative abundance of different 
microorganisms (Figure 1).
Once the samples have been processed, DNA is extracted, and the 16S rRNA 
gene is amplified using polymerase chain reaction (PCR). Next-generation 
sequencing allows elucidation of the precise gene sequences, and online reference 
databases can then be used to match each sequence to an organism and quantify its 
relative proportion within a multispecies population. However, it is important to 
note that sequencing of the 16S rRNA gene has limited resolution and often cannot 
distinguish species with similar gene sequences apart. Therefore, instead of distinct 
species, sequences are referenced against and assigned into operational taxonomic 
units (OTU) (see Table 1).
Given the large number of species identified even in healthy lungs, ecological 
theory and analyses are often employed to understand community dynamics [9]. 
According to ecological principles, the composition of the lung microbiome is 
determined by three factors:
1. Immigration of organisms into the lung
2. Elimination of microbes from the airways
3. Regional growth factors [11]
Figure 1. 
Schematic illustration of structure of the 16S rRNA gene. Orange regions—variable regions; blue region—
conserved region.
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The lung microbiome in healthy individuals is dictated largely by immigration 
and elimination and hence generally consists predominantly of those Gram-
negative anaerobes also resident in the oral flora such as Prevotella and Veillonella 
spp. [11]. However, in disease the regional growth conditions are altered, and 
niches for other species to thrive are created. In CF, for example, viscous secre-
tions, altered pH, nutrient availability and architectural disturbance may all help 
select for a community of altered composition to that of healthy individuals. How 
this community changes over time, in response to the intensive antibiotic treat-
ment that people with CF are exposed to, has been the subject of much interest in 
the last decade.
3. CF respiratory microbiota in early life
Understanding the development of the CF respiratory microbiota in early life 
has attracted interest in order to appreciate the driving factors behind the distinct 
microbiota seen later in life and also to identify potential opportunities for inter-
vention. Neonates and infants cannot expectorate sputum independently, and 
bronchoalveolar lavage (BAL) is only used sparingly; hence, upper respiratory 
tract samples are often used as surrogates. The imperfection of this approach was 
recently highlighted where large differences in concordance between BAL samples 
and upper respiratory tract (URT) samples were observed in some taxa [12]. 
Nevertheless, concordance was high for some important taxa such as Moraxella and 
Staphylococcus, and in the absence of less invasive techniques, URT sampling enables 
early estimation of the neonatal lower respiratory tract.
The composition of CF nasopharyngeal microbiota diverges from that of 
non-CF infants as early as the first few months of life [13, 14]. Newborn healthy 
infants appear to have nasopharyngeal microbiota dominated by Moraxella spp., 
Corynebacterium spp. and Haemophilus spp., a community structure that persists for at 
least the first 6 months of life. Conversely the CF nasopharynx microbiome is initially 
dominated by Staphylococcus aureus before a gradual increase in Streptococcus spp. and 
Moraxellaceae at 3 months of age [13]. Despite the increased S. aureus seen in CF, there 
were no decreases in measures of richness or diversity indicating that changes are due 
to differing microenvironment rather than interspecies competition [15].
Term Definition
Microbiome The microorganisms in a particular environment
16S rRNA gene A gene which codes for a ribosomal subunit. Present in all prokaryotes and has 
variable regions, which differ slightly between bacterial species
Richness A measure of the number of species in a community
Evenness A measure of similarity of the relative abundance for each species in a 
community That is, does one species dominate, or do all species have similar 
relative abundance?
Diversity A measure of variety in a community. Combination of richness and evenness
Alpha diversity Within-sample diversity
Beta diversity Between-sample diversity
Operational 
taxonomic unit (OTU)
Group of strains/species with similar 16S rRNA gene sequences
Table 1. 
Glossary of terms and definitions.
Cystic Fibrosis - Heterogeneity and Personalized Treatment
2
Studies utilising culture-independent techniques to analyse the lungs have iden-
tified the presence of bacterial communities that are much more complex than the 
previously appreciated. The lungs were long considered to be an inherently sterile 
environment, in part due to the fact that conventional culture techniques often 
yielded negative results during health and it was only during disease that pathogens 
were detected. However, the advent of culture-independent techniques has demon-
strated that multiple organisms comprise a community, termed the ‘microbiome’, 
in the lungs of patients, both healthy and diseased [7–9]. In this chapter, we discuss 
the techniques employed in 16S rRNA sequencing and the evidence these tech-
niques have generated so far in relation to cystic fibrosis.
2. 16S rRNA gene sequencing
The 16S rRNA gene codes for a ribosomal subunit present in nearly all bacteria. 
The gene itself is approximately 1.5 kb long and consists of conserved regions, 
similar in nearly all microorganisms, and nine variable regions labelled, V1–V9, 
which are practically specific to each microorganism [10]. The identification of a 
specific DNA sequence that corresponds to the known variable region of 16S rRNA 
gene can allow discrimination of the presence and relative abundance of different 
microorganisms (Figure 1).
Once the samples have been processed, DNA is extracted, and the 16S rRNA 
gene is amplified using polymerase chain reaction (PCR). Next-generation 
sequencing allows elucidation of the precise gene sequences, and online reference 
databases can then be used to match each sequence to an organism and quantify its 
relative proportion within a multispecies population. However, it is important to 
note that sequencing of the 16S rRNA gene has limited resolution and often cannot 
distinguish species with similar gene sequences apart. Therefore, instead of distinct 
species, sequences are referenced against and assigned into operational taxonomic 
units (OTU) (see Table 1).
Given the large number of species identified even in healthy lungs, ecological 
theory and analyses are often employed to understand community dynamics [9]. 
According to ecological principles, the composition of the lung microbiome is 
determined by three factors:
1. Immigration of organisms into the lung
2. Elimination of microbes from the airways
3. Regional growth factors [11]
Figure 1. 
Schematic illustration of structure of the 16S rRNA gene. Orange regions—variable regions; blue region—
conserved region.
3
The Pulmonary Microbiome in Cystic Fibrosis
DOI: http://dx.doi.org/10.5772/intechopen.91765
The lung microbiome in healthy individuals is dictated largely by immigration 
and elimination and hence generally consists predominantly of those Gram-
negative anaerobes also resident in the oral flora such as Prevotella and Veillonella 
spp. [11]. However, in disease the regional growth conditions are altered, and 
niches for other species to thrive are created. In CF, for example, viscous secre-
tions, altered pH, nutrient availability and architectural disturbance may all help 
select for a community of altered composition to that of healthy individuals. How 
this community changes over time, in response to the intensive antibiotic treat-
ment that people with CF are exposed to, has been the subject of much interest in 
the last decade.
3. CF respiratory microbiota in early life
Understanding the development of the CF respiratory microbiota in early life 
has attracted interest in order to appreciate the driving factors behind the distinct 
microbiota seen later in life and also to identify potential opportunities for inter-
vention. Neonates and infants cannot expectorate sputum independently, and 
bronchoalveolar lavage (BAL) is only used sparingly; hence, upper respiratory 
tract samples are often used as surrogates. The imperfection of this approach was 
recently highlighted where large differences in concordance between BAL samples 
and upper respiratory tract (URT) samples were observed in some taxa [12]. 
Nevertheless, concordance was high for some important taxa such as Moraxella and 
Staphylococcus, and in the absence of less invasive techniques, URT sampling enables 
early estimation of the neonatal lower respiratory tract.
The composition of CF nasopharyngeal microbiota diverges from that of 
non-CF infants as early as the first few months of life [13, 14]. Newborn healthy 
infants appear to have nasopharyngeal microbiota dominated by Moraxella spp., 
Corynebacterium spp. and Haemophilus spp., a community structure that persists for at 
least the first 6 months of life. Conversely the CF nasopharynx microbiome is initially 
dominated by Staphylococcus aureus before a gradual increase in Streptococcus spp. and 
Moraxellaceae at 3 months of age [13]. Despite the increased S. aureus seen in CF, there 
were no decreases in measures of richness or diversity indicating that changes are due 
to differing microenvironment rather than interspecies competition [15].
Term Definition
Microbiome The microorganisms in a particular environment
16S rRNA gene A gene which codes for a ribosomal subunit. Present in all prokaryotes and has 
variable regions, which differ slightly between bacterial species
Richness A measure of the number of species in a community
Evenness A measure of similarity of the relative abundance for each species in a 
community That is, does one species dominate, or do all species have similar 
relative abundance?
Diversity A measure of variety in a community. Combination of richness and evenness
Alpha diversity Within-sample diversity
Beta diversity Between-sample diversity
Operational 
taxonomic unit (OTU)
Group of strains/species with similar 16S rRNA gene sequences
Table 1. 
Glossary of terms and definitions.
Cystic Fibrosis - Heterogeneity and Personalized Treatment
4
The divergence observed in the first few months of life usually precedes antibi-
otic administration and demonstrates that CF itself is associated with compositional 
changes in the microbiota, but as CF infants grow older, exposure to antibiotics, 
either via acute treatment for respiratory illnesses or prophylaxis against classic CF 
pathogens, becomes inevitable. Mika et al. investigated the relationship between 
antibiotics and the nasal microbiota by prospectively following 30 newborn infants 
with CF with fortnightly sampling for the first 12 months of life [14]. Antibiotic 
administration was associated with an increase in the Shannon diversity measure  
(a measure of the richness and evenness of a community), but this was judged to be 
most likely secondary to an increase in transient colonisers. Interestingly, antibiotic 
therapy was staphylococcal directed, but decreases in Staphylococcus OTUs were 
not seen. Instead significant reductions in Moraxellaceae were observed, and when 
oligotyping was used to observe changes in Staphylococcus at the species level, mild 
reductions in S. aureus were offset by increases in S. epidermidis, leading the authors 
to suggest that S. epidermidis may act as a reservoir of resistance. These findings 
were supported by Prevaes et al. who conducted a similar study in a slightly older 
population (mean age 2 years old) [13]. Antibiotic treatment was observed to be 
associated with reductions in Moraxellaceae and S. aureus OTUs, with increases in 
other staphylococcal OTUs, although more specific oligotyping was not performed.
As babies grow older, sampling from the lower airways becomes more common, 
and comparisons between the lower and upper airways become feasible. Given the 
close proximity and interrelated spaces of the nose, throat and lungs, it could be 
expected that they all may share similar community structures; however, the reality 
is that the nasal community appears different from that of the throat and lung, 
which are much more closely aligned. Boutin et al. found differences in the commu-
nity structure of the nasal cavity compared to throat and sputum samples; in that 
diversity, richness and evenness were significantly higher in nasal samples, and up 
to 21 of the 76 most abundant nasal OTUs were not present in the throat or sputum 
samples [16]. Interestingly, the authors also found that subjects could be broadly 
defined into one of two ecotypes based on the presence or absence of Pseudomonas, 
and the similarities between throat and sputum samples began to diminish once 
Pseudomonas was present. Muhlebach et al. supported these findings in a recently 
published study, which for the first time included routine sequential BAL sam-
pling in young children as part of the large AREST-CF cohort in Australia and the 
USA. They showed that lower airway cultures mirrored that of the oral cavity until 
approximately age 2, when increasing predominance of known CF pathogens was 
observed and communities diverged [17]. This has a number of clinical implica-
tions in that, firstly, throat swabs can provide adequate representation of the lower 
airways in very young children and, secondly, prevention or delay of this transition 
point by manipulation of the microbiota could theoretically be a strategy to improve 
outcomes later in life.
4. Progressive loss of diversity
Once the lungs are colonised with CF pathogens, a pattern of progressively 
uneven community structures ensues. Cox et al. examined biobanked sputum 
samples from a cohort of 63 clinically stable people with CF of ages ranging from 
9 months to 72 years [7]. This cross-sectional approach identified the loss of 
community richness, evenness and diversity as age increased. Pseudomonas and 
Burkholderia OTUs began to progressively dominate in older subjects, and the 
changes in community structure were inversely associated with pulmonary func-
tion. In a similar study design with 269 patients, Coburn et al. also found sample 
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diversity inversely correlated with age and disease stage. Progressive loss of diver-
sity was particularly correlated with Pseudomonas and Burkholderia abundance, 
which notably increased after the age of 25 [18].
Zhao et al. were the first to confirm these findings longitudinally when they 
followed up six patients over a 9-year period with serial sputum collections. It 
was observed that the three patients with what they termed as more ‘progressive’ 
disease had significant decreases in community diversity over the course of several 
years. Decreasing lung function and increasing age were also associated with 
decreasing community diversity [19]. This study was soon followed by Fodor et al. 
who focussed more on changes in the microbiota associated with acute changes in 
clinical status but did observe a strong correlation between low species richness and 
poor lung function [20]. Stokell et al. followed up a single patient up to over 3 years 
and observed increasing total bacterial load as well as diminishing community 
richness and diversity [21].
Contrastingly, Whelan et al. recently published a study of six patients who 
submitted thrice-weekly sputum samples for a year [22]. No overall changes in 
community structure were observed over the course of the year, and the authors 
concluded that the respiratory microbiome is unique to each patient and the previ-
ously reported associations between community structure and clinical parameters 
may be true on a cohort/population level but not at an individual level. There is 
some merit in this argument, but it is also worth noting that the six patients in 
the study appeared relatively stable with a median of only one exacerbation in the 
12-month study period. It is also therefore a possibility that the follow-up period 
was not long enough to capture the more indolent changes likely to be present in 
those patients [23]. A much longer study period was adopted by Acosta et al. [24] 
who analysed samples from matched patients with biobanked sputum samples 
in three historic cohorts spanning nearly 20 years at a single centre. Across all the 
three cohorts, the core microbiome constituents were preserved, but the propor-
tion of Pseudomonas-dominated communities was reduced, and overall diversity 
increased in the more recent cohorts. Community structure improved gradually 
from the most historic cohort to the most recent, and these changes appeared to 
correlate with the generally improving clinical status of people with CF, confirming 
the previously described observed association between community structure and 
clinical outcomes [24].
The association reported in most studies between community structure and 
clinical outcomes has inevitably led to the question of whether a less diverse or even 
rich microbiome is simply a marker of increased pulmonary disease or is itself a 
driver in disease pathogenesis [25]. If the latter were true, efforts to promote a more 
diverse community could have the potential to slow pulmonary disease progression. 
An Italian group has led efforts to find patterns or signatures in the microbiome 
that may predispose patients to accelerated lung function decline; however, no 
causal association has been elucidated [26–28]. Instead, Zhao et al. found that the 
relationship between age, lung function and community diversity disappeared once 
controlled for antibiotic use, thus suggesting antibiotic therapy is the predominant 
driver of reducing community diversity [19]. The same group later developed a sta-
tistical approach to more precisely correct the antibiotic exposure when examining 
relationships between microbiota and clinical outcomes. The approach was applied 
to 478 sputum samples and confirmed that antibiotic use was an independent 
predictor for decreased diversity [29].
Accurately recording antibiotic use is troublesome in longitudinal studies due to 
the frequent episodic use of antibiotics in CF which is often self-directed by patients 
themselves, due to the widespread use of long-term antibiotics for which compli-
ance may be heterogeneous and also due to the retrospective nature of a number 
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The divergence observed in the first few months of life usually precedes antibi-
otic administration and demonstrates that CF itself is associated with compositional 
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most likely secondary to an increase in transient colonisers. Interestingly, antibiotic 
therapy was staphylococcal directed, but decreases in Staphylococcus OTUs were 
not seen. Instead significant reductions in Moraxellaceae were observed, and when 
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tion. In a similar study design with 269 patients, Coburn et al. also found sample 
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diversity inversely correlated with age and disease stage. Progressive loss of diver-
sity was particularly correlated with Pseudomonas and Burkholderia abundance, 
which notably increased after the age of 25 [18].
Zhao et al. were the first to confirm these findings longitudinally when they 
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and observed increasing total bacterial load as well as diminishing community 
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Contrastingly, Whelan et al. recently published a study of six patients who 
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community structure were observed over the course of the year, and the authors 
concluded that the respiratory microbiome is unique to each patient and the previ-
ously reported associations between community structure and clinical parameters 
may be true on a cohort/population level but not at an individual level. There is 
some merit in this argument, but it is also worth noting that the six patients in 
the study appeared relatively stable with a median of only one exacerbation in the 
12-month study period. It is also therefore a possibility that the follow-up period 
was not long enough to capture the more indolent changes likely to be present in 
those patients [23]. A much longer study period was adopted by Acosta et al. [24] 
who analysed samples from matched patients with biobanked sputum samples 
in three historic cohorts spanning nearly 20 years at a single centre. Across all the 
three cohorts, the core microbiome constituents were preserved, but the propor-
tion of Pseudomonas-dominated communities was reduced, and overall diversity 
increased in the more recent cohorts. Community structure improved gradually 
from the most historic cohort to the most recent, and these changes appeared to 
correlate with the generally improving clinical status of people with CF, confirming 
the previously described observed association between community structure and 
clinical outcomes [24].
The association reported in most studies between community structure and 
clinical outcomes has inevitably led to the question of whether a less diverse or even 
rich microbiome is simply a marker of increased pulmonary disease or is itself a 
driver in disease pathogenesis [25]. If the latter were true, efforts to promote a more 
diverse community could have the potential to slow pulmonary disease progression. 
An Italian group has led efforts to find patterns or signatures in the microbiome 
that may predispose patients to accelerated lung function decline; however, no 
causal association has been elucidated [26–28]. Instead, Zhao et al. found that the 
relationship between age, lung function and community diversity disappeared once 
controlled for antibiotic use, thus suggesting antibiotic therapy is the predominant 
driver of reducing community diversity [19]. The same group later developed a sta-
tistical approach to more precisely correct the antibiotic exposure when examining 
relationships between microbiota and clinical outcomes. The approach was applied 
to 478 sputum samples and confirmed that antibiotic use was an independent 
predictor for decreased diversity [29].
Accurately recording antibiotic use is troublesome in longitudinal studies due to 
the frequent episodic use of antibiotics in CF which is often self-directed by patients 
themselves, due to the widespread use of long-term antibiotics for which compli-
ance may be heterogeneous and also due to the retrospective nature of a number 
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of CF microbiome studies [30]. However, Pittman et al. were able to prospectively 
perform bronchoscopy and record antibiotic exposure of 32 subjects as part of the 
AREST-CF study. In that study, community diversity was much lower in the BAL of 
those patients receiving antibiotics [31].
Thus it appears likely that the strong association between community structure 
and degree of lung disease is related to the inevitable prolonged and aggressive use 
of antibiotics in CF rather than direct pathogenesis from a less diverse microbiome.
5. Community changes with acute pulmonary exacerbations
Despite the importance of exacerbations on long-term outcomes of people with 
CF, the pathophysiology of these events remains undefined [32, 33]. Clinically, 
exacerbations are frequent and are characterised by rapid changes in symptoms 
such as an increase in sputum volume or purulence, shortness of breath and fatigue. 
The precise mechanisms underlying these important events remain elusive, and 
studies looking for answers using culture-independent techniques have not found 
consistent answers. For example, one may expect to find evidence of increases in 
known pathogens at the time of exacerbations, yet there is no consistent evidence of 
this [23]. In fact, a number of studies have found the CF microbiota to be extremely 
stable over time and resilient to change at exacerbation and following subsequent 
treatment [19, 20, 34, 35].
However, when the community structure as a whole is considered, a number 
of larger studies have found reduced diversity or richness at the times of exacerba-
tion compared to clinical stability. Coburn et al. found small decreases in Shannon 
diversity in exacerbation samples compared to their baseline study of 269 people 
with CF [18]. Similarly, Filkins et al. found that samples taken during exacerbations 
had significantly lower diversity than samples taken when patients were stable 
[36]. Perhaps most convincingly, Li et al. collated data from 18 previous studies to 
analyse over 700 sputum samples and found that there were significant reductions 
in community richness at exacerbation [37].
Whilst increases in P. aeruginosa at the time of exacerbation have not been seen 
consistently, they have been observed in some cases. Carmody et al. followed up 
four patients for 3 months with daily sputum sampling and observed daily stability 
between exacerbations but increased P. aeruginosa abundance at the time of exac-
erbation in some patients and increases in Prevotella in others [38]. These findings 
help introduce two new concepts: firstly, the potential for exacerbations to appear 
similar phenotypically but have different underlying aetiology with only some 
being due to changes that can be observed in the microbiota and, secondly, that 
previously overlooked anaerobes may play a pathogenic role.
The first concept is supported by Whelan et al. who found in longitudinal 
sampling of six patients that some but not all exacerbations were associated with 
changes in the microbiota [22]. Attempts to identify different types of exacerba-
tions in COPD have identified four distinct aetiological clusters, bacterial, viral, 
eosinophilic predominant and ‘paucinflammatory’, and even though these clusters 
may not be mirrored in CF, it is plausible that not all exacerbation clusters would 
be associated with changes apparent in either individual taxa or overall bacterial 
community structure [39].
Changes in the metabolic activity of specific taxa or the community as a whole 
triggering an exacerbation could be another explanation for an apparent lack of 
change in the community structure seen in some studies. The metabolites lactate 
and putrescine were found by Twomey et al. to increase during exacerbation in 
the absence of clear changes in the community structure [40]. Quinn et al. used 
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the ecological functional networking to identify the non-mevalonate pathway of 
isoprenoid synthesis as a ‘keystone’ pathway in CF infections. Intriguingly fosmido-
mycin, an antimalarial agent, is known to be effective at targeting this pathway [41].
The second concept to emerge from the study of Carmody et al. relates to the 
changes in Prevotella abundance at the time of exacerbation and raises the prospect 
that species not considered conventional CF pathogens may play a role in exac-
erbations [42]. Anaerobic species are easily overlooked in conventional selective 
culturing due to the requirement for anoxic culture yet are identified frequently in 
culture-independent analyses of the CF lower airways. In addition to Gemella, both 
Prevotella and Streptococcus anginosus (milleri) have been found to have associations 
with clinical stability [36, 38, 42]. Anaerobes have been shown to have the potential 
to modulate P. aeruginosa gene expression in the polymicrobial setting; hence, even 
if they are not directly pathogenic, they may still play a contributory role to the 
pathogenesis of some exacerbations [43, 44].
To summarise, the aetiologies underpinning the transition from a stable state 
to an acute exacerbation are not well understood. It is likely that there multiple 
aetiological clusters but only some of which may be associated with changes in 
community structure.
6.  Community changes associated with treatment for acute pulmonary 
exacerbations
Traditional dogma would dictate that intensive, targeted antimicrobial therapy 
with dual anti-pseudomonal agents will result in significant reductions in abun-
dance of P. aeruginosa; however, in a similar vein to the findings from studies of 
the onset of exacerbations, microbiota responses to treatment for acute pulmonary 
exacerbations in CF have not aligned with this conventional understanding of 
infections.
One of the predominant themes that has emerged from studies of the respira-
tory microbiota response to acute antibiotics is that P. aeruginosa is not impacted to 
the same degree as other members of the community. For example, Daniels et al. 
studied 12 adult CF subjects across the cycle of an exacerbation and treatment and 
found that following initiation of anti-pseudomonal antimicrobials, the relative 
abundance of P. aeruginosa actually increased, alongside a reduction in the total 
number of species detected [45]. Cuthbertson et al. also found no evidence of 
reduced P. aeruginosa abundance in a study of 12 CF patients receiving treatment 
for pulmonary exacerbations [45]. Instead, reductions in Streptococcus sanguinis, 
Prevotella and Porphyromonas OTUs were observed [35]. Similarly, Li et al., in 
their analysis of over 700 sputum samples, found that antibiotic treatment had 
no effect on Pseudomonas abundance but did have significant effects on Gemella, 
Staphylococcus, Actinomyces, Moraxellaceae and Fusobacterium [37]. Further, Fodor 
et al. again found that dominant taxa such as Pseudomonas and Burkholderia were 
unchanged when compared at the beginning and end of an exacerbation but the 
relative abundances of Gemella, Streptococcus and a small number of other less 
abundant OTUs were all reduced [20].
In contrast, two studies have found reductions in P. aeruginosa following treat-
ment. Firstly, Zemanick et al. investigated the association between inflammation 
and changes to the airway microbiota during treatment for exacerbations and found 
that although bacterial load did not change, the relative abundance of P. aeruginosa 
was observed to decrease and that these changes correlated with improved lung 
function [46]. A reduction in P. aeruginosa abundance following treatment was also 
reported by Smith et al., who noted rapid decreases in P. aeruginosa abundance and 
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eosinophilic predominant and ‘paucinflammatory’, and even though these clusters 
may not be mirrored in CF, it is plausible that not all exacerbation clusters would 
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mycin, an antimalarial agent, is known to be effective at targeting this pathway [41].
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that species not considered conventional CF pathogens may play a role in exac-
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culturing due to the requirement for anoxic culture yet are identified frequently in 
culture-independent analyses of the CF lower airways. In addition to Gemella, both 
Prevotella and Streptococcus anginosus (milleri) have been found to have associations 
with clinical stability [36, 38, 42]. Anaerobes have been shown to have the potential 
to modulate P. aeruginosa gene expression in the polymicrobial setting; hence, even 
if they are not directly pathogenic, they may still play a contributory role to the 
pathogenesis of some exacerbations [43, 44].
To summarise, the aetiologies underpinning the transition from a stable state 
to an acute exacerbation are not well understood. It is likely that there multiple 
aetiological clusters but only some of which may be associated with changes in 
community structure.
6.  Community changes associated with treatment for acute pulmonary 
exacerbations
Traditional dogma would dictate that intensive, targeted antimicrobial therapy 
with dual anti-pseudomonal agents will result in significant reductions in abun-
dance of P. aeruginosa; however, in a similar vein to the findings from studies of 
the onset of exacerbations, microbiota responses to treatment for acute pulmonary 
exacerbations in CF have not aligned with this conventional understanding of 
infections.
One of the predominant themes that has emerged from studies of the respira-
tory microbiota response to acute antibiotics is that P. aeruginosa is not impacted to 
the same degree as other members of the community. For example, Daniels et al. 
studied 12 adult CF subjects across the cycle of an exacerbation and treatment and 
found that following initiation of anti-pseudomonal antimicrobials, the relative 
abundance of P. aeruginosa actually increased, alongside a reduction in the total 
number of species detected [45]. Cuthbertson et al. also found no evidence of 
reduced P. aeruginosa abundance in a study of 12 CF patients receiving treatment 
for pulmonary exacerbations [45]. Instead, reductions in Streptococcus sanguinis, 
Prevotella and Porphyromonas OTUs were observed [35]. Similarly, Li et al., in 
their analysis of over 700 sputum samples, found that antibiotic treatment had 
no effect on Pseudomonas abundance but did have significant effects on Gemella, 
Staphylococcus, Actinomyces, Moraxellaceae and Fusobacterium [37]. Further, Fodor 
et al. again found that dominant taxa such as Pseudomonas and Burkholderia were 
unchanged when compared at the beginning and end of an exacerbation but the 
relative abundances of Gemella, Streptococcus and a small number of other less 
abundant OTUs were all reduced [20].
In contrast, two studies have found reductions in P. aeruginosa following treat-
ment. Firstly, Zemanick et al. investigated the association between inflammation 
and changes to the airway microbiota during treatment for exacerbations and found 
that although bacterial load did not change, the relative abundance of P. aeruginosa 
was observed to decrease and that these changes correlated with improved lung 
function [46]. A reduction in P. aeruginosa abundance following treatment was also 
reported by Smith et al., who noted rapid decreases in P. aeruginosa abundance and 
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an associated increase in diversity following the initiation of intravenous antibiotic 
treatment for pulmonary exacerbations in CF, although these changes were tran-
sient and returned to baseline following the completion of treatment [47].
There are a number of factors that may explain the differences between the 
studies mentioned in this section, and many of them apply to studies of the CF 
microbiome in general. The most obvious is the heterogeneous study designs, 
which are mostly retrospective and observational in nature and include a wide 
range of antibiotic regimens. For example, some authors such as Cuthbertson and 
Daniels included exacerbations treated with oral antibiotics as well as those requir-
ing intravenous therapy [35, 45]. Milder exacerbations are often treated with oral 
antibiotics, and hence associated changes in the microbiota may also be expected to 
be more subtle. Even in those studies where only intravenous regimens were used, 
the antibiotic regimens or doses given are often not listed. The lack of a control or 
comparator group further makes interpreting results difficult [35, 45].
A further consideration is the sampling timeframes in each study, where again 
there exists a considerable variation that may have implications for interpreting 
results, particularly given that Smith et al. reported significant but transient reduc-
tions in P. aeruginosa abundance in the first few days of treatment [48].
Sample collection, storage, handling and DNA extraction techniques all also 
have the potential to impact on subsequent sequencing results. For example, mul-
tiple freeze–thaw cycles have been demonstrated to affect the results of microbiota 
analysis in respiratory samples [49]. Furthermore, different sequencing platforms 
can also produce different profiles [50].
There is no universally standardised protocol for the extraction of DNA from 
respiratory samples, and hence methods are often inconsistent between study 
groups. One obvious inconsistency is the use of propidium monoazide (PMA), a 
chemical compound that binds DNA in cells with damaged membranes and hence 
allows exclusion of non-viable DNA from sequencing. Excluding non-viable DNA 
has been suggested to be important for accurately identifying which members of 
the community are active at times of exacerbation and helps to avoid overestimation 
of viable microorganisms following treatment with antibiotics, but it is not utilised 
by all groups [51, 52]. There are concerns that PMA may incompletely penetrate 
sputum, hence only identifying a portion of non-viable cells. PMA is also known 
to stain viable cells of some species and stain dead cells in others [53]. In CF exac-
erbations, PMA treatment was not found to significantly alter the community as a 
whole, and only changes in low abundance ‘satellite’ taxa were apparent [51].
Overall, there is certainly evidence that acute antibiotic administration alters 
the respiratory microbiota; however, in the absence of prospective controlled trials, 
it is difficult to interpret these results given the confounders mentioned above. 
Indeed there have been calls for future clinical trials in CF to include biobanking of 
samples to allow a more rigorous scrutiny of the effect of antibiotic agents on the 
 microbiome [54].
7. Community changes associated with chronic suppressive antibiotics
Inhaled antibiotics such as colistimethate (COL), tobramycin (TOB), aztreo-
nam (AZLI) and levofloxacin (LIS) preparations are all licenced in the UK for the 
treatment of chronic P. aeruginosa infections and have, to varying degrees, dem-
onstrated improvements in lung function and exacerbation rates as well as sputum 
density of P. aeruginosa [55–58]. However, despite the near ubiquitous use of these 
inhaled anti-pseudomonals in the chronic P. aeruginosa treatment in CF, the effect 
of these treatments on the microbiome remains poorly defined. Furthermore, 
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many patients receive chronic macrolide therapy over many years, at least in 
part for its immunomodulatory effects, yet similarly little is known about the 
effects of this persistent selective pressure on the microbiota. When considering 
inhaled antibiotics, there is contrasting evidence as to their influence on the CF 
microbiome. For example, Kramer et al. [59] did not find any correlation between 
bacterial community structure and inhaled antibiotic treatments, although it is 
unclear which agents patients were using in that study. More recently Acosta et al. 
[24] utilised a prospectively collected Canadian sputum biobank primarily to 
investigate changes in CF cohort microbiota over time but also assessed whether 
different long-term antibiotics were associated with distinct microbiota. Eighty-
two samples from 42 patients were sequenced, and those receiving long-term 
tobramycin and colistimethate harboured significantly different respiratory com-
munities compared to those who were not, but interestingly no differences were 
seen in people receiving AZLI. The authors also assessed the impact of long-term 
oral azithromycin and nebulised dornase, but these agents were not associated 
with any differences. Perhaps intrigued by the failure of AZLI to be associated 
with microbiomic differences given its proven clinical benefits, the same group 
investigated its effects in more detail. In the only published study focussing on the 
microbiomic outcomes of a specific inhaled antibiotic, Heirali et al. [54] utilised 
the same Canadian biobank and sequenced 80 samples from 24 patients naive to 
AZLI and 82 samples from the same patients following initiation of AZLI. Overall 
no differences were observed in alpha or beta diversity measures, but at the OTU 
level, significantly lower relative abundances of Prevotella were seen following 
AZLI initiation. The authors then subclassified patients into AZLI ‘responders’ 
and ‘non-responders’ based on clinical outcomes and found ‘non-responders’ to 
have lower abundance of Pseudomonas and higher abundance of Staphylococcus. 
This novel approach raises the prospect of signatures in an individual’s microbiota 
acting as a biomarker for response to antibiotics and may represent an important 
step in the march towards personalised precision medicine in CF. Further stud-
ies are required to explore the potential for an individual’s microbiota to guide 
treatment.
8. Community changes associated with CFTR modulators
In the last 5 years, treatments targeted towards correcting the underlying 
defect in CF have become available. Ivacaftor, a cystic fibrosis transmembrane 
conductance regulator (CFTR) potentiator, is licenced specifically for the treatment 
of people with a G551D mutation and a number of other rare gating mutations, 
which together account for approximately 5–10% of the CF population in the UK 
[60]. In this subset of the CF population, ivacaftor use has been associated with 
improvements in lung function, reductions in exacerbations, reductions in sweat 
chloride, improved weight gain and improved quality of life [61, 62]. The restora-
tion of CFTR activity by ivacaftor and the associated clinical benefits, in particular 
improved lung function and reductions in exacerbation, has inevitably raised 
questions as to whether ivacaftor has an antimicrobial effect.
Theoretically, ivacaftor could have an antimicrobial effect in a number of 
ways. Firstly, the restoration of CFTR activity should result in a rehydrated airway 
surface layer, and this in turn will allow the mucociliary escalator to function 
physiologically. The improved clearance of airway secretions would then result 
in the elimination of bacteria. Secondly, the restoration of CFTR activity could 
result in a dramatic change in the local pulmonary microenvironment, turning a 
previously favourable environmental niche into an inhospitable one for resident 
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an associated increase in diversity following the initiation of intravenous antibiotic 
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 microbiome [54].
7. Community changes associated with chronic suppressive antibiotics
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inhaled anti-pseudomonals in the chronic P. aeruginosa treatment in CF, the effect 
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many patients receive chronic macrolide therapy over many years, at least in 
part for its immunomodulatory effects, yet similarly little is known about the 
effects of this persistent selective pressure on the microbiota. When considering 
inhaled antibiotics, there is contrasting evidence as to their influence on the CF 
microbiome. For example, Kramer et al. [59] did not find any correlation between 
bacterial community structure and inhaled antibiotic treatments, although it is 
unclear which agents patients were using in that study. More recently Acosta et al. 
[24] utilised a prospectively collected Canadian sputum biobank primarily to 
investigate changes in CF cohort microbiota over time but also assessed whether 
different long-term antibiotics were associated with distinct microbiota. Eighty-
two samples from 42 patients were sequenced, and those receiving long-term 
tobramycin and colistimethate harboured significantly different respiratory com-
munities compared to those who were not, but interestingly no differences were 
seen in people receiving AZLI. The authors also assessed the impact of long-term 
oral azithromycin and nebulised dornase, but these agents were not associated 
with any differences. Perhaps intrigued by the failure of AZLI to be associated 
with microbiomic differences given its proven clinical benefits, the same group 
investigated its effects in more detail. In the only published study focussing on the 
microbiomic outcomes of a specific inhaled antibiotic, Heirali et al. [54] utilised 
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and ‘non-responders’ based on clinical outcomes and found ‘non-responders’ to 
have lower abundance of Pseudomonas and higher abundance of Staphylococcus. 
This novel approach raises the prospect of signatures in an individual’s microbiota 
acting as a biomarker for response to antibiotics and may represent an important 
step in the march towards personalised precision medicine in CF. Further stud-
ies are required to explore the potential for an individual’s microbiota to guide 
treatment.
8. Community changes associated with CFTR modulators
In the last 5 years, treatments targeted towards correcting the underlying 
defect in CF have become available. Ivacaftor, a cystic fibrosis transmembrane 
conductance regulator (CFTR) potentiator, is licenced specifically for the treatment 
of people with a G551D mutation and a number of other rare gating mutations, 
which together account for approximately 5–10% of the CF population in the UK 
[60]. In this subset of the CF population, ivacaftor use has been associated with 
improvements in lung function, reductions in exacerbations, reductions in sweat 
chloride, improved weight gain and improved quality of life [61, 62]. The restora-
tion of CFTR activity by ivacaftor and the associated clinical benefits, in particular 
improved lung function and reductions in exacerbation, has inevitably raised 
questions as to whether ivacaftor has an antimicrobial effect.
Theoretically, ivacaftor could have an antimicrobial effect in a number of 
ways. Firstly, the restoration of CFTR activity should result in a rehydrated airway 
surface layer, and this in turn will allow the mucociliary escalator to function 
physiologically. The improved clearance of airway secretions would then result 
in the elimination of bacteria. Secondly, the restoration of CFTR activity could 
result in a dramatic change in the local pulmonary microenvironment, turning a 
previously favourable environmental niche into an inhospitable one for resident 
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microbiota. There is evidence to support a similar effect in the GI tract, where 
CFTR modulation with ivacaftor was associated with improved proximal small 
intestinal pH, likely secondary to improved bicarbonate secretion [63]. Thirdly, 
a direct bactericidal effect of ivacaftor itself has been postulated given that its 
chemical structure contains a quinolone ring and many quinolone derivatives have 
antimicrobial properties [64]. This theory is supported by evidence that ivacaftor 
exerted in vitro antibacterial effects on clinical respiratory isolates of S. aureus 
(MSSA and MRSA) and Streptococcus pneumoniae [65, 66]. However, these studies 
found very little activity against Gram-negative organisms, which is uncharacter-
istic of a quinolone-based antibiotic [65]. Interestingly, the authors of the same 
study noted synergism of ivacaftor with antibiotics commonly used in CF, and 
this was recently supported by Payne et al., who again found that ivacaftor had 
activity against Streptococcus spp. and S. aureus and that the effect was potentiated 
in the presence of tobramycin. Again there was no evidence of direct antibacterial 
 activity against P. aeruginosa [67].
Interest has since focussed on clinical microbiological outcomes of patients com-
menced on ivacaftor therapy in an effort to investigate differences post-treatment 
initiation. Interestingly, despite ivacaftor appearing to have no innate activity 
against P. aeruginosa, a number of studies have reported reductions in counts and 
density post initiation, perhaps suggesting that quinolone activity is not the only 
mechanism at play [68, 69].
In contrast to the relative lack of focus on inhaled antibiotics, a number of 
studies have investigated the effects of ivacaftor on the respiratory microbiome. 
Peleg et al. [70] conducted the only placebo-controlled trial in this field when they 
performed a double-blind, placebo-controlled, cross-over study of 28-day ivacaftor 
treatment. Sputum was collected at the start and end of each 28-day treatment 
period, and 16S rRNA sequencing with qPCR correlation was subsequently per-
formed. No significant differences were observed for either total bacterial load or 
P. aeruginosa load following ivacaftor therapy, and no significant difference in the 
microbiota composition (based on 16S rRNA microbiome analysis) was observed 
between the placebo and treatment samples. However, the authors noted that when 
they adjusted for consistent or changing antibiotic exposure in the 28-day study 
period, ivacaftor was associated with a significant reduction in P. aeruginosa load. 
That is to say, changes in the microbiota induced by acute changes in antibiotic 
administration during the 28-day treatment periods may have masked the effect 
induced by ivacaftor.
In longer-term observational studies, a number of changes have been observed. 
Bernarde et al. [71] noted no significant changes in bacteria load and also no 
significant changes in overall community composition at 1 year following ivacaftor 
initiation. However, individual taxa were observed to change in that the rela-
tive abundance of Streptococcus mitis group was significantly diminished and a 
Porphyromonas OTU was significantly increased. Elsewhere, in perhaps the most 
comprehensive study of microbiological outcomes following ivacaftor initiation, 
Hisert et al. [72] found marked reductions in P. aeruginosa sputum densities using 
conventional culture and also reduced sputum inflammatory markers in regular 
follow-up throughout the first 2 years of ivacaftor use. These findings were mir-
rored in the 16S rRNA-based analysis, where decreases in mean P. aeruginosa 
relative abundance and subsequent increases in diversity measures were observed. 
However, no patient eradicated P. aeruginosa, and after 12 months of treatment, 
relative abundance, sputum counts and inflammatory markers began to increase 
again. The authors interpreted these findings to suggest that P. aeruginosa may adapt 
to a CFTR-restored environment and this clearly has implications for the need for 
ongoing anti-infective chemotherapy in CF.
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9. Nontuberculous mycobacteria
Nontuberculous mycobacteria (NTM) are identified in approximately 10% of CF 
patients, but only a small proportion will go on to develop NTM pulmonary disease 
(NTM-PD) warranting treatment. First and foremost, the management of CF pulmo-
nary disease should be optimised, including antibiotic therapy targeted to the indi-
vidual’s usual airway bacteria, prior to considering treatment for NTM-PD. Those who 
fulfil criteria for NTM lung disease may not necessarily require treatment and could be 
monitored expectantly if symptoms and radiographic findings are minimal or stable 
over a period of surveillance. However, the presence of Mycobacterium abscessus com-
plex (MABSC), deteriorating lung function, worsening radiology and/or anticipated 
lung transplant should prompt NTM therapy initiation (Table 2). For CF patients 
with Mycobacterium avium complex (MAC), recommended treatment includes 
triple antibiotic therapy with a macrolide, rifampin and ethambutol. Azithromycin 
is generally the preferred macrolide of choice in CF as it is better tolerated and has 
fewer drug–drug interactions. An initial course of injectable amikacin or streptomycin 
should be considered in the presence of (i) acid-fast bacillus smear-positive respira-
tory tract samples, (ii) radiological evidence of lung cavitation or severe infection and 
(iii) systemic signs of illness. MABSC treatment is more complicated and requires an 
induction phase (oral macrolide and two IV agents including amikacin with one or 
more additional intravenous antibiotics including tigecycline, imipenem, cefoxitin) 
for 3 to 12 weeks as well as a maintenance phase (nebulised amikacin and a macrolide 
with two to three oral antibiotics including minocycline, clofazimine, moxifloxacin, 
linezolid). Baseline and interval testing for drug toxicity is essential. The treatment 
duration for both MAC and MABSC is extended 1-year post-culture conversion. 
However, in patients who do not achieve culture negative status but tolerate therapy, 
ongoing treatment for mycobacterial suppression and prevention of disease progres-
sion can be considered. There are no randomised controlled trials of MABSC therapy 
in the general population or in CF; however, there is MABSC treatment outcome data 
in non-CF populations from several clinical studies [74]. In a study of 57 non-CF 
Clinical (both required)
1. Pulmonary symptoms with nodular or cavitary opacities on chest radiograph or a high-resolution CT 
scan that shows multifocal bronchiectasis with multiple small nodules
2. Appropriate exclusion of other diagnoses.
Microbiologic (one of the following required)
• Positive culture results from at least two expectorated sputum samples. If the results from samples are 
non-diagnostic, consider repeat sputum acid-fast bacillus (AFB) smears and cultures.
• Positive culture results from at least one bronchial wash or lavage.
• Transbronchial or other lung biopsy with mycobacterial histopathological features (granulomatous 
inflammation or AFB) and positive culture for NTM or biopsy showing mycobacterial histopathologi-
cal features (granulomatous inflammation or AFB) and one or more sputum or bronchial washings that 
are culture positive for NTM.
• Expert consultation should be obtained when either infrequently encountered NTM or those usually 
representing environmental contamination are recovered.
• Patients who are suspected of having NTM-PD but who do not meet the diagnostic criteria should be 
followed up until the diagnosis is firmly established or excluded.
• Making the diagnosis of NTM-PD does not, per se, necessitate the institution of therapy, which is a 
decision based on potential risks and benefits of therapy for individual patients.
Table 2. 
ATS/IDSA clinical and microbiologic criteria for diagnosing nontuberculous mycobacterial pulmonary disease 
(NTM-PD) [73].
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subjects that compared M. abscessus ssp. massiliense and ssp. abscessus infections and 
treatment outcomes, all individuals were treated with clarithromycin-containing 
regimen in combination with an initial 4-week course of cefoxitin and amikacin, was 
given to 57 patients (24 with M. abscessus and 33 with M. massiliense) for more than 
12 months. The proportion of patients with sputum conversion and maintenance of 
negative sputum cultures was higher in patients with M. massiliense infection (88%) 
than in those with M. abscessus infection (25%; p < 0.001). Inducible resistance to 
clarithromycin (minimal inhibitory concentrations ≥ 32 μg/ml) was found in all tested 
M. abscessus isolates (n = 19), but in none of the M. massiliense isolates (n = 28) [75].
Inhaled liposomal amikacin for maintenance treatment has also drawn inter-
est. In a randomised placebo-controlled trial, CF subjects with NTM lung disease 
refractory to standard therapy were assigned to 590 mg OD inhaled liposomal 
amikacin or placebo, in addition to their standard CF treatments and ongoing 
NTM therapy [76]. The group of 90 patients was stratified based on MAC (64%) 
and MABSC (36%) [77]. At the end of the 6-month treatment period, there was a 
statistically significant increase in culture negativity overall and for the MAC group.
Reported NTM prevalence in CF ranges from 3 [78] to 23% [79]. The major-
ity (95%) of NTM isolated from CF patients are Mycobacterium avium complex 
(MAC) (M. avium-intracellulare and four M. avium subspecies) and M. abscessus 
complex (MABSC) (subspecies abscessus, massiliense, and bolletii) [80, 81]. Bryant 
et al. [82] reported the largest outbreak occurred in Cambridge, England, where 11 
of 31 patients with MABSC had a shared strain of M. abscessus subsp. massiliense with 
similar antibiotic resistance patterns by whole genome sequencing despite a lack of 
exposure to the same antibiotics, raising the possibility of cross infection amongst 
the CF cohort albeit conventional cross infection measures (Figure 2).
MABSC has been demonstrated to accelerate lung function decline in CF 
patients compared to uninfected CF controls [83, 84]. In CF, a common measure 
Figure 2. 
Typical treatment schedules for individuals with CF with Mycobacterium abscessus or MAC pulmonary 
disease [74].
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of lung disease severity is percent-predicted forced expiratory volume in 1 second 
(FEV1), with lower values indicating more severe lung disease. Qvist et al. showed 
that MABSC had a greater rate of FEV1% predicted decline than other organisms, 
including Pseudomonas aeruginosa and Burkholderia cepacia [84]. However, no lung 
function decline was noted in patients growing MAC [83]. Likewise, a large study 
found no significant effect of NTM infection on lung function decline, although 
analyses were not based on different NTM subtypes [80]. A diagnosis of NTM 
pulmonary disease must meet both clinical and microbiologic criteria as outlined by 
ATS guidelines, with exclusion of other aetiologies [73].
Individuals who are NTM culture positive but who do not meet ATS criteria 
for disease should be monitored closely [74]. Patients with CF meeting criteria for 
NTM-PD should be considered for therapy; however, treatment decisions should be 
individualised [74, 85]. It may be reasonable to monitor individuals with mild CF 
lung disease, MAC lung disease with mild symptoms and radiographic changes or a 
high possibility of drug intolerance or drug interactions [85]. However, CF patients 
with MABSC and/or severe CF lung disease should generally be treated in the 
absence of contraindications [85].
10. Fungal lung disease in CF
Clinical manifestations of respiratory fungal diseases in adult CF patients are 
very heterogeneous, ranging from asymptomatic colonisation to chronic infections, 
allergic disorders or invasive diseases in immunosuppressed CF patients following 
lung transplantation.
Aspergillus spp. are amongst the most widespread filamentous fungi in the 
environment, especially in areas with high humidity [86]. In CF patients, the 
most frequently isolated species is Aspergillus fumigatus, accounting for 67–73% 
of Aspergillus-positive sputum cultures [87]. Isolation of other species such as 
A. flavus, A. niger and A. terreus is less frequent but not rare (4, 4 and 2% of 
Aspergillus-positive sputum cultures, respectively) [87]. Notably, the prevalence of 
isolation of Aspergillus spp. from sputum cultures in CF patients increases with age, 
possibly reaching 46–78% in adult CF patients, although with important inter-
region and inter-centre variability [88–90]. However, knowledge of the prevalence 
of Aspergillus spp. isolation from sputum does not automatically allow to infer the 
prevalence of the various Aspergillus-related manifestations in CF patients, which 
range from asymptomatic colonisation to invasive diseases, especially in patients 
post-lung transplantation.
Allergic bronchopulmonary aspergillosis (ABPA) refers to a complex hypersen-
sitivity reaction which often occurs in patients affected by CF or asthma. ABPA is 
beyond the scope of discussion in this chapter.
In CF patients, the disease-related progressive damage of the lungs may favour 
the development of chronic Aspergillus infection, commonly defined as ‘Aspergillus 
bronchitis’, although aspergilloma(s) might also develop in some cases, especially 
in pre-existing cavities or bronchiectasis [91–93]. Aspergillus bronchitis has an 
estimated prevalence of ~2–8% in CF patients and may be suspected in the case of 
pulmonary exacerbation unresponsive to antibacterial treatment [94, 95]. As per 
Baxter et al.’s [96] classification, diagnosis of Aspergillus bronchitis can be made in 
the presence of a positive sputum galactomannan, high levels of Aspergillus-specific 
IgG and negative total and Aspergillus-specific IgE. Since Aspergillus bronchitis does 
reflect infection and not an immune-mediated response as in ABPA, corticosteroids 
are not the cornerstone of treatment. Treatment with azole derivatives is the cur-
rent standard of care, although the overall duration of treatment is still not clearly 
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allergic disorders or invasive diseases in immunosuppressed CF patients following 
lung transplantation.
Aspergillus spp. are amongst the most widespread filamentous fungi in the 
environment, especially in areas with high humidity [86]. In CF patients, the 
most frequently isolated species is Aspergillus fumigatus, accounting for 67–73% 
of Aspergillus-positive sputum cultures [87]. Isolation of other species such as 
A. flavus, A. niger and A. terreus is less frequent but not rare (4, 4 and 2% of 
Aspergillus-positive sputum cultures, respectively) [87]. Notably, the prevalence of 
isolation of Aspergillus spp. from sputum cultures in CF patients increases with age, 
possibly reaching 46–78% in adult CF patients, although with important inter-
region and inter-centre variability [88–90]. However, knowledge of the prevalence 
of Aspergillus spp. isolation from sputum does not automatically allow to infer the 
prevalence of the various Aspergillus-related manifestations in CF patients, which 
range from asymptomatic colonisation to invasive diseases, especially in patients 
post-lung transplantation.
Allergic bronchopulmonary aspergillosis (ABPA) refers to a complex hypersen-
sitivity reaction which often occurs in patients affected by CF or asthma. ABPA is 
beyond the scope of discussion in this chapter.
In CF patients, the disease-related progressive damage of the lungs may favour 
the development of chronic Aspergillus infection, commonly defined as ‘Aspergillus 
bronchitis’, although aspergilloma(s) might also develop in some cases, especially 
in pre-existing cavities or bronchiectasis [91–93]. Aspergillus bronchitis has an 
estimated prevalence of ~2–8% in CF patients and may be suspected in the case of 
pulmonary exacerbation unresponsive to antibacterial treatment [94, 95]. As per 
Baxter et al.’s [96] classification, diagnosis of Aspergillus bronchitis can be made in 
the presence of a positive sputum galactomannan, high levels of Aspergillus-specific 
IgG and negative total and Aspergillus-specific IgE. Since Aspergillus bronchitis does 
reflect infection and not an immune-mediated response as in ABPA, corticosteroids 
are not the cornerstone of treatment. Treatment with azole derivatives is the cur-
rent standard of care, although the overall duration of treatment is still not clearly 
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defined [97]. Invasive aspergillosis is described as the infection progresses across 
tissues and invades the vessels, with subsequent necrosis [96]. Usually, invasive 
aspergillosis is observed in severely immunocompromised non-CF populations, 
such as haematology patients with prolonged neutropenia and patients receiv-
ing high dosages of corticosteroids or other immunosuppressive agents. Clinical 
symptoms usually include fever, chest pain, shortness of breath and/or cough [96]. 
Haemoptysis and pneumothorax might also develop in some cases [98, 99]. Invasive 
aspergillosis is rarely seen in patients affected by CF. However, it could develop 
in end-stage CF patient and in immunosuppressed CF patients following lung 
transplantation, frequently in the form of Aspergillus tracheobronchitis, occur-
ring mainly in the first 3 months after transplants and associated with increased 
mortality (39%) [100, 101]. Frequent symptoms of Aspergillus tracheobronchitis 
are severe dyspnoea, cough and wheezing [97]. The histopathological examination 
may show different features: (1) obstructive bronchial aspergillosis; (2) ulcerative 
tracheobronchitis (characterised by the invasion of the tracheobronchial mucosa 
and cartilage); and (3) pseudomembranous tracheobronchitis (characterised by 
inflammation and invasion of the tracheobronchial tree). Invasive aspergillosis is 
usually treated with systemic azole therapy (possibly associated with nebulised 
amphotericin B in some cases of tracheobronchitis) [97]. The US guidelines recom-
mend a minimum of 6 to 12 weeks of therapy for patients with invasive pulmonary 
aspergillosis and at least 3 months in the case of Aspergillus tracheobronchitis [97].
11. Conclusion
The pulmonary microbiome of people with CF diverging significantly from that 
of the healthy individuals has been the focus of much research in the last 5 years 
often producing more questions than answers. As the disease progresses, com-
munity structure becomes progressively less diverse, most likely as a consequence 
of long-term aggressive antibiotic therapy. The impact of acute antibiotic therapy, 
antifungal treatments and CFTR modulators are less well defined, and prospective 
clinical trials with sputum biobanking are needed to answer these questions.
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Recent Approach in Microbial 
Pathogen Complications in 
Patients with Cystic Fibrosis
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Abstract
Cystic fibrosis (CF) is a multisystem genetic disease caused by mutations in 
the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Microbial 
infection is the defined characteristics of cystic fibrosis airway disease. This infec-
tion is caused by bacteria, fungi, and viruses which increase complications leading 
to patient death. Additionally, bacterial pathogens including Haemophilus influenza, 
Staphylococcus aureus, Pseudomonas aeruginosa, nontuberculous mycobacterium 
(NTM) species, and MRSA are attributed to pulmonary infections. Subsequently, 
fungal pathogens such as Candida sp. and filamentous fungi such as Aspergillus 
fumigatus can also lead to pulmonary infections. On the other hand, Pseudomonas 
aeruginosa is the most common bacterial pathogen leading to complications in 
CF distal airways disease. Also, Aspergillus fumigatus can lead to aspergillus lung 
diseases including allergic bronchopulmonary aspergillosis and aspergilloma for-
mation. Control of pathogenic microorganisms associated with cystic fibrosis may 
prevent pulmonary complications and has the potential to improve the prognosis of 
this life-limiting disease.
Keywords: cystic fibrosis, Pseudomonas aeruginosa, Aspergillus fumigatus, 
Haemophilus influenzae, MRSA, CFTR, NTM, microbial infection, respiratory 
diseases
1. Introduction
Cystic fibrosis (CF) is an autosomal recessive disease which basis on a dys-
functional cystic fibrosis transmembrane conductance regulator (CFTR) protein 
[1]. It is an inherited chronic disease that remains a common cause of morbidity 
and mortality in affected patients [2]. Also, it is a monogenic autosomal recessive 
condition affecting approximately 1 in 3000 of the Caucasian population and 
involves multiple organs, predominantly the lungs, gastrointestinal tract, pancreas, 
and liver [3].
Mutations in CFTR gene are resulted in defective mucociliary clearance leading 
to the production of thick and sticky bronchial mucus. This mucus facilitates the 
entrapment of viruses, bacteria, and fungal spores and acts as a suitable environ-
ment for growth of these microorganisms [4]. High morbidity and mortality rates 
are secondary to recurrent respiratory infections, which, when associated with 
this obstructive lung disease, lead to respiratory insufficiency [5]. Complex micro-
organisms and microbial communities can be identified in the distal airways in a 
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1. Introduction
Cystic fibrosis (CF) is an autosomal recessive disease which basis on a dys-
functional cystic fibrosis transmembrane conductance regulator (CFTR) protein 
[1]. It is an inherited chronic disease that remains a common cause of morbidity 
and mortality in affected patients [2]. Also, it is a monogenic autosomal recessive 
condition affecting approximately 1 in 3000 of the Caucasian population and 
involves multiple organs, predominantly the lungs, gastrointestinal tract, pancreas, 
and liver [3].
Mutations in CFTR gene are resulted in defective mucociliary clearance leading 
to the production of thick and sticky bronchial mucus. This mucus facilitates the 
entrapment of viruses, bacteria, and fungal spores and acts as a suitable environ-
ment for growth of these microorganisms [4]. High morbidity and mortality rates 
are secondary to recurrent respiratory infections, which, when associated with 
this obstructive lung disease, lead to respiratory insufficiency [5]. Complex micro-
organisms and microbial communities can be identified in the distal airways in a 
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variety of respiratory diseases, including CF [6]. Chronic infection is the defined 
characteristics of CF airway disease. Conditions within the airways of patients 
living with CF are conducive to colonization by a variety of opportunistic bacterial, 
viral, and fungal pathogens [7].
Also, bacterial strains that colonize the respiratory tract include Haemophilus 
influenzae, Staphylococcus aureus, Pseudomonas aeruginosa [8], and Burkholderia 
cepacia; these have been recorded as the main common CF pathogens. Traditionally, 
Pseudomonas aeruginosa has been regarded as the main pathogen in CF, and chronic 
infections have been linked to disease morbidity and mortality [9]. Little attention 
has been paid to the role of Aspergillus sp. and other filamentous fungi in CF. It has 
become more apparent, however, that Aspergillus sp. may play an important role in 
chronic lung disease in CF [10]. This chapter discusses the complications of micro-
organisms in patients with cystic fibrosis, including bacterial, fungal, and viral 
pathogens and their effects on this disease leading to an increased risk of mortality.
2. Defining causes and history of cystic fibrosis
Cystic fibrosis is a multisystem genetic disease that affects children and young 
adults [11]. It is caused by mutations in CFTR gene leading to defective or insuf-
ficient amounts of functional CFTR protein and causes abnormalities in chloride 
(Cl), bicarbonate (HCO3), and sodium (Na) transport across cell membranes with 
serious consequences on multiple organs. The CF lung disease is characterized by 
infection and inflammation with eventual bronchiectasis and eventual respiratory 
failure causing death in over 90% of CF patients [3].
Cystic fibrosis is an autosomal recessively inherited disorder caused by the pres-
ence of one of more than 1500 possible mutations in CFTR gene with an occurrence 
of the clinical disease being 1 in 2500 live births. This mutation leads to the non-
function or loss of function of CFTR (a cyclic AMP-regulated chloride ion channel) 
leading to defective chloride ion transport through epithelial cell surfaces [12].
Since its first description in 1938, study of the genetics, pathophysiology, and 
clinical manifestation of the disease has led to the creation of new therapies and 
significantly improved quality of life and survival [2].
In CF, the biology and treatment strategies are important to understand for 
several reasons. Firstly, it is the most common cause of chronic respiratory failure 
in children and adults. Secondly, CF is a common reason for the dysfunction of 
pancreatic exocrine in children and adults. Thirdly, the majority also develop pan-
sinusitis. Other potential consequences of CF include diabetes, liver disease, bone 
disease, and infertility [3].
Advances in research of CF have given a roadmap for the understanding of 
pathophysiology studies and treatment stages for other severe airway diseases, 
including chronic obstructive pulmonary disease, non-CF bronchiectasis, and 
asthma [11].
Survival of individuals with CF has improved significantly over the last half 
century from a median age of survival of 5 years in the 1970s to 40 years of age as 
of 2011. There are different reasons for improvement in clinical outcomes includ-
ing the intense use of antibiotic therapy, advancement in chest physiotherapy, 
nutritional support, specialized CF units, and introduction of CFTR modulators; 
however, the majority of CF deaths still occurred in young adult especially in the 
ages between 21 and 30 years as a consequence of respiratory failure [13]. Recent 
research also suggests that even asymptomatic genetic carriers for CF may be at risk 
for subclinical physiological derangements, which can be exacerbated by external 
stresses and other environmental triggers [14, 15].
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3. Microbial complications in patients with cystic fibrosis
Airways of patients with CF are usually infected with various microorganisms. 
In infected airways of CF patients, microhabitats can develop owing to local differ-
ences in the inflammatory reaction between the different focal areas of infection 
and also as a result of the competing activities of the many co-colonizing microbial 
populations [16]. Several bacterial strains are major causes of mortality and mor-
bidity and have therefore been studied intensely [12].
3.1 Microbial infection in patients with cystic fibrosis
Chronic infection is a characteristic of CF airway disease. So, conditions in the 
airways of patients with CF are conducive to forming colonization by different 
microorganisms such as bacterial, fungal, and viral pathogens. Molecular identifi-
cation of microorganisms has emphasized and recorded the polymicrobial nature of 
microbial infections in the CF airway microenvironment. Additionally, changes in 
airway of CF physiology through the loss of CFTR functionality lead to a variety of 
immune dysfunctions that permit microbial pathogen colonization and microbial 
persistence [7].
The prognosis of patients with the hereditary disease CF is substantially 
dependent on chronic respiratory infection and inflammation [17]. CF lungs are 
often colonized or infected with a complex microbial species, mainly composed of 
bacteria, provoking acute and chronic infections [18]. Airway infection accounts for 
90% of the morbidity and mortality observed in CF patients. These chronic infec-
tions are typically associated with a few bacterial pathogens such as Pseudomonas 
aeruginosa, Staphylococcus aureus, and Burkholderia cepacia complex [19].
High morbidity and mortality rates in cystic fibrosis patients are secondary 
to recurrent respiratory infections, which, when associated with this obstructive 
lung disease, lead to respiratory insufficiency, the main cause of death in these 
patients [5, 14].
CF lung disease is characterized by progressive colonization of respiratory tract 
infection by different bacterial strains leading to polymicrobial biofilms. Also, 
the emergence of nontuberculous mycobacteria (NTM) infections has caused 
additional challenges to patient management due to their multiresistance nature to 
antibiotics [20]. These are compounded by the impairment of mucociliary clear-
ance and the inability to mobilize thick secretions within the airways. These result 
in mucus impaction, microorganism colonization, recurrent infections, persistent 
inflammation and death from respiratory failure. With improvement in CF progno-
sis, new challenges emerge, including the management of fungal colonization and 
infection [1].
3.2 Host-microbe interactions with CF lung infection
Bacterial and fungal infections are hallmarks of CF lung disease. In the era of 
long-term inhaled antibiotics and increasing CF patient survival, new “emerging” 
pathogens are detected in CF airways, yet their pathophysiological impact remains 
largely controversial and incompletely defined. As a consequence to chronic 
microbial triggers, innate immune cells, particularly neutrophils, are continuously 
recruited into CF airways where they combat pathogens but also lead to tissue 
injury through the release of oxidants and proteases. The coordinated interplay 
between host immune cell activation and pathogens is essential for the outcome 
of CF lung disease. A better understanding of this phenomena may enhance the 
survival in CF [21–23].
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research also suggests that even asymptomatic genetic carriers for CF may be at risk 
for subclinical physiological derangements, which can be exacerbated by external 
stresses and other environmental triggers [14, 15].
25
Recent Approach in Microbial Pathogen Complications in Patients with Cystic Fibrosis
DOI: http://dx.doi.org/10.5772/intechopen.91635
3. Microbial complications in patients with cystic fibrosis
Airways of patients with CF are usually infected with various microorganisms. 
In infected airways of CF patients, microhabitats can develop owing to local differ-
ences in the inflammatory reaction between the different focal areas of infection 
and also as a result of the competing activities of the many co-colonizing microbial 
populations [16]. Several bacterial strains are major causes of mortality and mor-
bidity and have therefore been studied intensely [12].
3.1 Microbial infection in patients with cystic fibrosis
Chronic infection is a characteristic of CF airway disease. So, conditions in the 
airways of patients with CF are conducive to forming colonization by different 
microorganisms such as bacterial, fungal, and viral pathogens. Molecular identifi-
cation of microorganisms has emphasized and recorded the polymicrobial nature of 
microbial infections in the CF airway microenvironment. Additionally, changes in 
airway of CF physiology through the loss of CFTR functionality lead to a variety of 
immune dysfunctions that permit microbial pathogen colonization and microbial 
persistence [7].
The prognosis of patients with the hereditary disease CF is substantially 
dependent on chronic respiratory infection and inflammation [17]. CF lungs are 
often colonized or infected with a complex microbial species, mainly composed of 
bacteria, provoking acute and chronic infections [18]. Airway infection accounts for 
90% of the morbidity and mortality observed in CF patients. These chronic infec-
tions are typically associated with a few bacterial pathogens such as Pseudomonas 
aeruginosa, Staphylococcus aureus, and Burkholderia cepacia complex [19].
High morbidity and mortality rates in cystic fibrosis patients are secondary 
to recurrent respiratory infections, which, when associated with this obstructive 
lung disease, lead to respiratory insufficiency, the main cause of death in these 
patients [5, 14].
CF lung disease is characterized by progressive colonization of respiratory tract 
infection by different bacterial strains leading to polymicrobial biofilms. Also, 
the emergence of nontuberculous mycobacteria (NTM) infections has caused 
additional challenges to patient management due to their multiresistance nature to 
antibiotics [20]. These are compounded by the impairment of mucociliary clear-
ance and the inability to mobilize thick secretions within the airways. These result 
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Bacterial and fungal infections are hallmarks of CF lung disease. In the era of 
long-term inhaled antibiotics and increasing CF patient survival, new “emerging” 
pathogens are detected in CF airways, yet their pathophysiological impact remains 
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3.3 Nontuberculous mycobacteria species in patient with cystic fibrosis
NTM are wide environmental microorganisms causing chronic pulmonary 
infection in lung diseases such as CF. Also, pulmonary disease caused by NTM has 
a major threat with CF and difficult to diagnose and problematic to treat according 
to the US Cystic Fibrosis Foundation (CFF) and European Cystic Fibrosis Society 
(ECFS). Additionally, the most common NTM species identified in CF are the 
slow-growing Mycobacterium avium complex (MAC) including M. intracellulare, 
M. avium, and M. chimaera and the rapid-growing M. abscessus complex (MABSC) 
including subspecies of M. a. abscessus, M. a. massiliense, and M. a. bolletii. Other 
less common NTM species include M. kansasii, M. simiae, and M. fortuitum [24].
In addition, there are more than 100 types of NTM, and more are being found 
every year. The reported prevalence of NTM in CF varies widely from 45 to 40% 
with Mycobacterium avium complex and Mycobacterium abscessus complex being the 
most common [25, 26].
4. Airway colonization process in patients with cystic fibrosis
Colonization of microorganisms in respiratory tract infection within young CF 
patient includes common pathogens such as S. aureus or H. influenza then succeeded 
by P. aeruginosa infection in the latter stages of CF.
It is well established that Pseudomonas aeruginosa is a frequent and virulent 
pulmonary pathogen in patients with CF [27]. After a period of intermittent coloni-
zation, the organism becomes permanently established and is difficult to eradicate. 
Most patients with CF become chronically infected with wild-type P. aeruginosa 
strains in early childhood [28]; prevalence increases with age, so that as many as 
80% of patients with CF are infected by the time they reach 20 years [27]. During 
the years following initial colonization, the wild-type strains uniformly mutate into 
mucoid variants [28]. Conversion to the mucoid phenotype is thought to be driven 
by the unique CF microenvironment [29–31]. For patients with CF, this conversion 
results in a significant increase in morbidity and mortality accompanied by a mea-
surable decline in pulmonary function [28]. The mucoid matrix is believed to allow 
the formation of protected biofilm microcolonies [30, 32] and provide increased 
resistance to opsonization, phagocytosis, and digestion [33]. Furthermore, resis-
tance to various antibiotics is increased [27, 34].
The potentiality of pathogenic bacterial colony morphotypes in P. aeruginosa 
evolved to a non-swimming phenotype form. So, motility is considered as one of 
the first steps of P. aeruginosa in CF lungs that lead to adaptation steps including 
biofilm formation and progress to chronic infection. Also, impaired swimming 
motility seemed to be a candidate to disease marker of P. aeruginosa infection 
development. So far, the pathological changes in the lungs are best studied due to 
the high mortality rates linked to poorer lung function and recurrent development 
of infections [18].
Also, the lungs of people with cystic fibrosis are predominantly colonized with 
Pseudomonas aeruginosa using the following mechanism: firstly, reduced mucocili-
ary clearance combined with the malfunction of antibacterial peptides; secondly, 
impaired defense of the lungs due to low levels of glutathione and nitrous oxide; 
thirdly, reduced ingestion of bacteria by lung cells; and finally, increased numbers 
of bacterial receptors [35].
On the other hand, earlier age of infection with P. aeruginosa in our population 
was strongly associated with greater likelihood of severe lung disease later in life, 
most particularly in those subjects who acquired P. aeruginosa before the age 5; the 
27
Recent Approach in Microbial Pathogen Complications in Patients with Cystic Fibrosis
DOI: http://dx.doi.org/10.5772/intechopen.91635
observed association was stronger in females than in males. P. aeruginosa infection 
may be a cause of more severe CF lung disease but may also be a marker of some 
other processes determining lung function in children with CF [36].
5. Fungal infection in patients with cystic fibrosis
Fungi are generally divided into molds or yeasts with the latter circumferentially 
shaped with a one-celled thallus. Molds also known as filamentous fungi grow 
as branching cylindrical hyphae [1]. Aspergillosis is the most well-characterized 
and well-recognized Aspergillus disease in CF, but reported prevalence varies 
significantly and is likely to be underdiagnosed. Aspergilli are saprophytic, spore-
forming, filamentous fungi found ubiquitously in the environment. A. fumigatus is 
the most prevalent species causing human disease and is the species most frequently 
isolated from the respiratory secretions of CF patients [37].
Yet, the relative contribution of other emerging pathogens, such as S. maltophilia, 
Aspergillus, Candida, and Scedosporium species, remains less precisely defined. 
Aspergillus fumigatus is the only species that is associated with an increased risk for 
infection with P. aeruginosa [9]. Candida sp. is found in as many as 70% of patients 
with CF. The clinical significance of Candida in patients with CF is not clearly under-
stood, but most clinicians discount these organisms as not significant [38]. Fungemia 
caused by Trichosporon has been reported in two patients with CF, who were double 
lung transplant recipients [39]. Some species such as Exophiala dermatitidis grow as 
unicellular fungi (yeast) at human body temperature but in the case of filamentous 
fungi at room temperature. Trichosporon species as of any Candida species may 
produce true mycelium in culture conditions or in host tissues. So, there are varia-
tions in isolation and purification of yeast and filamentous fungi. Additionally, some 
fungal strains are thermotolerant filamentous mycota such as Aspergillus fumigatus 
which are the most common, and others include Scedosporium species and E. derma-
titidis [1]. A. fumigatus is frequently detected in respiratory secretions of both adults 
and children with CF. Once present in the airways, Aspergillus can exacerbate lung 
inflammation, establish infection, and trigger hypersensitivity responses [10].
In patients with CF, complications increased when exposed to A. fumigatus 
spores causing impaired mucociliary clearance and defective innate immune 
responses leading to accumulation and persistence of fungal spores within the 
smaller airways. Also, germination of spores leads to the formation of fungal 
hyphae and release of antigens, phospholipases, proteases, and other virulence fac-
tors which damage the airway of epithelial cells and allow a large dose of antigenic 
factors access to the interstitial and vascular compartments [40].
Also, exotic genera can be found in CF airway secretions, such as Penicillium, 
Alternaria, or Scedosporium. Some studies provide the first evidence that even 
healthy airways are not sterile and contain distinct fungi called “pulmonary myco-
biome.” The kinetics, dynamics, and disease relevance of the pulmonary myco-
biome, however, are poorly understood [7]. The majority of yeasts in CF belong 
to Candida species and the most common species such as Candida albicans and 
other yeast strains recorded such as Candida parapsilosis, Candida krusei, Candida 
glabrata, and Candida dubliniensis [1].
6. Viral infection in patients with cystic fibrosis
Progression of CF respiratory disease is influenced by viral infection. 
Respiratory viral infections include respiratory syncytial virus (RSV), rhinovirus, 
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influenza, para influenza, and adenovirus which is RSV and influenza infection 
leading to decreases in lung function [41]. Also, viral respiratory infections show 
pronounced and long-lasting effects on patients with CF, resulting in significant 
declines in forced vital capacity (FVC), forced expiratory volume in 1 second  
(FEV-1), and significant increases of both the frequency and duration of hospi-
talizations especially that the frequency of viral respiratory infections is closely 
associated with pulmonary deterioration in patients with CF [42]. Additionally, 
viral respiratory infections occur in equal frequency in CF patients and healthy 
controls which in CF patients viral upper respiratory tract infections are associated 
with lower respiratory tract symptoms in 31–76%. Viral infections cause long-term 
respiratory morbidity in CF patients [43].
7. Prevention and control of microorganisms in cystic fibrosis
Despite the development of antibiotics and vaccines, patients with CF are still 
faced with many debilitating and fatal infections, which demonstrate the adapt-
ability of microbial pathogens [44]. The choice of antibiotic depends on in vitro 
sensitivity patterns. Physicians treating patients with CF are increasingly faced with 
infection with multidrug-resistant strains of Pseudomonas aeruginosa. Also, innately 
resistant organisms such as Burkholderia cepacia, Stenotrophomonas maltophilia, and 
Achromobacter xylosoxidans become more prevalent [45].
Additionally, many studies resulted in strong indicator for a relevant importance 
of mutators in bacterial populations especially in infectious diseases. High preva-
lence and mutators are recorded environmentally in chronic respiratory infection 
with Pseudomonas aeruginosa in CF patients [46].
7.1 Strategies and guidelines for bacterial infection control within CF patients
Guidelines on infection control developed for general patient populations are 
applicable to CF patients. Historically, before 1998, guidelines on infection control 
were applied to acute-care hospitals. Recently it includes for non-acute-care set-
tings. Also, it has shifted from hospitals to home and outpatient clinics to reduce 
days of hospitalization and provide chronic suppressive treatments. Infection con-
trol in CF guidelines has been developed by Healthcare Infection Control Practices 
Advisory Committee (HICPAC) and Centers for Disease Control and Prevention 
(CDC) [47].
Common pathogens that infect the lungs of CF patients include Staphylococcus 
aureus, Haemophilus influenzae, Pseudomonas aeruginosa, and Burkholderia cepacia. 
Aggressively treating pulmonary infection with antibiotics has contributed to 
improved survival in patients with CF but has also promoted multiple drug-resis-
tant bacteria [48].
Antibiotic therapy leads to improvement in lung function, the best predictor of 
survival in CF patients which treat CF lung disease morbidity based on decisions 
with which antibiotics are selected according to broad empirical and based on the 
severity of the patient’s pulmonary exacerbation, the colonizing microorganisms, 
and the patient’s age [49].
A range of anaerobic bacterial species are present in huge numbers in the lungs 
of CF patients, which contribute significantly to infection and inflammation in the 
CF lung. So, informed alterations of antibiotic treatment to target anaerobes is done, 
in addition to the primary infecting pathogens, may improve management [50].
A positive approach to the protection of the lung from early in life seems to be 
the only way to change the slope of the survival curves [51]. Ticarcillin can be used 
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in the treatment of pulmonary exacerbations of cystic fibrosis due to susceptible 
strains of Pseudomonas aeruginosa [52, 53].
Also, Alcaligenes bacterial strains are characterized as motile, Gram-negative, 
producing oxidase enzyme. The most common is Alcaligenes xylosoxidans known as 
Achromobacter xylosoxidans. The bacterial genus is composed of three main species 
such as Achromobacter piechaudii, Achromobacter xylosoxidans, and Achromobacter 
faecalis. These bacterial strains observed multiple antibiotic resistance especially 
grouped of aminoglycosides and recorded sensitivity to cephalosporins (third 
generation) [54].
7.2 Inhalational antibiotics for the treatment of Pseudomonas aeruginosa
In recent years, there are emergences of inhaled antibiotics to treat patients with 
Gram-negative bacterial infection such as P. aeruginosa infection. The benefits of 
which are explained below [55, 56].
Inhaled tobramycin, inhaled colistin, and inhaled aztreonam are used to control 
chronic P. aeruginosa infections in patients with CF [57]. In CF, tobramycin inhala-
tion solution contributed to improved survival and reduced lung function decline 
[58]. Subsequently, the development of antibiotic agents can achieve high tissue 
concentrations to control bacterial infection that is difficult to treat in hosts [59]. 
Inhaled tobramycin achieves a sputum concentration of drug at least 25 times the 
MIC, with a median serum/sputum concentration of 0.01. Such high concentrations 
are required for the effective killing of P. aeruginosa because aminoglycosides bind 
to mucins in sputum and reduce the availability of effective antibiotic. Also, early 
randomized, double-blind, placebo-controlled trials conducted in patients with CF 
were short-term but demonstrated positive results with the use of aztreonam solu-
tion for inhalation compared to placebo. Colistin is bactericidal and active against 
Gram-negative bacteria including P. aeruginosa. Nebulized colistin is a preferred 
inhaled therapy for patients with CF and chronic P. aeruginosa [59]. Inhaled levo-
floxacin was studied in patients with CF and P. aeruginosa lung infection. Also, 
nebulized levofloxacin solution (MP-376) is a novel therapy that is currently being 
evaluated in phase I, II, and III clinical trials among patients with stable CF and 
recent isolation of Pseudomonas aeruginosa from sputum [60].
7.3 Antifungal therapy to control yeasts and filamentous fungi with CF patients
Antifungal therapy is usually considered when the deteriorating respiratory 
function is not responding to antibacterial therapy and A. fumigatus is growing and 
identified in sputum cultures [61]. Long-term antifungal treatment with mold active 
azoles, the only class of antifungals with an oral formulation, is not without risk of 
toxicity and adverse events and should be carefully balanced against its benefit [10].
A. fumigatus can grow in sputum cultures, and antifungal therapy is not effective 
[61]. Also, Scedosporium sp. is the second most frequent cystic fibrosis associated 
filamentous fungi which is resistant to many antifungal agents [62].
In CF, Candida albicans causes 95% of all Candida infections, whereas the 
remainder is caused by Candida glabrata, Candida parapsilosis, and Candida krusei. 
Also, Candida dubliniensis has been isolated in CF; however, little is known about its 
potential for virulence, and treatment modality is not clearly defined [63].
7.4 Antiviral therapy to control respiratory viruses with CF patients
Respiratory viruses associated with exacerbations in CF patients and upper 
respiratory symptoms are strong predictors for their presence. Some studies have 
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influenza, para influenza, and adenovirus which is RSV and influenza infection 
leading to decreases in lung function [41]. Also, viral respiratory infections show 
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in the treatment of pulmonary exacerbations of cystic fibrosis due to susceptible 
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inhaled therapy for patients with CF and chronic P. aeruginosa [59]. Inhaled levo-
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nebulized levofloxacin solution (MP-376) is a novel therapy that is currently being 
evaluated in phase I, II, and III clinical trials among patients with stable CF and 
recent isolation of Pseudomonas aeruginosa from sputum [60].
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identified in sputum cultures [61]. Long-term antifungal treatment with mold active 
azoles, the only class of antifungals with an oral formulation, is not without risk of 
toxicity and adverse events and should be carefully balanced against its benefit [10].
A. fumigatus can grow in sputum cultures, and antifungal therapy is not effective 
[61]. Also, Scedosporium sp. is the second most frequent cystic fibrosis associated 
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respiratory symptoms are strong predictors for their presence. Some studies have 
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suggested a role played by respiratory viruses in exacerbation of CF. The impact of 
respiratory viruses is likely to be underestimated due to the low detection rate by 
conventional laboratory methods. Molecular techniques such as multiplex PCR have 
improved their diagnostic accuracy identifying respiratory viruses in CF patients 
which are important in clinical decision-making and are potentially important 
as new antivirals are becoming readily available [64]. A few therapeutic options 
recorded to treat virus-induced CF pulmonary exacerbations include macrolide 
antibiotic (azithromycin). It has antiviral properties of the human bronchial epi-
thelial cells and stimulates antiviral mechanisms in bronchial epithelial cells within 
the CF airway control infection with rhinovirus by reducing rhinovirus replication 
as an interferon pathway [65]. Also, there are exciting prospects such as antiviral 
host defense peptides in development and can be novel therapeutics targeting 
rhinovirus [66].
Additionally, CF patients infected with influenza A(H1N1) showed increased 
case fatality rate (CFR) and morbidity compared to patients with other chronic 
respiratory diseases, so, early antibiotic and antiviral treatment strategies are 
important to control it in CF patients [67].
8. Conclusion
This chapter concludes that complications of microorganisms associated with 
cystic fibrosis disease are very high and can lead to patient death. Pathogenic 
microorganisms isolated from CF patients included Gram-negative bacteria, Gram-
positive bacteria, unicellular fungi, multicellular fungi, and viruses.
The most common Gram-negative bacterial pathogens are Pseudomonas aerugi-
nosa and Haemophilus influenzae. Also, the most common Gram-positive bacterial 
pathogen is Staphylococcus aureus especially MRSA. Other bacterial pathogens 
are isolated from CF patients, such as NTM species, Alcaligenes xylosoxidans, and 
Burkholderia cenocepacia.
In addition, Candida albicans is the most common unicellular fungi, and 
Aspergillus fumigatus is the most common filamentous fungi. Influenza A and B 
viruses are major viruses in causing respiratory exacerbations in CF, and both 
viruses are more commonly detected during pulmonary exacerbations.
To prevent this microbial complication, appropriate antimicrobials can be 
used to treat bacterial infections, antifungal therapy for treating pathogenic fungi 
and antiviral to manage viral infections. With prospects, researchers must work 
to produce new therapeutic options to control multidrug-resistant bacteria and 
resistant fungi and virus. These new treatment options may further enhance the 
prognosis in patients with CF.
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Overview of CFTR Modulators 
and Gene Therapy
Catherine Rang, Tom Kotsimbos and John Wilson
Abstract
Individuals with cystic fibrosis (CF) have seen a substantial change in their life 
expectancy since the introduction of coordinated multi-disciplinary care. This is 
expected to continue with the recent availability of treatment options that focus on 
targeting the underlying genetic defect. Two different approaches to altering the 
consequence of mutations in the cystic fibrosis transmembrane conductance regula-
tor (CFTR) gene include “genetic medicines”, in particular gene therapy, and CFTR 
modulator agents. Gene therapy requires further development prior to it being a 
treatment option because to date the best clinical outcomes are that of a reduction 
in the rate of lung function decline. Modulator therapies on the other hand have 
provided exciting results in both clinical trials and real-world settings. Potentiator 
agents alter dysfunctional ion channel gating and are suitable for gating mutations. 
Corrector agents target abnormal protein trafficking. The combination of potentia-
tor and corrector therapy provides options for homozygotes with the commonest 
mutation Phe508del and for those with Phe508del and some residual function 
mutations. Newer modulator therapies are in continued development with progres-
sively impressive outcomes. It is likely that future CF care will comprise of personal-
ized strategies with the focus centered upon an individual’s specific mutations.
Keywords: cystic fibrosis, CF pathophysiology, CFTR modulator therapy,  
gene therapy
1. Introduction
Cystic fibrosis (CF) is an autosomal recessive condition that results from 
mutations in the cystic fibrosis transmembrane conductor regulator (CFTR) gene 
located on the long arm of chromosome 7. The gene was identified 30 years ago 
and since then over 2000 CFTR mutations have been discovered with more than 
300 known to be disease causing [1, 2]. The commonest mutation is Phe508del 
(F508del; c.1521_1523delCTT), where a phenylalanine is substituted at position 508 
on chromosome 7. Worldwide approximately 80–90% of individuals with CF have 
at least one copy of the Phe508del-CFTR mutation, although mutation rates varying 
depending upon the population cohort [3–5].
CF is a multi-system disease with the highest disease prevalence being in 
Europe, North America and Australia. There are approximately 80,000 people with 
CF worldwide. The disease is characterized by chronic airway infection, pancreatic 
insufficiency and malnutrition, diabetes, liver disease, absent vas deferens and 
premature death.
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on chromosome 7. Worldwide approximately 80–90% of individuals with CF have 
at least one copy of the Phe508del-CFTR mutation, although mutation rates varying 
depending upon the population cohort [3–5].
CF is a multi-system disease with the highest disease prevalence being in 
Europe, North America and Australia. There are approximately 80,000 people with 
CF worldwide. The disease is characterized by chronic airway infection, pancreatic 
insufficiency and malnutrition, diabetes, liver disease, absent vas deferens and 
premature death.
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Due to the multi-system nature of the disease, treatment has classically focused 
on therapies and systems of care that aim to improve salt and fluid balance and 
nutritional status, alongside reducing airway inflammation and lung parenchymal 
destruction. These multi-disciplinary management approaches have been instru-
mental in the improvements seen in life expectancy. The median predicated survival 
of an individual born today with CF is 47 years, compared with 20 years at the time 
when CFTR was discovered in 1989 [2]. However, to have a true impact upon the 
management of these patients and to alter the disease trajectory, treatment options 
needed to also include approaches targeting the underlying genetic mutation.
This chapter will include a review of the structure of the CFTR protein, its 
biosynthesis and the pathophysiology of CF so as to provide a basis from which to 
discuss the various therapeutic strategies that have more recently been developed 
for modulating CFTR protein function. Also, a discussion regarding gene therapy 
will be included so as to enable contrasts and comparisons to be made between the 
different therapies being evolved to address the underlying genetic defect in CF 
patients.
2. Pathophysiology of cystic fibrosis
2.1 CFTR protein structure
CFTR codes for a complex protein, which is present in every nucleated cell of 
the body, however it is normally concentrated on the apical membrane of epithelial 
cells, primarily within the glandular epithelia. High expression of this apical anion 
channel is seen within the lungs, pancreas, gastrointestinal tract, vas deferens and 
sweat glands; reflecting the main organs affected in CF [6].
The CFTR protein is a large, unique member of the subclass C family of the ATP 
binding cassette (ABC) transporter proteins, which functions as an ion channel 
rather than an active transporter protein [7–9]. It consists of two membrane-
spanning domains (MBDs) that form the ion channel. These domains are both 
connected to two cytoplasmic nucleotide-binding domains (NBD1 and NBD2), 
which function to gate the channel. This conformation of two MBDs and two NBDs 
that hydrolyse ATP are typical for most ABC transporters. However, CFTR has an 
additional cytoplasmic regulatory domain (R domain), inserted between NBD1 
and MSD2 linking the two transporter domains. Phosphorylation of the R domain 
by protein kinase A enables channel opening to occur and channel activity is 
increased upon phosphorylation. Once phosphorylation has taken place, ATP binds 
to the NBDs resulting in the two NBDs forming tightly interacting dimers, which 
gates the channel. These movements are transmitted to the MBDs causing the ion 
pore to open. Channel closure results from ATP hydrolysis. The exact mechanisms 
underlying the regulation of the R domain and ATP-dependent gating are still not 
completely understood [10, 11].
2.2 CFTR protein synthesis
CFTR protein synthesis is a complex process, in part related to the size of the 
functional protein. As with all protein synthesis, transcription of the CFTR DNA 
takes place within the nucleus to create the messenger RNA (mRNA), which is trans-
ported across the nuclear membrane to the cytosolic ribosomes. There the initiation 
of translation occurs to create a 1480-amino acid polypeptide chain based upon the 
genetic code. Initially a 135- to 140-kDa core-glycosylated precursor is produced 
(immature CFTR). CFTR biosynthesis then proceeds through the endoplasmic 
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reticulum (ER) followed by the Golgi apparatus to a mature 150- to 160-kDa CFTR 
form which has undergone conformational folding [12]. During the secretory 
pathway through the ER to the Golgi and then on to the cell membrane various post-
translational modifications take place (Figure 1).
The maturation process to create the final relatively compact CFTR protein 
structure is inefficient and slow. Less than 30% of newly synthesized wild-type (wt) 
immature CFTR molecules develop into mature CFTR proteins. For folding of the 
polypeptide chain to occur chaperones are required, in particular the 70 k-Da heat 
shock proteins (HSP70) and calnexin. In cells of individuals with the Phe508del-
CFTR mutation, almost all immature molecules fail to reach final maturity and thus 
are degraded. This is the due to the quality control mechanisms in place within the 
ER, specific signals and distinct processes exist that recruit misfolded proteins to the 
ER-associated degradation as a final endpoint. These proteins are then directed for 
degradation via the ubiquitin-proteasome pathway [12–14] (Figure 1).
Certain steps within the CFTR biosynthesis pathway are still unknown, how-
ever, data does support each domain folding independently. The native structure 
develops through a co-translational mechanism, possibly together with post-
translational processes that take place to create the compactly folded domains. 
Domain-domain interactions are key in the creation of conformationally correct 
CFTR [15]. Furthermore, it appears that CFTR is more sensitive to mutations in 
NBD1 compared with homologous mutations in NBD2, leading to issues with the 
conformational maturation of the whole CFTR protein. For example, the deletion 
of the Phe508 does not appear to grossly alter the structure of NBD1 but subsequent 
issues arise during the maturation process, possibly through the disruption of the 
interaction between NBD1 and NBD2 and despite each domain folding indepen-
dently. Maturation thus requires precise folding of each domain together with the 
Figure 1. 
Cell biology of CFTR - abnormal CFTR protein results in the uncoupling of CFTR dependent processes at all 
levels from intracellular dynamics to cell membrane function. Reproduced with permission of the © ERS 2020: 
European Respiratory Journal; DOI: 10.1183/13993003.02443-2019: Accepted for publication and in press.
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polypeptide chain to occur chaperones are required, in particular the 70 k-Da heat 
shock proteins (HSP70) and calnexin. In cells of individuals with the Phe508del-
CFTR mutation, almost all immature molecules fail to reach final maturity and thus 
are degraded. This is the due to the quality control mechanisms in place within the 
ER, specific signals and distinct processes exist that recruit misfolded proteins to the 
ER-associated degradation as a final endpoint. These proteins are then directed for 
degradation via the ubiquitin-proteasome pathway [12–14] (Figure 1).
Certain steps within the CFTR biosynthesis pathway are still unknown, how-
ever, data does support each domain folding independently. The native structure 
develops through a co-translational mechanism, possibly together with post-
translational processes that take place to create the compactly folded domains. 
Domain-domain interactions are key in the creation of conformationally correct 
CFTR [15]. Furthermore, it appears that CFTR is more sensitive to mutations in 
NBD1 compared with homologous mutations in NBD2, leading to issues with the 
conformational maturation of the whole CFTR protein. For example, the deletion 
of the Phe508 does not appear to grossly alter the structure of NBD1 but subsequent 
issues arise during the maturation process, possibly through the disruption of the 
interaction between NBD1 and NBD2 and despite each domain folding indepen-
dently. Maturation thus requires precise folding of each domain together with the 
Figure 1. 
Cell biology of CFTR - abnormal CFTR protein results in the uncoupling of CFTR dependent processes at all 
levels from intracellular dynamics to cell membrane function. Reproduced with permission of the © ERS 2020: 
European Respiratory Journal; DOI: 10.1183/13993003.02443-2019: Accepted for publication and in press.
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correct inter-domain assembly to create a stable structure that will not be submitted 
to ER-associated degradation [13, 16].
If the protein passes through all the checkpoint steps within the ER, it can exit 
and be transported through the Golgi apparatus in vesicles where the removal and 
addition of new glycan units takes place, increasing the molecular size of CFTR. It 
is becoming clear that some wt-CFTR might bypass these processes in the delivery 
pathway to the plasma membrane. Once at the membrane, levels of CFTR vary 
depending upon the balance of anterograde trafficking, endocytosis and recycling. 
Recycling of internalized CFTR to the plasma membrane is thought to assist with 
sustaining a functional pool of CFTR at the membrane level [15].
2.3 Pathophysiology
CFTR functions as a chloride and bicarbonate channel. Loss of functional CFTR 
proteins result in reduced chloride efflux from epithelial cells leading to depletion 
of the cell surface fluid and altering its pH and osmolarity. CFTR also regulates the 
activity of various other key processes within the cell, including the activity of other 
ion channels, such as the sodium epithelial channel (ENaC; the amiloride-sensitive 
sodium channel). Suppressed CFTR activity can lead to unopposed reabsorption of 
sodium and water via ENaC, causing additional dehydration of the cell surface layer 
[6]. Mucociliary clearance is further delayed due to abnormally adherent mucus. 
Dysfunctional CFTR also impacts upon mitochondrial function, the innate immunity 
and dysregulates inflammation [17–19]. Within the airways, this results in an environ-
ment that is susceptible to unchecked inflammation and chronic bacterial infection.
Although multiple processes both intra- and extra-cellularly are altered by 
dysfunctional CFTR proteins, chloride transport at the cell surface is generally con-
sidered to be the major driver of the pathophysiological disease. Functional chloride 
channel changes are thus likely to represent an easily accessible surrogate marker 
of all processes affected in CF, with sweat chloride testing being relatively easy to 
perform. In vitro studies have shown that only 6–10% of residual CFTR function is 
required to restore chloride transporting properties seen in 100% correct cells, with 
cell-cell coupling providing a means of amplification of the functional properties 
[20]. Individuals with CF who have approximately 10% CTFR expression per cell do 
not generally develop lung disease or the full range of classical CF disease. To date, 
it is unclear whether low level expression (10%) of CFTR in all cells is comparable 
to 10% of CFTR cells with full correction [21]. In addition, even individuals with a 
single CFTR mutation may have organ dysfunction in the context of a second “hit” 
such as smoking [22].
The general identification of mutations in the structure of CFTR has been 
centralized for clinician reference. CFTR2.org identifies over 2000 variants of the 
protein, of which over 400 are disease-associated. The majority of variants are rare 
and not confirmed to be disease-associated, however the large number of variants 
indicates the lack of stability of the CFTR gene in population dynamics [1].
3. Classification of CFTR mutations
Classification systems of common CFTR mutations have been developed to 
assist with understanding of the consequential molecular defect. The established 
classification system includes six different classes (Figure 2). Different mutations 
can result in no functional protein production, impaired protein trafficking, altered 
channel gating, decreased channel conductance, reduced protein synthesis and 
decreased protein stability [6]. Each class confers a different disease severity, which 
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is related to the degree of CFTR dysfunction and has prognostic implications for 
patients. However, each mutation may have features of more than just one class. 
For example, Phe508del is predominately a class II mutation but also has both class 
III and class VI properties. More recently, other classification systems have been 
proposed, which subdivide class I mutations (no functional CFTR protein) into 
two groups so as to take into account whether the mutation leads to no mRNA or no 
functional protein [23].
4. Genetic medicines
Traditional CF care has focused upon the management of the systems affected 
in individuals with CF. However, the identification of the CFTR gene enabled 
researchers to focus on treatments strategies, which could address the underlying 
genetic defect. The major cause of morbidity and mortality in CF is secondary to 
lung disease. Hence, if abnormal CFTR in the lungs could be replaced with wt-
CFTR during the neonatal period, prior to parenchymal lung damage or bacterial 
colonization, morbidity and mortality could be significantly altered within the 
CF population [24]. Various approaches have been investigated within the field of 
“genetic medicines” and unfortunately to date none are a viable treatment option 
outside of clinical trials.
Figure 2. 
CFTR classification table. The classification systems divide mutations into discrete groups determined by 
the predominant CFTR defect. However, these systems may not be mutually exclusive for all mutations. 
For example, the p.Phe508del-CFTR is predominately class II but does also have some class III and class 
VI properties. Reproduced with permission of the © ERS 2020: European Respiratory Journal; DOI: 
10.1183/13993003.02443-2019: Accepted for publication and in press.
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pathway to the plasma membrane. Once at the membrane, levels of CFTR vary 
depending upon the balance of anterograde trafficking, endocytosis and recycling. 
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of the cell surface fluid and altering its pH and osmolarity. CFTR also regulates the 
activity of various other key processes within the cell, including the activity of other 
ion channels, such as the sodium epithelial channel (ENaC; the amiloride-sensitive 
sodium channel). Suppressed CFTR activity can lead to unopposed reabsorption of 
sodium and water via ENaC, causing additional dehydration of the cell surface layer 
[6]. Mucociliary clearance is further delayed due to abnormally adherent mucus. 
Dysfunctional CFTR also impacts upon mitochondrial function, the innate immunity 
and dysregulates inflammation [17–19]. Within the airways, this results in an environ-
ment that is susceptible to unchecked inflammation and chronic bacterial infection.
Although multiple processes both intra- and extra-cellularly are altered by 
dysfunctional CFTR proteins, chloride transport at the cell surface is generally con-
sidered to be the major driver of the pathophysiological disease. Functional chloride 
channel changes are thus likely to represent an easily accessible surrogate marker 
of all processes affected in CF, with sweat chloride testing being relatively easy to 
perform. In vitro studies have shown that only 6–10% of residual CFTR function is 
required to restore chloride transporting properties seen in 100% correct cells, with 
cell-cell coupling providing a means of amplification of the functional properties 
[20]. Individuals with CF who have approximately 10% CTFR expression per cell do 
not generally develop lung disease or the full range of classical CF disease. To date, 
it is unclear whether low level expression (10%) of CFTR in all cells is comparable 
to 10% of CFTR cells with full correction [21]. In addition, even individuals with a 
single CFTR mutation may have organ dysfunction in the context of a second “hit” 
such as smoking [22].
The general identification of mutations in the structure of CFTR has been 
centralized for clinician reference. CFTR2.org identifies over 2000 variants of the 
protein, of which over 400 are disease-associated. The majority of variants are rare 
and not confirmed to be disease-associated, however the large number of variants 
indicates the lack of stability of the CFTR gene in population dynamics [1].
3. Classification of CFTR mutations
Classification systems of common CFTR mutations have been developed to 
assist with understanding of the consequential molecular defect. The established 
classification system includes six different classes (Figure 2). Different mutations 
can result in no functional protein production, impaired protein trafficking, altered 
channel gating, decreased channel conductance, reduced protein synthesis and 
decreased protein stability [6]. Each class confers a different disease severity, which 
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is related to the degree of CFTR dysfunction and has prognostic implications for 
patients. However, each mutation may have features of more than just one class. 
For example, Phe508del is predominately a class II mutation but also has both class 
III and class VI properties. More recently, other classification systems have been 
proposed, which subdivide class I mutations (no functional CFTR protein) into 
two groups so as to take into account whether the mutation leads to no mRNA or no 
functional protein [23].
4. Genetic medicines
Traditional CF care has focused upon the management of the systems affected 
in individuals with CF. However, the identification of the CFTR gene enabled 
researchers to focus on treatments strategies, which could address the underlying 
genetic defect. The major cause of morbidity and mortality in CF is secondary to 
lung disease. Hence, if abnormal CFTR in the lungs could be replaced with wt-
CFTR during the neonatal period, prior to parenchymal lung damage or bacterial 
colonization, morbidity and mortality could be significantly altered within the 
CF population [24]. Various approaches have been investigated within the field of 
“genetic medicines” and unfortunately to date none are a viable treatment option 
outside of clinical trials.
Figure 2. 
CFTR classification table. The classification systems divide mutations into discrete groups determined by 
the predominant CFTR defect. However, these systems may not be mutually exclusive for all mutations. 
For example, the p.Phe508del-CFTR is predominately class II but does also have some class III and class 
VI properties. Reproduced with permission of the © ERS 2020: European Respiratory Journal; DOI: 
10.1183/13993003.02443-2019: Accepted for publication and in press.
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“Genetic medicines” comprise of four different treatment approaches:
i. Gene therapy: the delivery of wt-CFTR to the cell nucleus resulting in the 
production of normal CFTR protein;
ii. mRNA therapy: the delivery of correct CFTR mRNA to the cytoplasm 
resulting in the production of normal CFTR protein;
iii. Gene editing: repair of the mutant CFTR DNA with normal CFTR pro-
tein resulting. This requires wt-CFTR DNA to be delivered to the nucleus 
together with mRNA encoding a nuclease that causes a break in the DNA 
leading to recombination occurring;
iv. mRNA editing: CFTR mRNA delivery to the cytoplasm leading to repair of 
the CFTR mRNA [21].
The potential benefit of these therapies is that theoretically they should be suit-
able for the treatment of all individuals with CF, regardless of genotype. Currently 
gene therapy has made the greatest advancement towards being a clinical treatment 
and so the main focus of this section will be around gene therapy.
As the respiratory system is so central to CF disease and because initial thoughts 
were that gene therapy targeting the lungs would be easy to deliver, locally directed 
gene therapy to the respiratory epithelium was the method of choice. Furthermore, 
gene therapy can complement any CFTR causing mutation. However, for such 
treatment to be successful various issues had to be addressed, including the choice 
of delivery vector, method of delivery to the airways, translocation of the genetic 
information and ultimately ensuring that there was appropriate expression of the 
normalized CFTR gene [25]. These various issues will each be discussed to provide 
insight in the difficulties experienced in trying to develop “genetic medicines.”
The lungs are comprised of terminally differentiated epithelial cells, which are 
slowly replaced by stem/progenitor cells. Any form of gene therapy must be able to 
be either repeatedly delivered to the terminally-differentiated cell surface or be able 
to alter the stem/progenitor cells within the lungs. However, the lung has evolved 
physical and immune mechanisms to protect against pathogens and particulate 
materials, which impacts upon choice of vector delivery [26, 27].
Delivery vectors are largely either viral or non-viral in nature with viral ones 
felt to be more efficient. This is because they have evolved to overcome the barrier 
mechanisms present within the lungs. Adenoviruses (Ad) and adeno-associated 
viruses (AAV) have a natural trophism for the lungs, are DNA-based and thus were 
the initial choices to study. Adenoviruses are small in size and thus to insert the 
CFTR DNA correctly within the adenoviral genome, viral DNA must be removed, 
impacting upon the viral cytopathic effect. These vectors were found to have poor 
efficacy due to the pre-existing and induced immune responses, and thus cannot be 
repeatedly administered as required for these treatments because of the short life 
span of bronchial epithelial cells.
Other viral vectors that have been investigated are recombinant lentivirus (rLV). 
These agents are RNA-based and can integrate into the genome. This can be advan-
tageous as it ensures that the vector is passed down the cell lines during division but 
it also does have the risk of inducing insertional mutagenesis [21, 26, 28]. However, 
ultimately other vectors were needed to be formulated, ones which had a minimal 
risk of immunogenicity and thus could be repeatedly administered.
Non-viral gene transfer agents complexed to plasmid DNA were therefore devel-
oped [21, 29]. These have been more successful than their viral vector counterparts 
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and have been investigated in Phase IIb studies. Patients who were 12 years and 
older were treated with the non-viral CFTR gene-liposomal complex pGM169/
GLG7A as a nebulized therapy over a one-year period. The repeated nebulization 
each month resulted in a reduction in the progression of CF lung disease by a 
modest amount when compared with placebo. The percentage change in the forced 
expiratory volume in 1 second (FEV1) over 12 months was −0.4% versus −4.0% 
in the placebo arm. Hence, although no improvement in lung function was seen, 
this study was promising as rate of lung function decline does impact morbidity 
and mortality in CF. However, disappointingly also there were no improvements in 
quality of life measures [30].
As described in the above study the agents utilized were delivered via inhala-
tion methods. This has been found to be the easiest method for repeated treatment 
applications. However, difficulties have arisen ensuring adequate lung deposition 
of drug, related to particle size and the type of nebulisers used. Additionally, any 
aerolised drug delivered must retain its biological function post-delivery [31, 32].
Other strategies for ensuring corrected CFTR protein production is through 
mRNA therapy and mRNA repair as described above. The benefit of these 
approaches is that they do not require translocation of the therapy across the 
nuclear membrane. Nanoparticle-chemically modified mRNA has resulted in lung 
function improvements in animal models without any immune reactions despite 
repeated applications. Also, there is evidence that these therapies can restore chlo-
ride channel activity [33, 34]. Ongoing work and investigation are required prior to 
these options being viable in the clinical setting.
5. CFTR modulator agents
CFTR modulator agents are small molecules which ‘modulate’ the function 
of the abnormal CFTR protein. Unlike gene therapy, they do not alter the CFTR 
gene. However, these agents do manipulate the underlying genetic consequence 
of CF mutations. Currently two different classes of modulator agents have been 
developed;
i. potentiators which ‘potentiate’ the cAMP-mediated gating of the CFTR 
channel; and
ii. correctors which ‘correct’ defects in protein trafficking.
5.1 CFTR modulator drug design
High-throughput drug discovery programs enabled the development of such 
agents. These discovery programs were established to identify active compounds 
(“hits”) from large chemical libraries suitable for industrial-scale screening. 
High-throughput screening (HTS) assays need to be robust, have high throughput 
using small sample volumes together with adequate sensitivity, reproducibility and 
accuracy to ensure differentiation between a very large amount of compounds [35]. 
Ion channels are key targets for drug design and thus HTS have been an important 
part of such drug discovery processes, including for CF [36, 37].
The two classes of small molecules for CFTR protein modulation were identified 
via HTS techniques from libraries that consisted of chemically diverse drug-like 
and lead-like compounds acquired from both commercial vendors and internal 
medicine chemistry programs. If compounds had an activity >2.5 standard devia-
tions (SD) from the mean, then they received further testing. For example, from 
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materials, which impacts upon choice of vector delivery [26, 27].
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viruses (AAV) have a natural trophism for the lungs, are DNA-based and thus were 
the initial choices to study. Adenoviruses are small in size and thus to insert the 
CFTR DNA correctly within the adenoviral genome, viral DNA must be removed, 
impacting upon the viral cytopathic effect. These vectors were found to have poor 
efficacy due to the pre-existing and induced immune responses, and thus cannot be 
repeatedly administered as required for these treatments because of the short life 
span of bronchial epithelial cells.
Other viral vectors that have been investigated are recombinant lentivirus (rLV). 
These agents are RNA-based and can integrate into the genome. This can be advan-
tageous as it ensures that the vector is passed down the cell lines during division but 
it also does have the risk of inducing insertional mutagenesis [21, 26, 28]. However, 
ultimately other vectors were needed to be formulated, ones which had a minimal 
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each month resulted in a reduction in the progression of CF lung disease by a 
modest amount when compared with placebo. The percentage change in the forced 
expiratory volume in 1 second (FEV1) over 12 months was −0.4% versus −4.0% 
in the placebo arm. Hence, although no improvement in lung function was seen, 
this study was promising as rate of lung function decline does impact morbidity 
and mortality in CF. However, disappointingly also there were no improvements in 
quality of life measures [30].
As described in the above study the agents utilized were delivered via inhala-
tion methods. This has been found to be the easiest method for repeated treatment 
applications. However, difficulties have arisen ensuring adequate lung deposition 
of drug, related to particle size and the type of nebulisers used. Additionally, any 
aerolised drug delivered must retain its biological function post-delivery [31, 32].
Other strategies for ensuring corrected CFTR protein production is through 
mRNA therapy and mRNA repair as described above. The benefit of these 
approaches is that they do not require translocation of the therapy across the 
nuclear membrane. Nanoparticle-chemically modified mRNA has resulted in lung 
function improvements in animal models without any immune reactions despite 
repeated applications. Also, there is evidence that these therapies can restore chlo-
ride channel activity [33, 34]. Ongoing work and investigation are required prior to 
these options being viable in the clinical setting.
5. CFTR modulator agents
CFTR modulator agents are small molecules which ‘modulate’ the function 
of the abnormal CFTR protein. Unlike gene therapy, they do not alter the CFTR 
gene. However, these agents do manipulate the underlying genetic consequence 
of CF mutations. Currently two different classes of modulator agents have been 
developed;
i. potentiators which ‘potentiate’ the cAMP-mediated gating of the CFTR 
channel; and
ii. correctors which ‘correct’ defects in protein trafficking.
5.1 CFTR modulator drug design
High-throughput drug discovery programs enabled the development of such 
agents. These discovery programs were established to identify active compounds 
(“hits”) from large chemical libraries suitable for industrial-scale screening. 
High-throughput screening (HTS) assays need to be robust, have high throughput 
using small sample volumes together with adequate sensitivity, reproducibility and 
accuracy to ensure differentiation between a very large amount of compounds [35]. 
Ion channels are key targets for drug design and thus HTS have been an important 
part of such drug discovery processes, including for CF [36, 37].
The two classes of small molecules for CFTR protein modulation were identified 
via HTS techniques from libraries that consisted of chemically diverse drug-like 
and lead-like compounds acquired from both commercial vendors and internal 
medicine chemistry programs. If compounds had an activity >2.5 standard devia-
tions (SD) from the mean, then they received further testing. For example, from 
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~164,000 synthetic compounds initial screened, approximately 100 were suitable 
for further study in one study [38]. The molecules identified were optimized and 
evaluated in terms of pharmacokinetics and toxicology [39, 40].
5.2 Potentiator therapy
The first small molecule clinically available for individuals with CF following 
HTS was Ivacaftor (Kalydeco®). It is an oral CFTR potentiator agent, which can be 
given to CF individuals who have gating, residual function, splice or conduction 
mutations [41–44]. It was originally developed for the Gly551Asp-CFTR muta-
tion (G551D; a class III mutation), which results in defective cAMP CFTR channel 
gating. The gating of the channel reflects the opening and closed states of the CFTR 
protein. If gating is defective, then a low probability of CFTR channel opening 
occurs and in turn reduced overall CFTR function. Ivacaftor treatment results in 
increased chloride transportation across the cell membrane by improving channel 
gating and thus the time that activated CFTR channels remain open.
The initial phase 3 studies in individuals aged 12 years and older (STRIVE) 
and those aged between 6 and 12 years of age (ENVISION) evaluated ivacaftor or 
placebo in patients with at least one Gly551Asp-CFTR mutation. STRIVE identi-
fied a significant improvement in percentage predicted (pp) FEV1 in the treatment 
arm of 10% at 24 weeks (primary endpoint) that was maintained at 48 weeks. This 
was together with a 3 kg weight gain, an 8-point increase in the Cystic Fibrosis 
Questionnaire Revised (CFQ-R) score (an increase in the score out of 100 reflects 
an improvement in quality of life with a 4-point change being clinically relevant) 
alongside a reduction in sweat chloride to below the definite diagnostic threshold 
for CF to a mean of 47.8 mmmol/l [41]. Similar results were demonstrated in chil-
dren in ENVISION [45]. Participants from both of these studies were then enrolled 
into the open-labeled extension study (PERSIST) where all individuals received 
ivacaftor therapy. These individuals maintained the improvements in lung func-
tion, weight and exacerbation rates at 144 weeks [46].
5.3 Monotherapy for Phe508del mutations
Such exceptional clinical outcomes were a major advancement in the treatment 
options for individuals with CF. However, initially modulator therapy was only 
suitable for approximately 5% of CF individuals as it was only available for gated 
mutations. Agents that could alter abnormal protein trafficking together with CFTR 
channel gating and cell membrane surface stability that results from the Phe508del-
CFTR mutation (class II mutation) would have a far greater impact upon the CF 
community. As multiple stages in the CFTR conformational maturation process are 
affected with the Phe508del-CFTR mutation, different treatment approaches were 
needed.
HTS therefore progressed to evaluating agents that would be suitable for other 
mutation classes, focusing on agents could have an impact on dysfunctional protein 
trafficking [38]. Lumacaftor is an oral corrector agent, which in vitro studies have 
demonstrated can corrects protein misfolding [47]. However, monotherapy with 
either ivacaftor or lumacaftor did not lead to clinically relevant improvements in 
individuals homozygous for the p.Phe508del-CFTR mutation [48, 49].
5.4 Combination therapy: potentiator and corrector agents
As monotherapy only lead to minimal clinically relevant outcomes for 
Phe508del-homozygotes, the argument strengthened for the use of lumacaftor in 
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combination with ivacaftor. Hence, these two therapies were trialed in combination 
(Orkambi®). Phase 3 multicentre studies (TRAFFIC and TRANSPORT) of this 
combination versus placebo elicited a modest gain in absolute pp. FEV1 of 3% at 
24 weeks (primary endpoint) together with significant increases in body mass index 
(BMI) [50]. The lung function increase being comparatively small to that seen with 
ivacaftor for gated mutation. However, importantly the 96-week open label exten-
sion study (PROGRESS), where all individuals within the initial trials received 
lumacaftor in combination with ivacaftor, did demonstrate a 42% reduction in the 
annual rate of lung function decline when compared with matched US registry 
controls [51]. As rate of lung function decline is known to correlate with morbidity 
and mortality, this is still a significant outcome [52, 53].
Although lumacaftor in combination with ivacaftor is associated with stabiliza-
tion of lung disease together with weight improvement, patients can experience 
various side-effects. Respiratory related adverse events were the commonest 
complications in the trials and up to 7% of patients discontinued treatment in 
PROGRESS. In real-world experiences, there have been even higher discontinu-
ation rates of up to 30% [54, 55]. Also, lumacaftor is a potent inducer of the 
CYP3A4 enzymes and can have interactions with various concurrent medications. 
Development of other corrector agents with an improved side-effect profile and the 
potential for enhanced correction of the protein trafficking were therefore required.
This led to the development of tezacaftor, another small molecule correc-
tor agent. Tezacaftor in combination with ivacaftor (Symdeko®/Symveki®), for 
individuals homozygous for the Phe508del-CFTR mutation, when compared with 
placebo resulted in a 4% absolute improvement in ppFEV1, together with a five-
point improvement in CFQ-R scores but without any significant change in BMI 
(EVOLVE). Although the increments in lung function were still not as substantial 
as that seen in ivacaftor use for gating mutations, the adverse events were much 
lower than with lumacaftor/ivacaftor treatment. The discontinuation rate in the 
active treatment arm was only 2.9% and none of these were due to respiratory 
events [56, 57]. It thus appears that the corrector lumacaftor has a poorer side-effect 
profile than tezacaftor, rather than it being a complete class effect. Tezacaftor/
ivacaftor can also be given to patients who have certain residual function and splice 
mutations (E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, 
R352Q , A455E, D579G, 711+3A➔G, E831X, S945L, S977F, F1052V, K1060T, A1067T, 
R1070W, F1074L, D1152H, D1270N, 2789+5G➔A, 3272-26A➔G, 3849+10kbC➔T) 
[58]. Patients with Phe508del and a residual function mutation were studied in the 
phase III trial EXPAND, which was a crossover study where patients either received 
tezacaftor-ivacaftor, ivacaftor monotherapy or placebo. The patients were studied 
for two 8-week intervention periods separated by an 8-week washout period. 
Change in ppFEV1 (the primary endpoint) was greatest in the treatment arms with 
a 6.8% increase with tezacaftor-ivacaftor and 4.7% increase with ivacaftor. Both 
therapies were associated with significant improvements in CFQ-R.
5.5 Future modulator therapy
The combination corrector therapies described, enable individuals with the 
commonest CF mutation the potential of receiving modulator therapy. However, 
lumacaftor/ivacaftor and tezacaftor/ivacaftor do not fully restore CFTR protein 
function. Furthermore, there is still no small molecule therapy for 30% of the 
individuals with CF who are heterozygotes for Phe508del and have a minimal 
function (MF) mutation. MF mutations give rise to either the production of 
defective proteins or no protein production. They include insertion, deletion, 
nonsense and canonical splice mutations. As up to 90% of CF individuals have one 
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~164,000 synthetic compounds initial screened, approximately 100 were suitable 
for further study in one study [38]. The molecules identified were optimized and 
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protein. If gating is defective, then a low probability of CFTR channel opening 
occurs and in turn reduced overall CFTR function. Ivacaftor treatment results in 
increased chloride transportation across the cell membrane by improving channel 
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either ivacaftor or lumacaftor did not lead to clinically relevant improvements in 
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5.4 Combination therapy: potentiator and corrector agents
As monotherapy only lead to minimal clinically relevant outcomes for 
Phe508del-homozygotes, the argument strengthened for the use of lumacaftor in 
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combination with ivacaftor. Hence, these two therapies were trialed in combination 
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sion study (PROGRESS), where all individuals within the initial trials received 
lumacaftor in combination with ivacaftor, did demonstrate a 42% reduction in the 
annual rate of lung function decline when compared with matched US registry 
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for two 8-week intervention periods separated by an 8-week washout period. 
Change in ppFEV1 (the primary endpoint) was greatest in the treatment arms with 
a 6.8% increase with tezacaftor-ivacaftor and 4.7% increase with ivacaftor. Both 
therapies were associated with significant improvements in CFQ-R.
5.5 Future modulator therapy
The combination corrector therapies described, enable individuals with the 
commonest CF mutation the potential of receiving modulator therapy. However, 
lumacaftor/ivacaftor and tezacaftor/ivacaftor do not fully restore CFTR protein 
function. Furthermore, there is still no small molecule therapy for 30% of the 
individuals with CF who are heterozygotes for Phe508del and have a minimal 
function (MF) mutation. MF mutations give rise to either the production of 
defective proteins or no protein production. They include insertion, deletion, 
nonsense and canonical splice mutations. As up to 90% of CF individuals have one 
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Phe508del mutation, if small molecule therapy could significantly increase the 
amount of functional protein for this mutation, a greater range of CF individuals 
could be treated as then the therapy would be suitable for those individuals with the 
Phe508del-MF mutations.
Next generation CFTR correctors are under evaluation in combination with 
tezacaftor/ivacaftor. Phase 2 and 3 trials of these triple therapy agents; VX-659 
and VX-445 have provided further exciting results. These corrector agents have a 
different structure and mechanism of action and provide additive function to the 
other two agents. For individuals homozygous for Phe508del an increase in abso-
lute ppFEV1 was 9.7% for VX-659 treatment and 11% for VX-445 therapy. Greater 
increases in lung function were seen for patients with Phe508del-MF mutations; the 
absolute change in ppFEV1 was 13.3 and 13.8% for VX-659 and VX-445 respectively. 
These increases were also alongside significant improvements in quality of life and 
have been maintained in subsequent phase 3 interim report analyses [59–62]. These 
are incredible outcomes for individuals with more severe mutations and thus who 
typically have more severe disease phenotypes.
6. Implications of modulator therapy
Important advances in the clinical outcomes for individuals with CF have been 
possible since the introduction of modulator therapy. Unfortunately these treat-
ments are currently associated with a substantial cost and as a result are not avail-
able for all eligible patients. In the United States the Food and Drug Administration 
(FDA) has approved all four of the currently available modulator therapies. Some 
European countries and Australia, have access to ivacaftor, lumacaftor/ivacaftor 
and tezacaftor/ivacaftor [63]. However, worldwide there is significant inequality of 
access to these agents.
As an increasing number of modulator agents become available, the CF commu-
nity will need to determine how they can enable patients to receive these expensive 
therapies. If funding bodies are going to approve them, it is likely that they will 
require significant clinical outcomes from their use, especially when funding is 
through a public system.
7. Future directions
The introduction of modulator therapy, particularly when its use becomes 
widespread, is likely to have an impact upon the range of CF phenotypes. The 
amount of phenotypic variations should decrease as fewer patients have significant 
CFTR channel dysfunctional, and it is likely that the disease manifestations will be 
less severe. It is well known that respiratory related CF disease is associated with 
less than 10% CFTR channel function and so there is the potential for modulator 
therapy to have an impact upon this [21]. However, measurements of the degree 
of change in CFTR channel functionally with the use of modulator therapy is not 
being undertaken in the clinical setting. The markers being assessed are all surro-
gate markers of CFTR channel function and include lung function, sweat chloride, 
weight and quality of life questionnaires. Hence, it will be interesting to see the 
long-term impact of significant CFTR modulation on the CF cohort when individu-
als have been on such treatment for many years from birth. Currently a significant 
improvement is felt to be an increase in ppFEV1 greater than 10%. Time will tell as 
to whether such changes have a significant impact upon this long-term multi-system 
disease.
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8. Conclusion
The advancements in CF care over the last decade have been remarkable. The use 
of HTS drug discovery programs have been instrumental in enabling the develop-
ment of the CFTR modulator agents, first the potentiators and subsequently the 
corrector agents. The fact that such therapies target the underlying consequence of 
the CFTR mutation has led to exciting clinical outcomes for individuals with certain 
CFTR mutations because altering the function of the CFTR protein at the molecular 
level is essential for true disease change to occur. “Genetic medicines” require a 
significant improvement in their clinical outcomes before they can become a viable 
option to modulator therapy. They do however have the advantage that they are 
not specific for individual mutation classes and could be used as treatment for all 
patients.
The introduction of newer targeted therapies is transforming CF care, although 
it remains to be seen how these treatments will impact the CF community in the 
longer term. Nevertheless, a shift is starting to occur whereby treatments are 
determined based upon an individual’s genetic mutations. It is likely that this will 
lead to a more personalized model of care and it is hoped a step closer to a cure for 
this life-limiting disease.
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Abstract
Treatment and disease registries have played a vital role in understanding the
heterogeneous nature of cystic fibrosis (CF) disease progression. The maturity of so
many patient registries and recent national focus on their potential to improve patient-
centered outcomes have led to the establishment of guidelines for the conduct of
registry data analyses. Despite the insights garnered from utilizing CF patient regis-
tries, the analyses are plagued with methodological challenges, such as confounding,
missing data, time varying treatment and/or covariates, and treatment-by-selection
bias. Nonetheless, these registry studies have been essential for CF clinical effective-
ness research. They reflect real-world clinical practice and allow for evaluating patient
outcomes in a realistic clinical environment. In this chapter, we reflect on these
advancements in registries and study results broadly and specifically in CF.We iden-
tify the key statistical challenges with the analysis of CF registry data from start to
finish, including design considerations, quality assurance, issues with selection bias,
covariate effects, sample size justification and missing data.We describe how these
approaches are implemented to answer clinical effectiveness questions and undertake
an illustrative example on tobramycin effectiveness and lung function decline.
Keywords: confounding-by-indication bias, instrumental variables, lung function
decline, propensity scores, treatment-selection bias
1. Introduction
A registry is “an organized system that uses observational study methods to
collect uniform data (clinical or otherwise) to evaluate specified outcomes for a
population defined by a particular disease, condition or exposure, and that serves a
predetermined scientific, clinical or policy purpose(s)” [1]. Registries and other
non-intervention studies are often referred to as real-world data to distinguish them
from clinical trials or experimental studies.
Treatment and disease registries play a vital role in the advancement of patient-
centered outcomes research. These patient registries often include data arising from
patient surveillance in observational settings. Numerous epidemiologic studies have
used patient registries to characterize disease progression. In more recent years,
patient registries have been used for a variety of health-related inquiries, ranging
from comparative effectiveness studies to informing clinical decision making at the
point of care (see [2], for an example). The maturity of so many patient registries and
recent national focuses on their potential to improve patient-centered outcomes have
led to the establishment of guidelines for the conduct of registry data analyses [1].
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Although these guidelines are recent, the statistical challenges posed in these
observational settings were noted decades ago in epidemiology and public health
research [3]. Indeed, registry analyses are plagued with methodological challenges,
such as confounding, missing data, time varying treatment and/or covariates, and
treatment-by-selection bias.
Despite these challenges, registry studies are essential for clinical effectiveness
research. They reflect real-world clinical practice and allow for evaluating patient
outcomes in a realistic clinical environment. A registry encompasses the general
patient population, including those who are severely ill or less likely to adhere with
assigned treatment. These patients commonly are excluded from the randomized
controlled trials, and are likely to have very different treatment responses. Further,
registry study offers the opportunity to examine important factors such as physi-
cian’s practice behavior, prescription preference and other covariates pertaining to
quality of care, which are impossible to assess in an experimental study. Registry
studies commonly include long-term observation and therefore can reflect change
of treatment practices, in order to provide a timely assessment of emerging research
questions. The use of registry data to evaluate outcomes is of mutual benefit to both
patients and clinicians, and it facilitates management of patient care, thereby
improving the health care system.
1.1 Evaluating the effectiveness of tobramycin on lung function decline
Throughout the chapter, we will refer to an example from a retrospective longi-
tudinal cohort study, which used the Cystic Fibrosis Foundation Patient Registry
(CFFPR) to evaluate the clinical effectiveness of a treatment for lung function
decline [4]. Cystic fibrosis (CF) is a lethal autosomal disease in which respiratory
failure is the primary cause of death. Pseudomonas aeruginosa (Pa) is a common,
chronic pulmonary infection in CF patients. Inhaled tobramycin (hereafter, Tobi)
has been shown to improve lung function in CF patients with Pa in the clinical trial
setting. In this example, it is our objective to evaluate the clinical effectiveness—as
opposed to efficacy—of Tobi using the CFFPR. We will refer to this case study, in
order to illustrate statistical methods for registry data analysis. The Appendix
includes analysis implementation using SAS 9.3 (SAS Institute, Cary, NC).
In this chapter, we focus on the design and statistical analyses of patient registry
studies. We begin in Section 2 by describing processes to design a study involving
registry data, in accordance with the aforementioned guidelines from Gliklich and
colleagues. We follow this section with overviews of inferential analyses methods
that can be used in registry study to combat selection bias, missing data, time
varying treatment or covariates in Section 3. In Section 4, we describe details of
the application to the aforementioned patient registry. We discuss the utility of
existing methods and remaining analytic challenges in Section 5. Finally, we
provide an appendix in Appendix A with implementation of the statistical analyses
in our illustrative application.
2. Design considerations for registry studies
Registries may be organized around conditions or exposures (e.g., a cystic fibro-
sis registry, stroke registry); a healthcare service (e.g., procedure); or a product
(drug or device) and can address questions ranging from treatment effectiveness
and safety to the quality of care delivered. Registries vary in complexity from
simply recording product use as a requirement for reimbursement to more system-
atic efforts to collect prospective data on many types of treatment, risk factors, and
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clinical events in a defined population. Follow-up can be retrospective, prospective,
or a combination of both. The mode and duration of follow-up can range from days
(e.g., hospital admission registry) to decades (e.g., orthopedic implant registry).
Constructing and maintaining a large registry requires substantial resources, col-
laborative effort, and often requires a multi-center or inter-institutional agreement,
and a governing body that oversees and coordinates all activities. Typically, there
are standard guidelines or written procedures in place that help researchers to gain
familiarity and/or access to the registry study.
Before utilizing data from any registry, it is imperative to define the research
question and develop a study protocol. Clinical or public health questions of interest
should be stated as research questions. Each research question should correspond to
a testable hypothesis, which may be assessed using an approach fully described in
the statistical considerations (this is particularly important for comparative effec-
tiveness studies).
2.1 Selecting a registry and target population
Finding a registry that is appropriate to answer the research question of interest
will require us to review preliminary information about each of the prospective
registries, particularly regarding the data elements. For example, consider the fol-
lowing two studies. In each study, it is of interest to determine treatment effective-
ness for cystic fibrosis (CF) lung disease. The first study utilized the Cystic Fibrosis
Foundation Patient Registry (hereafter, CFFPR) [5] to examine the association
between ibuprofen and lung function decline [6, 7]. In a subsequent study, Konstan
et al. [8] assessed the relationship between a different treatment, dornase alfa, and
lung function decline using registry data from the Epidemiologic Study of Cystic
Fibrosis (ESCF) [9]. Although both studies examined treatment effectiveness on
the same outcome (lung function decline), each study required distinct data ele-
ments to answer the research questions regarding treatment effectiveness. The
CFFPR includes data collected on ibuprofen usage; however, the ECSF does not
include information for this treatment, eliminating this database as an option for
the first study. On the other hand, the ECSF has detailed information on pulmonary
symptoms (e.g., coughing), which are known predictors of more rapid lung func-
tion decline [7] and therefore need to be considered as potential confounders to
assessing treatment effectiveness. Although both registries include data elements to
measure dornase alfa usage, which are necessary to answer the research question in
the second study, the ECSF enabled the authors to consider detailed pulmonary
symptoms as potential confounders. If our research question involves a newly
diagnosed condition or rare disorder, we may be limited to a single patient registry.
In those instances, the research question may need additional refinement.
In the study protocol, we will need to state the specific objectives. The objective
of our CF study is to evaluate the effect of tobramycin on lung function decline.
Once the objectives are clarified, we consider the most appropriate study design. In
registry analyses, the selection of our study design often depends on how the
registry was structured. Registries constructed to capture natural histories are often
amenable to studies with longitudinal cohort designs. We can identify the popula-
tion of interest at this point in the study protocol. Acquiring the subset of data
which best reflects the population of interest, exposure variables, and primary and
secondary endpoints may include some manipulation of the original registry data
files. In our CF example, it is of interest to limit our cohort to individuals chronically
infected with Pseudomonas aeruginosa (Pa). We target this population, since our
research question is related to the effectiveness of tobramycin, which is a drug
recommended for treating CF chronic Pa in patients with CF. In our example, we
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determine chronic Pa status for each patient by examining the number of recorded
Pa infections throughout the calendar year. Our primary endpoint is the mean
change in FEV1% predicted over a 2-year period. We selected additional exposure
variables of interest, which are known predictors of change in FEV1% (see Table 1).
2.2 Data elements and quality assurance
For many different types of research, particularly comparative effectiveness
research or research involving children and/or rare disease conditions, no single
institution has a large enough patient population to perform a proper study. This,
along with the growing infrastructures of electronic medical records, has led to an
increased effort to create distributed research networks. The widespread adoption
of electronic health records (EHRs) has enabled them to become a main source for
registry data, capable of capturing the necessary elements as part of routine clinical
care, and the ever-changing clinical practices.
The number of data elements and scope of collection often increase over the life
of the registry. Well-maintained registries typically include data dictionaries, but
verifying data quality specific to our study is essential. In our CF example, we had to
calculate specific variables for analysis. Understanding how the data have been
collected over time and to what extent (e.g., every clinical encounter) will help
determine the appropriate subset of data to extract from the registry. For example,
the CFFPR data are collected at every clinical encounter and hospitalization, as well
as on an annual basis, on each patient and provided to the CF Foundation. Using
descriptive statistics, such as the 5-number summary, mean and standard deviation
for each variable, and histograms or boxplots can highlight data discrepancies in
continuous variables. Similarly, computing the frequency and percentage of each






Age, mean  SD (n), y 12.82  4.68 (6451) 12.78  4.59 (6255) 0.84
Male sex, % (n) 47.2% (3046) 53.5% (3346) <0.0001
FEV1, mean  SD (n), % predicted 74.46  25.33 (6451) 83.69  22.68 (6255) <0.0001
Weight-for-age percentile,
mean  SD (n)
30.05  26.08 (6446) 33.92  26.88 (6252) <0.0001
CF-related diabetes, % (n) 2.3% (150) 1.5% (96) 0.0012
Pancreatic insufficiency, % (n) 95.3% (6145) 94.8% (5932) 0.27
No or state/federal insurance, % (n) 32.3% (2082) 30.5% (1910) 0.0348
Prior hospitalizationsb — — —
None, % (n) 57.2% (3360) 75.7% (4448) <0.0001
1, % (n) 23.9% (1401) 16.0% (940)
2, % (n) 9.3% (546) 4.6% (273)
3 or more, % (n) 9.6% (566) 3.7% (219)
Dornase alfa, % (n) 79.3% (5116) 49.4% (3087) <0.0001
Abbreviations: CF, cystic fibrosis; FEV1, percentage predicted of forced expiratory volume in 1 s.
aP-values from Wilcoxon Mann-Whitney or chi-square test.
bNumber of hospitalizations in the year before baseline.
Table 1.
Descriptive analysis of CF registry variables.
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entries. Furthermore, summary statistics stratified by calendar year can inform
selection of an optimal time frame from natural history registries. In our example,
CF-related diabetes, a known predictor of lung function decline that should be
included in the analysis, was not collected in earlier calendar years in the CFFPR.
Access to most registries requires approval by a local institutional review board
(IRB) prior to data release, and this approval is often necessary to have results of the
study peer-reviewed and published. In our experience, developing a protocol that is
in accordance with the aforementioned guidelines is sufficient for the IRB review.
Although registries rarely contain patient names or medical record numbers, they
often include clinical encounter and/or discharge dates. Having this type of
protected health information in the data often requires IRB approval.
3. Statistical considerations for comparative effectiveness using registry
studies
Statistical analyses in the registry data setting are subject to the statistical chal-
lenges previously described for analyses of observational studies [10]. Registries are
often established for the purpose of evaluating the effects of interventions. The
statistical analysis plan should include appropriate methods to test each hypothesis,
methods to address biases and confounding arising from various sources, and
sample size/power considerations.
3.1 Selection bias
Regardless of the research question, a registry study will likely be plagued with
numerous sources of bias. Selection bias, although inevitable, is typically the most
concerning. This type of bias distorts the results for the association of interest and
may yield misleading results. Failure to sample from the correct target population
and loss to follow-up due to death or some other event are types of selection bias.
A pervasive type of selection bias is confounding by indication, arising from
nonrandomized treatment assignment that is often related to the patient’s risk to
experience poor outcomes. This treatment-by-selection bias creates distinctions
between the risk profiles of treated and comparator groups and may violate statis-
tical assumptions in our analyses. In our CF example, treatment selection bias may
be more pronounced because the drug in question should only be prescribed to
individuals with CF who have a specific chronic infection. Narrowing the cohort to
“sicker” individuals can intensify the aforementioned risk profile imbalance
between Tobi and non-Tobi groups.
Statisticalmethods to combat treatment selectionbias have been applied inprevious
studies. Approaches to adjust for treatment selection bias includemultivariable regres-
sion, propensity scoremethods, matching and instrumental variables analysis. Stukel
et al. [11] applied each of these four approaches to examine the association between
cardiac catheterization and long-term acute myocardial infarctionmortality. The
authors found that the results differed according to the choice of statistical approach.
Next, we describe and outline each approach in the context of our CF example.
3.2 Statistical analyses of comparative effectiveness utilized for registry data
analysis
3.2.1 Multivariable regression
In the absence of randomization, intervention and comparator groups may
exhibit large differences with respect to observed covariates recorded in the
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et al. [11] applied each of these four approaches to examine the association between
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exhibit large differences with respect to observed covariates recorded in the
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registry. This approach, sometimes referred to as covariate adjustment, attempts to
account for such differences that may distort estimates of intervention effects
(Figure 1). Most biomedical studies employ ordinal least squares (OLS) regression
to adjust the association between the treatment indicator variable Tið Þ and outcome
variable Yð Þ for measured confounders X1;…XKð Þ. The OLS regression model for
each subject i ¼ 1;… lð Þ specifies
yi ¼ β0 þ β1X1 þ⋯þ βKXK þ γTi þ ui (1)
where β0 is the parameter for the model intercept and μi is an error term. Each of
the model parameters β1,… βK correspond to the association between the measured
confounder and outcome variable. The parameter for treatment effect is γ; we
denote its OLS estimate as γ̂ . OLS estimation requires that the error term uð Þ is not
correlated with the measured confounders X1;…XKð Þ or the treatment Tð Þ. There-
fore, the only effect of T on outcome variable Yð Þ is the direct effect estimated as γ̂ .
The challenge of utilizing multivariable regression model for comparative effec-
tiveness is that we must appropriate account for necessary set of confounders.
Failure to fully account for necessary confounder may lead to bias estimate of
treatment effect.
3.2.2 Propensity score regression
The propensity score (PS) is a summary balancing score indicating the
likelihood for a patient to receive the active treatment Ti ¼ 1ð Þ using observed
set of confounders X1;…XKð Þ, represented in Figure 1. It is a balance score,
because by conditioning on the propensity score, one could achieve independence
between the treatment assignment and confounders; therefore, propensity scores
help to achieve quasi-experiment design for natural occurring treatment assign-
ment in a registry study. The PS can be estimated through a logistic regression
modeling
logitP Ti ¼ 1ð Þ ¼ β0 þ β1X1 þ⋯þ βKXK (2)
Figure 1.
Causal diagram. The multivariable regression in Model (1) examines the treatment-outcome association, after
adjustment for measured confounders. The propensity score methods outlined in Model (2) use the measured
confounders to balance the treatment groups (exposure). The IV regression from Model (3) examines the
treatment-outcome association, to the extent that the exposure is associated with the instrument. The instrument
should not be related the measured confounders; therefore no arrow is drawn for this relationship.
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where logit�1 pð Þ ¼ log p1�p, and the propensity score is estimated by
π̂ i ¼ logit�1 β0 þ β1X1 þ⋯þ βKXKð Þ. There are several propensity score approaches:
propensity score adjustment, stratified analyses by the quintiles of propensity score,
propensity score sub classification matches treated and untreated patients on
their propensity score sub-classes (often by percentiles), and inverse weighting of
propensity scores. The first approach includes propensity score directly in the
regression equation as a covariate to obtain adjusted treatment effect,
yi ¼ β0 þ β1π1 þ γT þ ui (3)
The second and the third approaches often categorize patients into five groups
using propensity score quintiles. The stratified analyses will perform the regression
model of yi ¼ β0, k þ γkTi for k ¼ 1,… , 5, and estimate the treatment effect by
γ ¼ ∑k¼1…5γk=5. The PS sub-classification matched analyses will be matching the
Tobi and non-Tobi patients on their propensity score groups, then perform analyses
for matched pairs. The propensity matching could also be performed on a finer
grouping, for example, using 10 groups, or fine matching where a Tobi patient
finding matching non-Tobi patient(s) though a distance measure. The method of
inverse PS weighting assigns higher (lower) weight to patients who has lower
(higher) propensity of receiving Tobi, where the weight is defined as wi ¼ Tifti þ
1�Ti
1�fti.
The intuition behind the weighting approach came from the survey sampling
method, and through inverse weighting, one could align the Tobi and non-Tobi
patients to have comparable distribution of the confounders. There are advantages
and disadvantage of each propensity score methods. Comparisons of these methods
can be found in an excellent review paper by Austin and Mandani [12] and the
references therein. Different methods are available for deriving propensity score.
Other than the logistic regression, one could use more flexible classification and
regression tree [13], boosted logistic regression [14], and covariate balancing pro-
pensity score method [15]. When applying PS approaches, it is important to check
PS balance between the two treatment groups. Patients who have extremely high or
low PS values that are not compatible with values from any patients in the other
treatment group should be excluded from the PS analyses. The balancing check can
be presented in graphic presentation, usually presenting the absolute standardized
mean difference (SMD).
3.2.3 Instrumental variables (IV) analysis
One of our primary analysis goals in the registry setting is to identify potential
sources of confounding and make the appropriate adjustments in our statistical
analysis. Failure to identify sources of measured confounding results in residual
confounding. This type of unaddressed confounding goes into the error term, u,
which was introduced in Model (1).
Inferential results can also be impacted by what is known as unmeasured
confounding. McClellan et al. [16] propose a technique known as instrumental
variables (IV) to combat both measured and unmeasured confounding. We
introduce the following notation for IV regression. From Model (1), recall that the
variables Yi;Ti;Xið Þ correspond to data from the ith patient in the registry, and we
assume that there is no correlation between the treatment variable, Ti, and the error
term, ui. This correlation is present when patients receive treatment based on
unmeasured characteristics. Let Ri represent an instrument. Consider the following
example of a randomized controlled trial. If Ri represents random assignment to
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treatment, it is the ideal instrument. By construction, it is related to outcome only
through treatment assignment [17].
In the typical clinical setting, a provider does not flip a coin to determine
whether she will prescribe her patient treatment A, as opposed to some alternative.
By construction, real-world data contained in registries represent non-random
assignment to treatment. Instead, we identify a variable—“an instrument”—that
is related to the outcome only through treatment. The variable Ri is a valid
instrument, provided the following assumptions are met:
i. Ri is associated with the treatment variable or exposure of interest, Ti;
ii. Ri is not directly associated with the outcome, Yi; Ri is only associated with
Yi through the treatment variable, Ti
Fortunately, assumption (i) is testable by performing least-squares regression of
the proposed IV on the treatment variable and measured confounders:
Ti ¼ b0 þ λRi þ b1X1 þ⋯þ bKXK þ δi, (4)
where b0 is the intercept; b1,… bK are the parameters corresponding to the
aforementioned measured confounders, X1,…XK; λ is the parameter estimate of the
association between the treatment variable, Ti, and the IV, Ri. The magnitude of
this association is a measure of the strength of the instrument [17]. Higher magni-
tude corresponds to greater strength. Let Ti be the resulting prediction of the
treatment value, obtained from Model (4). This association is illustrated in Figure 1
by the arrow moving downward from the instrument to exposure.
We continue this approach, often referred to as two-stage least squares regres-
sion, by substituting Ti from Model (4) into the multiple linear regression defined
in Model (1):
yi ¼ β00 þ β01X1 þ⋯þ β0KXK þ γ0T̂ i þ ηi (5)
In this regression, the same method of estimation is used; however, we use
distinct notation because parameter estimates and residual error will differ from
Model (1). Finally, we use the estimate of γ0 from Model (5) for our interpretations
of treatment effect on the outcome. This estimate corresponds to the association in
Figure 1 from treatment to outcome. Note that it is the same path as the multiple
linear regression, but the treatment effect has been “instrumented.” Assumption
(ii) cannot be formally tested, but can be explained in the context of the registry
analysis at-hand. We provide this type of explanation in our illustrative application.
Sensitivity analyses are imperative to determine the robustness of the IV. We
recommend analyzing the data in subgroups to understand how these groups may
drive heterogeneous treatment effects.
3.3 Time varying treatment/exposure and covariate
Incorporating time-varying treatment and/or covariate effects is a pervasive
issue in registry data analyses. The fundamental challenge arising from the change
in treatment and covariates over time often results from a patient’s responses and/or
experiences with the previous treatment assignment. Thus, simply including the
time varying treatment or covariate in such cases could induce bias in estimating
treatment effect. Special attention is needed to address this issue when analyzing
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registry data. Relatively few statistical approaches are available to assess time-
varying treatment effects or intermediate outcomes. Hogan and Lancaster [18]
proposed inverse probability weighting and instrumental variables as time-varying
treatment approaches; another population-based approach is the G-computation
formula [19].
3.4 Sample size justification
Completing this process implies that we have carefully considered the
hypothesis test and analysis variables, ultimately arriving at a statistical
model that will rigorously address the research question. Sample size
assessments will differ according to the statistical approach proposed to test the
hypothesis, and should incorporate previously established public health or clinical
information.
If the statistical approach entails adjustment for confounding and other sources
of bias, the sample size calculation is often straightforward. Suppose we plan to test
the significance of the treatment effect, γ0, previously defined in Model (1), and we
have already identified measured confounders (i.e., covariates) that should be
included in the model, referred to as X1,⋯XK. Our null hypothesis corresponds to
γ ¼ 0, while our alternative hypothesis corresponds to γ 6¼ 0. Testing this hypothe-
sis corresponds to determining sample size/power for a multiple linear regression
model [20].
We now reconsider the importance of sample size justification for analyses
involving a large registry. Statistical significance depends on the sample size and is
typically declared if the P value obtained from the test statistic falls below a
predetermined threshold (e.g., 0.05). This type of significance may be reached in
any study, provided that the sample size is large enough; therefore, in addition to
this mathematical criterion, we recommend specifying conditions that must be met
to achieve practical (public health or clinical) significance within the context of the
research question. In biomedical studies, these criteria can often be defined by
determining the minimal clinically important difference (MCID). This technique
was originally proposed for clinical trials [21] but has spawned several other
approaches [22] to determine the MCID. Once we incorporate the MCID into our
null and alternative hypothesis statements, we can perform the sample size
calculation that corresponds to our proposed inferential analysis.
3.5 Missing data mechanisms and missing data modeling
Missing data can occur in the registry setting for a variety of reasons. Simply put,
a missing data point is an observation that should have been recorded; however, for
some reason, it was not recorded. It is our desire, as analysts, to understand the
reason for this “missingness.” In this section, we outline practical analytic
approaches to identify potential sources attributable to missing data and methods to
combat the resulting bias. We begin with a brief description of the three funda-
mental missing data mechanisms. For an elegant mathematical treatment of the
distinctions among the mechanisms, we refer the reader to the original work by
Rubin [23].
3.5.1 Missing completely at random (MCAR)
If the registry data are MCAR, then the reason for missingness is not related to
the data that we were able to observe or to the data that we were not able to observe.
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We now reconsider the importance of sample size justification for analyses
involving a large registry. Statistical significance depends on the sample size and is
typically declared if the P value obtained from the test statistic falls below a
predetermined threshold (e.g., 0.05). This type of significance may be reached in
any study, provided that the sample size is large enough; therefore, in addition to
this mathematical criterion, we recommend specifying conditions that must be met
to achieve practical (public health or clinical) significance within the context of the
research question. In biomedical studies, these criteria can often be defined by
determining the minimal clinically important difference (MCID). This technique
was originally proposed for clinical trials [21] but has spawned several other
approaches [22] to determine the MCID. Once we incorporate the MCID into our
null and alternative hypothesis statements, we can perform the sample size
calculation that corresponds to our proposed inferential analysis.
3.5 Missing data mechanisms and missing data modeling
Missing data can occur in the registry setting for a variety of reasons. Simply put,
a missing data point is an observation that should have been recorded; however, for
some reason, it was not recorded. It is our desire, as analysts, to understand the
reason for this “missingness.” In this section, we outline practical analytic
approaches to identify potential sources attributable to missing data and methods to
combat the resulting bias. We begin with a brief description of the three funda-
mental missing data mechanisms. For an elegant mathematical treatment of the
distinctions among the mechanisms, we refer the reader to the original work by
Rubin [23].
3.5.1 Missing completely at random (MCAR)
If the registry data are MCAR, then the reason for missingness is not related to
the data that we were able to observe or to the data that we were not able to observe.
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We now consider the CF example. MCAR could correspond to the following. The
probability of a lung function observation (the outcome variable) being missing
from the registry does not depend on any of the observed data (e.g., patient’s age)
or any of the unobserved data (e.g., having lower lung function does not alter the
risk of the observation being missing). Our analysis results from this subset of data
will be no different (aside from larger standard errors) than if we had been able to
perform the analysis on the entire dataset.
3.5.2 Missing at random (MAR)
This assumption is more relaxed than MCAR but still has specific requirements.
For MAR to hold, the missingness cannot be related to unobserved data, given what
we have been able to observe. In other words, the missingness can depend upon
data that we have already observed (i.e., data entries that were recorded in the
registry). Referring again to our CF example, the probability of a lung function
observation being missing does not depend upon the actual lung function value,
provided that we have the other covariate data. In this case, missingness can depend
upon characteristics that have been recorded in the CFFPR (e.g., gender).
3.5.3 Missing not at random (MNAR)
We are more likely to encounter this mechanism in registry data, compared to
the other mechanisms. If data are MNAR, then the missingness is related to
unobserved data (unlike MAR). The missing observation follows a different distri-
bution than the observed data, regardless of whether the two types of data have
other characteristics that are the same. Despite the fact that we have registry data,
the data that we are able to observe are not representative of the entire population.
Within the CFFPR example, consider the longitudinal data. According to CF Foun-
dation guidelines, patients are supposed to have at least one pulmonary function
test per quarter [5]. Suppose there is a subset of patients who do not have lung
function data recorded at every clinical encounter. There are many plausible expla-
nations for why these data are missing. For an individual patient, there may be a
lack of interest in managing his disease progression, or it could be an entry error.
In general, we may lack relations to observed values or those relations may be
irrelevant.
In practice, we do not have the information necessary to declare the reason for
the missingness. Even thoughtfully developed, well-maintained registries will have
missing data; therefore, sensitivity analyses are needed as part of the statistical
considerations. As a preliminary step, we recommend creating an indicator
(dummy) variable to indicate whether the observation is missing (=1) or otherwise
(=0). Regress this dichotomous variable on the other variables to determine
whether the missing indicator is associated with observed characteristics. If no
association is found, we may conclude that the data are MCAR; however, we still
encourage caution when making the MCAR assumption for statistical models using
registry data. Although small sample size may produce this result, it is not a likely
culprit in settings with large data sources. It is possible that the extent of the
missingness may be too low (e.g., 5% of observations are missing) to substantially
alter results, but having a low proportion of missing observations is also unlikely in
a registry setting. If there is a significant association from our preliminary regres-
sion with the indicator variable, then we can rule out the MCAR assumption and
more intently investigate the MAR and MNAR assumptions.
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We can further examine the MAR assumption by checking for variables that are
often missing simultaneously or other potential patterns of missingness. Whenever
possible, we recommend performing the analysis under the MAR assumption. The
two most common approaches under this mechanism are direct modeling and
multiple imputation. Direct modeling implies that we will consider all available data
points in our parameter estimation. This method is sometimes referred to as “avail-
able case analysis” [24]. In other words, the analysis will not exclude the records of
any individual subject who has at least one observed entry. There is a second
approach, multiple imputation [25], which has gained favor among analysts with
the expansion of computing resources. To perform this approach, several data
points for each missing data point are generated, resulting in several distinct
dataset. We employ our proposed statistical model separately on each dataset and
obtain parameter estimates. The estimates are combined to produce an aggregate
estimate. The aggregate estimate and standard error are used to make interpreta-
tions of results. This technique is available in many software packages (e.g., SAS
proc mi, proc mianalyze).
Unfortunately, there is no way to know whether the data are MAR or MNAR.
Previous work by experts in the analysis of missing data has shown that any
model we develop under the MNAR assumption will have an equivalent MAR
counterpart [26]. Developing an MNAR model requires technical steps that are
beyond the scope of our current chapter. Dmitrienko et al. [27] provide an
applied approach to investigating MNAR assumptions in the context of sensitivity
analyses. Although their text focuses on analyses for data from clinical trials, their
approach and accompanying SAS implementation may be adapted to registry data
analyses.
3.6 Interpretations of registry data analyses
To simplify interpretation and improve accuracy of the results, sources of
potential confounding (measured or unmeasured) should be considered as much in
advance as possible. Propensity score regression offers an effective method to
further balance the treatment and non-treatment groups. Like multivariable
regression, this approach accounts for treatment selection bias [28] only for mea-
sured confounders (e.g., measured comorbidities and severity of illness). The pro-
pensity score could utilize measured confounders to remove treatment-selection
bias. However, when there are unmeasured confounders that determine treatment-
selection bias, the propensity-score approach will be limited. In analyzing registry
data, IV analyses should be considered when unmeasured confounders are
suspected.
Although the IV analysis is a powerful approach, this method has some note-
worthy constraints. Large sample size is essential for performing IV analysis, but
this issue may not be a challenge in the registry setting. The IV must only affect
treatment assignment and have no direct association with outcome. If these
assumptions are satisfied, then the IV analysis will yield a consistent estimate of the
average causal effect [29]. Assumption (i) is directly testable, but making a heuris-
tic argument for assumption (ii) is a common approach. See Kahn et al. [30] for an
example. A weak IV will produce larger standard errors and may lead to incorrect
inferential results. This approach is ideal in the presence of small/moderate
confounding but becomes less reliable in the presence of large confounding.
Admittedly, this is a limitation of the IV analysis in the registry setting. On the other
hand, an appropriate IV minimizes the potential impacts of measured and
unmeasured confounding [31].
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Sensitivity analyses should be performed to examine potential impacts of miss-
ing data and particular subgroups that may drive inferential results. Analyses
corresponding to the missing at random assumption should be explored in the
registry setting. Subgroup analyses are essential to identify heterogeneous treat-
ment effects, particularly in the IV analysis. These sensitivity analyses should be
performed regardless of the statistical model that we choose to employ.
4. Illustrative application
4.1 Data summary and descriptive analysis
The CFFPR contains data on individuals receiving care from any CF center in
the United States, which has been accredited by the CF Foundation. Like many
registries, we underwent an application process to receive the data. The CFFPR data
that we received were in separate databases. We used the following two databases.
The encounter-level database had one record per patient, per clinical encounter.
The annual-level database contained one record per patient, per year. We merged
these data to extract the information necessary to determine whether there is a
significant association between the use of inhaled tobramycin and lung function in
individuals with CF who are chronically infected with Pa. Our primary outcome,
lung function, was defined as mean change in FEV1% predicted (FEV1). In this
application, we study short-term effectiveness of inhaled tobramycin, in order to
facilitate use of instrumental variables, which still pose several challenges in longi-
tudinal settings with multiple data points and time-varying exposures [17].
We considered the following restrictions to target the study cohort of interest.
We requested CFFPR data ranging from January 1, 1998 to December 31, 2009, in
order to capture the time at which inhaled tobramycin (Tobi) was recorded in the
registry on a consistent basis. We did not consider study records with individuals
<6 years of age, due to limitations of modality to measure lung function in young
children. We limited the maximum age to 21 years, in an effort to focus on first
occurrence of chronic Pa. We identified the first chronic Pa infection for each
individual by examining all Pa culture results available in the encounter-level data.
Patients recorded as having a positive Pa culture more than 50% of time in a given
year were considered as eligible for the study. This was determined by using the Pa
culture (indicator) variable available in the CFFPR. We took the first year that the
patient had chronic Pa infection as the baseline year. In an effort to keep our study
data to one record per patient, we only considered the first chronic Pa infection for
each patient. Patients who also had another infection at the same time, Burkholderia
cepacia complex, were not considered as part of the study cohort, because of previ-
ously established criteria [32]. An indicator variable for patient-level tobramycin
use was defined as receiving inhaled tobramycin within 6 months of initial chronic
Pa. Baseline FEV1 was defined as the closest FEV1 measurement recorded within
6 months after initial chronic Pa record. Follow-up FEV1 was defined as the closest
recorded FEV1 within 1.5–2.5 years of the baseline FEV1. Patients who did not have
a recorded FEV1 measurement within 6 months after meeting criteria for chronic Pa
infection were excluded. The outcome variable, decline in FEV1, was calculated as
the difference between follow-up and baseline FEV1 for each patient. A negative
value implies that FEV1 declined over the 2-year period; a positive value indicates
that FEV1 increased over the 2-year period. Figure 2 illustrates steps to determining
the analysis cohort and resulting sample size.
We identified potential confounders by looking at previous literature (see [6],
for example). These variables, measured in the CFFPR, included gender, baseline
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measurements for age, FEV1, weight-for-age percentile, insurance coverage, CF-
related diabetes (with or without fasting hyperglycemia), dornase alfa use, pancre-
atic insufficiency (defined as taking pancreatic enzymes) and number of hospitali-
zations in the preceding year. We can compare Tobi and non-Tobi groups with
respect to each of these variables using basic inferential testing (i.e., nonparametric
test for continuous variables and Chi-square test for categorical variables). Results
of the descriptive analysis are presented in Table 1. Our descriptive analysis reveals
that Tobi and non-Tobi groups differed by several demographic and clinical char-
acteristics. We note that the groups did not differ according to age or being pan-
creatic insufficient. Next, we utilize the aforementioned statistical models to test
this association.
4.2 Multiple linear regression
We use Model (1) to test the association between lung function and tobramycin
use, adjusting for potential confounders as covariates, represented as X1,⋯XK.
Table 2 shows the results of the multiple linear regression, which suggest that the
treated group experienced greater mean decline in FEV1% predicted than the
Figure 2.
Diagram of study population in the illustrative CF example, showing inclusion and exclusion steps to obtain an
analysis cohort from the registry. CFFPR, Cystic Fibrosis Foundation Patient Registry; Pa, Pseudomonas
aeruginosa.
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untreated group. Although most covariates were statistically significant at P < 0.05,
we found that CF-related diabetes, pancreatic insufficiency, and dornase alfa use
were not significant predictors of outcome.
Type of model
Multiple linear regressiona Propensity score regressionb
Covariates Coefficient (SE), (P-value) Coefficient (SE), (P-value)
Patient tobramycin use
Treated 1.74 (0.31) (<0.0001) 1.71 (0.30) (<0.0001)
Not treated 0 0
Age 0.87 (0.04) (<0.0001) 0.86 (0.04) (<0.0001)
Baseline FEV1 0.27 (0.01) (<0.0001) 0.27 (0.01) (<0.0001)
Sex
Female 1.16 (0.30) (<0.0001) 1.15 (0.31) (0.0002)
Male 0 0
Weight-for-age percentile 0.06 (0.01) (<0.0001) 0.05 (0.01) (<0.0001)
CF-related diabetes
Yes 2.06 (1.44) (0.15) 2.19 (1.36) (0.11)
No 0 0
Pancreatic insufficiency — —
Yes 0.52 (0.83) (0.54) 0.44 (0.83) (0.60)
No 0 0
Insurance — —
None or state/federal 1.66 (0.34) (<0.0001) 1.66 (0.34) (<0.0001)
Other 0 0
Baseline hospitalizations+ — —
None 5.05 (0.70) (<0.0001) 4.63 (0.69) (<0.0001)
1 2.74 (0.74) 2.26 (0.74)
2 0.40 (0.87) 0.37 (0.87)
3 or more 0 0
Dornase alfa use — —
Yes 0.46 (0.39) (0.25) 0.38 (0.40) (0.34)
No 0 0
Abbreviations: CF, cystic fibrosis; FEV1, percentage predicted of forced expiratory volume in 1 s.
aFor each categorical variable in the first-stage model, the coefficient is the difference in patient tobramycin use
between the indicated category and the reference category (labeled as coefficient = 0). For each continuous variable, it
is the change in patient tobramycin use when the variable is increased by 1 unit. A negative value implies decreased
patient tobramycin use.
bPredicted treatment obtained in Stage 1 serves as propensity score in Stage 2. For each categorical variable in the
second-stage model, the coefficient is the difference in FEV1 decline between the indicated group and the reference group
(labeled as coefficient = 0).
+significant at 2-sided p value < 0.05
For each continuous variable, it is the change in FEV1 when the variable is increased by 1 unit. A negative value
implies greater FEV1 decline.
Table 2.
Multiple linear regression and propensity score method to predict lung function decline.
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4.3 Propensity score method
The patient characteristics at the baseline, which are known to impact FEV
outcomes, are considered into the multivariable logistic regression model (Eq. (2))
for estimating propensity scores. Figure 3 presented the histograms of propensity
score for the Tobi treated and not-treated patient groups, showing different but
overlapping propensity scores between the two groups. Propensity scores are
grouped into five groups by quintiles. The distribution of propensity scores are
compared between the Tobi treated and not treated patients within each of the five
PS categories; as one could see from Figure 4, within each quintile categories, the
two patient groups present comparable patterns in their likelihood of receiving
Figure 4.
Box-Whisker plots of the distribution of propensity scores by Tobi use (red) and not use (blue) groups stratified
by the quintiles.
Figure 3.
Histogram of the propensity score distributions by Tobi use (red) and not-group groups (blue). Related the
measured confounders; therefore no arrow is drawn for this relationship.
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Tobi. To check for propensity score balance, we compared the Tobi treated and not
treated patients on their baseline covariates, the standardized differences between
the treated and not treated groups are presented in Table 3. The results show that
there is a significant difference between the treated and not treated patients groups
according to their gender, baseline FEV1, CF-related diabetes, pancreatic insuffi-
ciency, insurance status, prior hospitalization and dornase alfa use. After matching
patients on their PS categories, as well as after adjusting by inverse propensity score
weighting, we are able to achieve balance between the Tobi treated and not treated
groups. Subsequently, we proceed with the propensity score analyses using the
inverse propensity score weighted approach. The results are presented in Table 4,
which can be contrasted with the results from the multivariable regression analyses
in Table 2. The results from these two approaches are very similar; both are






Mean P-value Mean P-value Mean P-value
Sex Treated Male 47.8% <0.01 49.1% 0.44 50.8% 0.91
Not treated 54.0% 48.2% 50.9%
FEV1% predicted Treated 76.38 <0.01 81.68 0.86 81.26 0.85
Not treated 85.25 81.75 81.17
Age Treated 12.10 0.51 11.98 0.73 12.01 0.94
Not treated 12.05 12.01 12.01
Weight-for-age
percentile
Treated 30.24 <0.01 30.34 0.80 32.33 0.79
Not treated 33.78 30.18 32.19
CF-related
diabetes
Treated Yes 1.5% <0.01 1.3% 0.53 1.2% 0.49




Treated Yes 96.0% 0.94 96.6% 0.85 96.5% 0.72





30.7% 0.53 30.2% 0.62 30.7% 0.81
Not treated 30.2% 30.7% 30.5%
Prior
hospitalizations
Treated None 58.5% <0.01 69.1% 0.12 67.4% 0.95
1 23.8% 18.9% 19.8%
2 9.4% 6.3% 6.9%
3 or more 8.4% 5.7% 5.9%
Not treated None 75.9% 70.2% 67.4%
1 16.3% 19.5% 19.7%
2 4.6% 5.8% 6.9%
3 or more 3.3% 4.6% 6.0%
Dornase alfa Treated Yes 77.6% <0.01 68.7% 0.24 63.2% 0.88
Not treated 49.3% 67.4% 63.3%
Abbreviations: CF, cystic fibrosis; FEV1, percentage predicted of forced expiratory volume in 1 s; PS, propensity score.
Calculations for standardized differences are described in Section 4.3.
Table 3.
Standardized difference (T-val) between Tobi treated and untreated patients.
68
Cystic Fibrosis - Heterogeneity and Personalized Treatment
suggesting negative Tobi treatment effect on the improvement of FEV. The results
from randomized clinical trials, however, all suggest a positive Tobi treatment
effect. Such differences might be explained by unmeasured confounding that is
Stage 1 (predicts patient
tobramycin use)a
Stage 2 (predicts change in lung
function)b




Treated — 2.55 (1.22), (0.0366)
Not treated — 0
Age 0.013 (0.003), (0.0002) 0.86 (0.04), (<0.0001)
Baseline FEV1 0.010 (0.001), (<0.0001) 0.27 (0.01), (<0.0001)
Sex — —




0.000 (0.001), (0.74) 0.06 (0.01), (<0.0001)
CF-related diabetes — —















None 0.598 (0.064), (<0.0001) 5.44 (0.69), (<0.0001)
1 0.251 (0.068) 2.89 (0.74)
2 0.148 (0.080) 0.48 (0.87)
3 or more 0 0
Dornase alfa use — —
Yes 0.224 (0.036), (<0.0001) 0.28 (0.40), (0.48)
No 0 0
Abbreviations: CF, cystic fibrosis; FEV1, percentage predicted of forced expiratory volume in 1 s.
*Each model is adjusted for measured confounders by including each listed variable as a covariate. For each categorical
variable, the coefficient is the difference in FEV1 decline between the indicated category and the reference category
(labeled as coefficient = 0). For each continuous variable, it is the change in FEV1 decline when the variable is
increased by 1 unit. A negative value implies greater FEV1 decline.
aMultivariable analysis with standard adjustment for confounding by including characteristics as covariates.
bMultivariable analysis weighted using propensity scores.
Table 4.
Instrumental variable analysis to predict lung function decline*.
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related to treatment selection bias but not recorded in the registry. We further
proceed with IV analyses to examine the Tobi treatment effect.
4.4 Instrumental variables analysis
It is possible that the discrepancy between the previously described registry
analysis and clinical trial findings of the treatment effect are due to unmeasured
confounding. It is common in observational settings to encounter confounding by
indication bias that is not recorded in registries. In this application, we selected a
preference-based instrument, center-level prescribing patterns, to combat this bias.
The CFFPR includes more than 240 centers. For each center, we calculated the
tobramycin-prescribing rate during the time frame of the study. This rate was
calculated as the number of times the center prescribed tobramycin to the patient
when eligible divided by the total number of times the center should have pre-
scribed tobramycin. We considered a patient to be eligible for the treatment once he
met the CFF guidelines for its use.
We had to determine whether the IV met the previously mentioned criteria to be
a valid instrument. We began by performing the first-stage analysis outlined in
Model (4). We include all potential confounders as explanatory variables, and we
include the IV. The response variable in this equation is the tobramycin use. The
first-stage results are presented in Table 4 and reflect what we found in the
exploratory analysis from Table 1. The IV included in this regression was a highly
significant predictor of tobramycin use. The corresponding t-statistic was 28.2,
P < 0.0001. These results indicate that we have met assumption (i) for center-level
prescribing to be a valid instrument. We also note that Table 4 shows that dornase
alfa use is strongly associated with tobramycin use. We will revisit this finding in
sensitivity analysis of our instrument. We performed the multiple linear regression
specified in Model (5) to determine the association between tobramycin and lung
function decline. This regression accounts for observed patient characteristics and
provides an instrumented version of tobramycin use. The last column in Table 4
shows that tobramycin was associated with less FEV1 decline, suggesting the
existence of a positive treatment effect.
Assumption (ii) is not directly testable, but we examine it through sensitivity
analyses of heterogeneous treatment effects. These effects may be caused by
confounding from other medication use or differences in quality of care received
across centers. We performed three different types of sensitivity analyses. First, we
extracted quality of care markers through the CF Foundation Annual Report (1) and
calculated them for each center. We correlated each marker with our IV and found
no significant association. Second, we used subgroup analyses to determine the
impact of dornase alfa use on tobramycin effectiveness. We divided the cohort into
two distinct groups according to whether they reportedly used dornase alfa. We
performed the IV analysis separately on each group. The two sets of results were
similar with regard to first- and second-stage analyses. Third, we performed a
secondary analysis of patients with B. cepacia. Although these patients are tradi-
tionally excluded from clinical trials and other effectiveness assessments because of
their significantly poorer outcome, they often receive tobramycin in clinical prac-
tice. The first-stage analysis of this cohort was similar to the primary results;
however, their second-stage analysis showed no significant treatment effect.
4.5 Concluding remarks
Registry data plays an increasingly important role in health care research.
Appropriate design and careful statistical approaches to the analyses of registry data
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are essential. In this chapter, we have described a step-by-step approach to formu-
lating and implementing a registry data analysis. Understanding the research ques-
tion, selecting the appropriate data source and identifying potential sources of bias
are necessary before beginning to construct an analytic plan. The statistical consid-
erations should include data quality assessments and descriptive analyses, and it is
critically important to address selection bias due to both measured and unmeasured
confounding. This is because selection bias is ubiquitous; failure to adequately
address selection bias will lead to biased conclusions. Multivariable regression has
been the primary means to combat selection bias. While this technique can help to
minimize differences between groups, it is limited to relatively fewer covariates in
the adjustment process. Propensity scores, which correspond to the probability of
treatment assignment given pre-treatment characteristics, provide a way to sum-
marize multiple covariates into a single score for each individual. Therefore, this
approach is capable of handling a large dimension of confounders, which is partic-
ularly useful in registry studies when confounders are measured. Another advan-
tage of PS is that it allows one to check between the treatment groups when
conditioning on propensity score whether the confounding factors is balanced out.
However, when important confounders are not measured, the PS method is limited.
One solution is to perform sensitivity analyses by evaluating how estimated treat-
ment effectiveness might change if there exists an unmeasured confounder with
varying levels of prevalence. Such practice will allow one to gauge the impact of
unmeasured confounders to the treatment effect.
In this example, the likelihood of tobramycin use depends on unmeasured char-
acteristics at the patient, family or care level. The adjustment of unmeasured
confounding that is possible through IV analysis may have led to more intuitive
conclusions regarding treatment effect. Since CF care is organized by care center, it
was reasonable to examine the validity of a preference-based instrument to combat
treatment-selection bias. Thorough sensitivity analyses are necessary to examine
the robustness of the IV. We limit our illustrative application to a single instrument.
It is possible to include multiple instruments and gain more formal properties to
testing assumption (ii).
5. Conclusions
When designing and analyzing registry data, it is critically important to address
biases and confounding that are inherent in this type of study. Although we have
focused, in this chapter, on describing methods for controlling selection biases,
registry data are often subject to other types of biases related to measurement and
miss-classification error, immortal time bias, loss to follow up, and missing data.
We encourage use of sensitivity analyses to understand the impacts of these poten-
tial biases to the study conclusions. There are rich literature sources and several
guidelines for design and analysis of registry data. In addition to the literature
referenced in this chapter, a very useful resource is the recent report on standards in
the conduct of registry studies for patient centered outcomes research and the
references therein [33].
In addressing selection bias, most often, treatment effects are examined using
multiple linear regression with measured confounders included as covariates [34].
Increasingly, PS methods are employed. However, existing statistical methods to
address unmeasured confounding may be underutilized in registry settings. The
models that we have presented are by no means exhaustive. There is room to
develop more methodology, particularly to combat time-varying treatment effects
and utilize time-varying instruments [12]. It is possible that preference-based
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multiple linear regression with measured confounders included as covariates [34].
Increasingly, PS methods are employed. However, existing statistical methods to
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and utilize time-varying instruments [12]. It is possible that preference-based
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instruments will provide a feasible approach to interrogating registries [14].
Admittedly, there are some situations, such as the IV regression specified in Model
(3), where the sample size/power analysis calculation is not straightforward.
There are approaches to simulate power for this model, but additional assumptions
are necessary. Furthermore, in most controlled studies, we can follow up with
subjects who drop out. We rarely have this capability in registry settings, which
further limits our ability to diagnose the missing data mechanism.
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A. Appendix
Below, we present code from SAS 9.3 (SAS Institute, Cary, NC) to implement
the statistical analyses for the application in Section 5.4. See Leslie and Ghomrawi
[35] for additional details on the implementation of instrumental variables regres-
sion using the QLIM procedure in SAS.
/*For each implementation below, we begin with analysis_data, which is the
cleaned version of the registry data with all coded variables necessary for analyses.
The variable Tobi is the indicator variable for whether the subject received
tobramycin; dfev1 refers to the outcome variable (change in FEV1% predicted).






/*The code below performs a multivariable linear regression to determine the
association between tobramycin and change in lung function, with adjustment for
the previously described measured confounders. The variables below correspond to
sex (gender), baseline measures of age (age), FEV1% predicted (base_fev1), weight-
for-age percentile (wtpct), insurance coverage (inscat), CF-related diabetes (cfrd),
dornase alfa (dnase), pancreatic insufficiency (pancr), and number of hospitaliza-
tions in year prior to baseline year (numhosp), categorized as 0, 1, 2, 3 or more*/
title ‘Model (1): Traditional Regression’;
proc glm data=analysis_data;
class Tobi inscat cfrd dnase pancr numhosp gender;
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/*Next, we implement the propensity score regression model previously
described. First, we use logistic regression to estimate propensity scores for each
subject.*/
title ‘Model (2): Propensity Score Regression’;
proc logistic data=analysis_data;
class inscat cfrd dnase pancr numhosp gender;




/*We use the commands below to assign a subject-specific weight that corre-
sponds to his or her propensity score from the logistic regression above. Since the
propensity score, denoted ps below, corresponds to predicted probability of receiv-
ing the treatment, each subject who received the treatment will have weight 1/ps,
while each subject who did not receive the treatment will have weight 1/(1-ps). The
resulting dataset, props2, will consist of the analysis_data, propensity scores that
were previously created and stored in props, and the ps_weight corresponding to
each subject’s weighting derived from the propensity score.*/
data props2;
set props;
if Tobi=1 then ps_weight=1/ps;
if Tobi=0 then ps_weight=1/(1-ps);
run;
/*We now implement the weighted multivariable regression. The commands are
similar to our previous regression, except for our use here of the weight statement.
By using this statement, we request computation of weighted means and variance
estimates that are inversely proportional to the corresponding sum of weights.*/
proc glm data=props2;
class Tobi inscat cfrd dnase pancr numhosp gender;





/*Finally, we present commands for the instrumental variables regression. The
first model statement performs the first-stage regression of the treatment indicator
Tobi on the instrument (cid_iv) and all measured confounders. The result is a probit
model with predicted probabilities of tobramycin use for each subject. The second
model statement performs multiple linear regression with the instrumented version
of the tobramycin variable from the first model statement.
title ‘Model (3): Instrumental Variables Regression’;
proc qlim data=analysis_data;
class inscat cfrd dnase pancr numhosp gender;
model Tobi=cid_iv base_fev1 wtpct age inscat cfrd dnase pancr numhosp gender
/discrete;
model dfev1=base_fev1 wtpct age inscat cfrd dnase pancr numhosp gender /
select(Tobi=1);
output out=Tobi prob proball predicted residual;
run;
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Liver damage observed in cystic fibrosis is a complicated process comprised of 
fibrogenesis, inflammation, remodeling, apoptosis, and cholestasis. Complexity 
of processes which take place in the liver and bile ducts in the course of this disease 
are not clearly defined. Changes in the liver are observed in 5–20% of patients with 
diagnosed cystic fibrosis; however they can increase mortality, shorten time of life, 
and deteriorate quality of life. The aim of the chapter was to review the risk factors, 
clinical symptoms, diagnostic methods, and treatment of liver changes in the course 
of cystic fibrosis.
Keywords: liver, cystic fibrosis
1. Introduction
Hepatic lesions concern only 5–20% of patients with diagnosed cystic fibrosis. 
However they increase the level of fatalities, shorten the survival rate, and impair 
the quality of life. Liver diseases are the most common, non-pulmonary cause 
of death among patients with cystic fibrosis. They most often occur in the first 
decade of life. Cirrhosis is detected in about 10% of CF children under the age of 18 
compared to 2% of adults with the same condition. The average age of the CF liver 
disease manifestation is about 10 years [1–7].
1.1 Etiopathogenesis of liver’s change in patients with cystic fibrosis
Liver and bile duct diseases are a combination of complex processes of fibrosis, 
inflammation, remodeling, apoptosis, and cholestasis. They are a consequence 
of the abnormal functioning of the CFTR protein, immunologic reactions, and 
response to oxidative stress [5, 8–11].
1.1.1 Pathophysiological changes to the bile acids in the course of cystic fibrosis
The important roles played by the pathophysiological changes of the bile duct 
include changes to the components of the bile (abnormal water and electrolyte 
contents and change to the pH of the bile) and changes to the profile of bile 
acids—to hydrophobic, abnormal transport of the bile, retention of toxic bile acids 
(taurocholic acid), and induction of pro-inflammatory chemokines which influ-
ence on biliary fibrogenesis. Factors contributing to the processes of precipitation 
of bile acids in the bile ducts include decreased synthesis of the salts of the bile 
acids, decreased absorption of bile acids from the lumen of the small intestine, and 
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narrowing of the bile ducts impairing the outflow of the bile from the liver to the 
lumen of the duodenum [5, 8, 10].
1.1.2 Genetic factors
So far, no specific mutation relating solely to liver damage in the course of 
cystic fibrosis has been discovered. Most commonly, these are the so-called “seri-
ous mutations” of the CFTR gene (delta F508,G524X, N1303K, CFTRdel21kB, 
1811 + 1G- > C). The delta F508 mutation plays a particular role in the develop-
ment of hepatic lesions in the course of cystic fibrosis due to its stimulation of 
an increased loss of bile acids with stools and the fact that it leads to the forma-
tion of more hydrophobic bile acids. Hepatic lesions co- occurring with cystic 
fibrosis in patients with the 3849 + 10kB C- > T mutation have not yet been the 
subject of interest. However, the clinical course in patients with diagnosed cystic 
fibrosis and the same mutation of the CFTR gene tends to vary. There is no strict 
phenotype–genotype corelation. The role of the SERPINE1 mutation: it occurs in 
about 2% of the patients with cystic fibrosis and in about 5% of the patients with 
cystic fibrosis and co-occurring hepatic lesions. Responsible for the synthesis 
of the inhibitor of serine protease. The protein connected to allele Z is concen-
trated within the endoplasmic reticulum of hepatocytes leading to their damage, 
inflammation, and cirrhosis. In about 10% of allele Z homozygotes, the accu-
mulation of the SERPINA gene protein leads to neonatal hepatitis and in 2–3% 
of cases to fibrosis and cirrhosis. In pathogenesis some genes were suspected as a 
factor inducing pathological processes in the liver and bile duct in patients with 
cystic fibrosis (gene of plasminogen activator inhibitor type 1, genes relating to 
metalloproteinases, P1 glutation s-transferase gene, transforming growth factor 
beta gene, uridylyltransferase gene (UGT1A1). But the role is not strictly con-
firmed [12–17].
1.1.3 Immunological factors
Chemokines play a role as an activator of stellate cells (source: hepatic macro-
phages, endothelial cells, bile duct epithelial cells, lymphocytes, blood platelets, 
and hepatocytes). The main chemokines are monocyte chemoattractant pro-
tein-1 (MCP1), macrophage inflammatory protein-1 beta (MIP1B), TGF-beta, 
TNF-alpha, platelet-derived growth factor (PDGF), and interleukins IL-1, IL-6, 
and IL-10 [11, 18–23].
Pathogenesis of hepatic lesions the course of cystic fibrosis according to 
Colombo [1, 2, 8].
   Abnormalities of cholangiocytes.
     ↓
         Mucous plugs in bile ducts.
     ↓
            Inflammatory and proliferative processes.
     ↓
         Focal biliary fibrosis (25–30%).
     ↓
                   Multilobular biliary cirrhosis (10%).
     ↓
                 Portal hypertension.
     ↓
                 Hepatic insufficiency.
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1.2 Organ lesions contributing to the manifestation of CFLD
In the examination of Wilchanski et al., the presence of hepatic lesions (cystic 
fibrosis liver damage (CFLD)) was concluded in 28% (80/288) of CF patients. 
All patients with hepatic lesions were diagnosed with pancreatic insufficiency. 
No correlation between the occurrence of hepatic lesions and pulmonary lesions, 
respiratory insufficiency, the level of malnutrition, meconium ileus, and/or distal 
intestinal obstruction syndrome (DIOS) was concluded [24]. Lindblad observed 
meconium ileus in only 12% of CF patients, out of whom only 6/15 patients with 
meconium ileus had the symptoms of liver damage [6]. Siano did not prove the 
correlation between the occurrence of hepatic lesions in the course of cystic fibrosis 
and the pancreatic efficiency and the level of nutrition. In 2–5% of patients, focal 
biliary cirrhosis develops into multilobular cirrhosis [25].
1.2.1 Nutritional factors
Malnutrition influences on liver function in children with cystic fibrosis. Children 
with diagnosed cystic fibrosis and liver damage have lower body mass, height, 
circumference of the upper arm, and BMI. Patients with cystic fibrosis also have 
significantly lower levels of linoleic (LA), docosahexaenoic (DHA), and docosa-
pentaenoic (DPA) acids. The influence of parenteral nutrition and antioxidant and 
vitamin deficiency is confirmed [26–29]. Sometimes in children with cystic fibrosis 
especially with meconium ileus, total parenteral nutrition is necessary. Total paren-
teral nutrition (TPN) therapy is a well-recognized cause of liver injury. The histologic 
changes attributed to TPN in the literature vary widely. Total parenteral nutrition-
induced liver disease develops in 40–60% of infants who require long-term TPN. The 
clinical spectrum includes cholestasis, cholelithiasis, hepatic fibrosis with progression 
to biliary cirrhosis, and the development of portal hypertension and liver failure in 
a significant number of children who are totally parenterally fed. The pathogenesis 
is multifactorial and is related to prematurity, low birth weight, and duration of 
TPN. The degree and severity of the liver disease are related to the recurrent sepsis 
including catheter sepsis, bacterial translocation, and cholangitis. The lack of enteral 
feeding leading to reduced gut hormone secretion, reduction of bile flow, and biliary 
stasis may be important mechanisms in the development of cholestasis, biliary sludge, 
and cholelithiasis.
1.2.2 The role of medications
In patients with cystic fibrosis, abnormal functions of oxidases and P450, 
CYP2C8, CYP2C9, and CYP3A4 cytochromes are observed. The dose of beta-lactam 
should be reduced by 20%. The doses of aminoglycosides should be decided upon 
depending on the level of the medication in the blood serum. Increased microsomal 
metabolism relating to theophylline and methylxanthine through the affected first 
phase of the biotransformation of the medications. Increased hepatic clearance of 
the second phase, which may be reflected in the abnormal metabolism of furose-
mide, lorazepam, and ibuprofen [30–32].
1.2.3 Defects of the gall bladder and bile ducts
In about 30% of patients with cystic fibrosis, atrophic gall bladder, or the lack 
thereof, also its defects and/or of bile ducts is reported. No correlation between 
cirrhosis and abnormalities in the gall bladder and/or bile ducts has been observed. 
Gallbladder hydrops and lithiasis are more commonly observed in patients with 
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cystic fibrosis than the healthy population. The narrowing of the distal regions of 
the bile ducts is frequent and may occur in even 90% of CF patients and contribute 
to the formation of gallstones [33, 34].
1.2.4 Cholelithiasis
Cholelithiasis concerns 14–24% of CF patients. The following play a role in the 
pathogenesis of the formation of gallstones: abnormal bile content, increased excre-
tion of bile acids with stools, and the formation of lithogenic bile where bile acids 
are interlocked with glycine. No correlation between the formation of gallstones 
and supplementation with pancreatic enzymes has been confirmed [1, 3, 22].
Risk factors for the development of liver diseases in cystic fibrosis:
1. Male gender—three fourths of patients with CFLD are male. Protective role of 
estrogens in female.
2. Coexisting meconium ileus (inconsistent data—from a five-time higher risk of 
developing hepatic lesions to a similar risk). Only 25% of patients with CFLD 
who had meconium ileus in the medical interview was identified. Meconium 




5. Severe genotype (delta F508) [1, 12, 24, 35, 36].
1.3 Clinical picture
In most CF patients, the course of hepatic complications is symptomless. 
Pruritus sometimes occurs and jaundice in patients whose condition is advanced. 
Incidental finding of hepatomegaly is usually the first sign. In newborns, steatosis 
may be incidentally discovered in a routine abdominal ultrasound.
Clinical changes of the liver in patients with cystic fibrosis:
1. Focal hepatic fibrosis (72%)
2. Focal biliary cirrhosis (20–30%)
3. Multilobular biliary cirrhosis (5–15%)
4. Portal hypertension (2–5%)
5. Small atrophic gallbladder and narrowing of bile ducts (15–45%)
6. Cholelithiasis (14–24%)
7. Steatosis (25–60%)
8. Cholestasis in newborns (<10%)
9. Primary sclerosing cholangitis (rarely)
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10. Cholangiocarcinoma (rarely)
11. Drug-induced, toxic liver damage [1, 3, 12, 24, 37–40]
1.3.1 Laboratory tests
1.3.1.1 Periodic laboratory tests
The levels of AlAT, AspAT, GGTP, bilirubin and bile acids, the APRI index, and 
FibroTest are recommended. It is believed that elevated levels of at least two hepatic 
parameters above the norm within at least 3 months is an indication of advancing 
hepatic lesions. But they have low sensitivity and specificity. Most patients with 
multifocal cirrhosis have normal test results. Isolated elevation of aminotransfer-
ases with concurrent normal GGTP index may indicate steatosis.
1.3.1.2 Abdominal ultrasound with a Doppler option and elastography
Ultrasound is inexpensive and is a noninvasive test. It allows assessment of the level 
of steatosis, symptoms of portal hypertension, and cirrhotic transformation of the liver. 
However, normal imaging of the liver does not exclude the ongoing process of fibrosis.
FibroScan is an effective and noninvasive tool to quantify fibrosis and steatosis 
in the liver diseases including cystic fibrosis. The stiffness of the liver tissue can be 
assessed based on shear wave velocity (the stiffness increases with the speed).
1.3.1.3 Liver biopsy with histopathological assessment.
Liver biopsy is an invasive procedure and is prone to side effects and sampling. 
This is not a routine recommended procedure in patients with CFLD.
1.3.1.4 Noninvasive parameters of liver fibrosis
Fibroindex, aminopeptides of type III procollagen, collagen I, collagen IV, 
laminine, hyaluronic acid, and/or cytokines and chemokines relating to the process 
of fibrosis. There are studies on their usefulness in minimally invasive clinical 
diagnostics [27, 41–48].
1.4 Treatment
1. Background therapy of cystic fibrosis include pancreas enzyme supplemen-
tation, vitamin supplementation, extensive physiotherapy, and nutritional 
support,
2. Diet therapy. In patients with cystic fibrosis, nutrition and survival are inti-
mately related. Growth failure and body mass deficiency are the prognostic 
factors in patients with CF. Prevention of undernourishment in cystic fibrosis, 
sometimes feeding tube or PEG nutrition, is recommended. Hypercaloric 
diet, which is rich in protein, carbohydrates, and fat, is recommended. 
The energy needs of patients with CF vary widely and have been stated as 
120–150% of those required by healthy individuals of the same age, sex, and 
size. Reduction of protein only in situation of encephalopathy. Correction 
of fat-soluble vitamin deficiency is essential. Lower serum levels of vitamin 
A and E were associated with a higher rate of pulmonary exacerbations and 
worse liver function.
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3. Ursodeoxycholic acid (UDCA). UDCA has a cytoprotective effect on the 
cell membranes of cholangiocytes. It stimulates the secretion of chloride ions 
through calcium-dependent chloride channel. It reduces the ratio of cholic acid 
in bile (less than 5%), reduces its synthesis, and lowers its overall volume. It 
also stimulates cholangiocytes and hepatocytes to secrete. It has antiapoptotic 
effect and reduces the toxic effects of hydrophobic bile acids.
The dose is 15–20 mg/kg b.m. in two divided doses over 24 hours.
There are only a few clinical trials assessing the effectiveness of ursodeoxycholic 
acid. There is insufficient evidence to justify its routine use in cystic fibrosis as a 
preventative measure. Present data suggesting that UDCA should be started before 
severe liver damage is present as it might be able to prevent the progression of CFLD 
and has the potential to induce a reversal of fibrosis [1, 2, 4, 40, 49–51].
4. The treatment of portal hypertension should include:
• Beta blockers—mild oesophageal varices in patiens without contrindications
• Endoscopic methods for the treatment of severe oesophageal varices [37, 51–53]
5. Liver transplant. Advancing dysfunction of the liver, progressing ascites 
and jaundice, recurrent bleeding from esophageal varices and hepatopulmonary 
syndrome, and recurring peritonitis and hepatocarcinoma are indications for liver 
transplantation. MELD/PELD scores are helpful to evaluate the eligibility for liver 
transplantation. Model for End-Stage Liver Disease (MELD) includes bilirubin 
level, albumin, and creatinine concentration. Pediatric end-stage liver disease 
(PELD) consists of age, bilirubin level, INR index, albumin concentration. PELD/
MELD score obtained upon admission may be of help to establish the optimal 
timing for LT evaluation and listing. A higher score correlates with a more critical 
condition and worse survival.
In patients with cystic fibrosis following isolated liver transplantation, there is 
an increased risk of pulmonary complications (severe infections). It seems that an 
FEV1 < 50% was associated with poor outcomes in isolated liver transplantation, 
and thus patients with poor lung function should be considered for combined 
lung-liver transplantation. For isolated liver transplantation, if the FEV1 is <40%, 
patients are listed with their MELD/PELD score plus a 10% mortality equivalence. 
If listed for a combined liver-lung transplantation with an FEV1 < 40%, the liver 
listing starts with a MELD of 40 [54, 55]. Simultaneous liver-pancreas transplanta-
tion restores exocrine and endocrine pancreatic function in patients with CFLD and 
enables improved nutritional outcomes concurrent with the potential for discon-
tinuation of insulin and pancreatic enzyme supplementation therapies. Diabetes 
has been reported to exert a negative effect on the already decreased pulmonary 
function, observed in CF patients. FEV1 in CF patients with diabetes is markedly 
reduced in all age groups compared to CF patients without diabetes. Simultaneous 
liver-pancreas transplantation is associated with an improved BMI in the post-
transplant course [56, 57].
The outcome for combined heart/lung/liver grafting in adult people with CF 
was poor, whereas liver transplantation alone had acceptable waiting times and 
good survival outcome. High incidence of renal impairment in this group, and in 
contrast to previous studies, largely in pediatric patients, respiratory function can 
decline dramatically [55, 58–61].
European recommendations for the treatment of cystic fibrosis and hepatic lesions:
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1. Biochemical tests (AlAT, AspAT, GGTP, FA, prothrombin time, blood plate-
lets) every 6 months.
2. Imaging tests—abdominal ultrasound with Doppler option and elastography, 
alternatively annual CT or MR.
3. Ursodeoxycholic acid at 20 mg/ g daily with divided doses being more 
effective.
4. Panendoscopy performed every 2–3 years is necessary in patients with cirrho-
sis and or splenomegaly in order to exclude esophageal varices.
5. Assessment of the hepatopulmonary syndrome—assessment of intrapulmo-
nary shunts as they intensify hypoxemia.
6. In the case of cirrhosis—assessment of the levels of alpha-fetoprotein (AFP) 
every 6 months.
7. Mild esophageal varices—nonselective beta blockers? Level 2–3 varices—
endoscopic treatment or intrahepatic portosystemic shunts.
8. Prevention of undernutrition (via feeding tube or PEG).
2. Summary
1. The etiopathogenesis of hepatic lesions in the course of cystic fibrosis is very 
complex and not yet fully explained.
2. The clinical symptoms of CFLD are not characteristic, and the clinical picture 
is often symptomless or limited.
3. Further studies into the causes of hepatic lesions in cystic fibrosis are neces-
sary, which will contribute to the reduction in the number of deaths, extended 
survival rate, and improvement in patients’ quality of life.
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Chapter 6
Video Call Educational Program
for Cystic Fibrosis Adolescents
Annalisa Fogazzi, Fabianna Timelli, Annalisa Vezzoli,
Valentina Tradati and Rita Padoan
Abstract
Airway clearance technique (ACT) and inhalation therapy (IT) are essential in
cystic fibrosis (CF) lung disease management. We here present our experience with
a video-call educational program, which could maintain or improve adherence in
adolescents. A 6-month program was offered to adolescents: a physiotherapist
would monitor their ACT and IT home program via scheduled video-calls. A struc-
tured form evaluating patients’ independence and awareness during a session
would be filled in at the start and after 6 months. After informed consent was
obtained, subjects filled in a questionnaire about their expectations and a satisfac-
tion questionnaire at the end of the program. Student's t-test for paired data was
performed for quantitative evaluation of the variables considered in forms filled
during video calls. Eleven CF subjects were enrolled; most of them adhered sponta-
neously, as they expected to improve technique and receive helpful advice. About
301 educational video-calls were performed, 75% being the scheduled calls. Two
patients dropped out. In the end, better awareness and self-management in ACT
and IT was evident, and patients showed better performances (P < 0.01), reporting
they received helpful advice. Video-call education is a simple and feasible tool
which could be useful to support adherence to ACT and IT in CF adolescents.
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Adherence to “time-consuming” therapies in chronic patients is a well-
recognized issue to overcome.
Low adherence has been described in adolescents suffering from diabetes mellitus
[1] and reported in almost 50% of patient prescriptions for respiratory physiotherapy
in cystic fibrosis (CF) [2] as well as more recently in prescriptions for drugs targeting
cystic fibrosis transmembrane regulator (CFTR) protein function [3].
CF patients from adolescence to adulthood are at risk of their clinical condition
worsening, due to several issues: a claim of autonomy (self-management), refusing
therapies or parents’ authority, and a misunderstanding or low perception of the
treatment necessity and efficacy.
It is imperative for CF Centres to ensure awareness, knowledge, and autonomy
in adolescents.
A recent review [4] focused on the existing evidence base regarding adherence
interventions in adolescents with CF. Among potential strategies to improve
91




[51] Pereira T, Lewindon P, Greer R, 
et al. Transcriptional basis for hepatic 
fibrosis in cystic fibrosis- associated 
liver disease. Journal of Pediatric 
Gastroenterology and Nutrition. 
2012;54(3):328-335. DOI: 10.1097/
MPG.0b013e3182432034
[52] Efrati O, Barak A, Modan-Moses D, 
et al. Liver cirrhosis and portal 
hypertension in cystic fibrosis. 
European Journal of Gastroenterology 
& Hepatology. 2003;18:1073-1078
[53] Stonebraker J, Ooi C, Pace R, 
et al. Features of severe liver disease 
with portal hypertension in patients 
with cystic fibrosis. Clinical 
Gastroenterology and Hepatology. 
2016;14(8):1207-1215
[54] Arnon R, Annunzjato R, 
Miloh T, et al. Liver and combined 
lung and liver transplantation for 
cystic fibrosis: Analysis of the UNOS 
database. Pediatric Transplantation. 
2011;15:254-264
[55] Freeman AJ, Sellers ZM, 
Mazariegos G, Kelly AA. Multidisciplinary 
approach to pretransplant and 
posttransplant management of cystic 
fibrosis-associated liver disease. Liver 
Transplantation. 2019;25(4):640-657. 
DOI: 10.1002/lt.25421
[56] Frost F, Dyce P, Ochota A, et al. 
Cystic fibrosis related diabetes: 
Optimizing care with a 
multidisciplimaty approach. Diabetes, 
Metabolic Syndrome and Obesity: 
Targets and Therapy. 2019;12:545-552. 
DOI: 10.2147/DMSO.S180597
[57] Gan HW, Bhatt JM, Denvir L, 
et al. Monogenic diabetes mellitus in 
cystic fibrosis. Archives of Disease in 
Childhood. 2019;104(9):887-889. DOI: 
10.1136/archdischild-2018-316141
[58] Arkwright P, Pravica V, Geraghty P, 
et al. End-organ dysfunction in 
cystic fibrosis. American Journal of 
Respiratory and Critical Care Medicine. 
2003;167:384-389
[59] Bandsma R, Bozic M, Fridell J, 
et al. Simultaneous liver-pancreas 
transplantation for cystic fibrosis-
related liver disease. A multicenter 
experience. Journal of Cystic Fibrosis. 
2014;13:471-477
[60] Nash K, Collier J, French J, et al. 
Cystic fibrosis liver disease to transplant 
or not to transplant? American Journal 
of Transplantation. 2008;8:162-169
[61] Young A, Giles C, Mervyn T, et al. 
A combined liver-pancreas en-bloc 
transplant in a patient with 
cystic fibrosis. Transplantation. 
2005;5:605-607
Chapter 6
Video Call Educational Program
for Cystic Fibrosis Adolescents
Annalisa Fogazzi, Fabianna Timelli, Annalisa Vezzoli,
Valentina Tradati and Rita Padoan
Abstract
Airway clearance technique (ACT) and inhalation therapy (IT) are essential in
cystic fibrosis (CF) lung disease management. We here present our experience with
a video-call educational program, which could maintain or improve adherence in
adolescents. A 6-month program was offered to adolescents: a physiotherapist
would monitor their ACT and IT home program via scheduled video-calls. A struc-
tured form evaluating patients’ independence and awareness during a session
would be filled in at the start and after 6 months. After informed consent was
obtained, subjects filled in a questionnaire about their expectations and a satisfac-
tion questionnaire at the end of the program. Student's t-test for paired data was
performed for quantitative evaluation of the variables considered in forms filled
during video calls. Eleven CF subjects were enrolled; most of them adhered sponta-
neously, as they expected to improve technique and receive helpful advice. About
301 educational video-calls were performed, 75% being the scheduled calls. Two
patients dropped out. In the end, better awareness and self-management in ACT
and IT was evident, and patients showed better performances (P < 0.01), reporting
they received helpful advice. Video-call education is a simple and feasible tool
which could be useful to support adherence to ACT and IT in CF adolescents.
Keywords: adherence, patient education, telemedicine
1. Introduction
Adherence to “time-consuming” therapies in chronic patients is a well-
recognized issue to overcome.
Low adherence has been described in adolescents suffering from diabetes mellitus
[1] and reported in almost 50% of patient prescriptions for respiratory physiotherapy
in cystic fibrosis (CF) [2] as well as more recently in prescriptions for drugs targeting
cystic fibrosis transmembrane regulator (CFTR) protein function [3].
CF patients from adolescence to adulthood are at risk of their clinical condition
worsening, due to several issues: a claim of autonomy (self-management), refusing
therapies or parents’ authority, and a misunderstanding or low perception of the
treatment necessity and efficacy.
It is imperative for CF Centres to ensure awareness, knowledge, and autonomy
in adolescents.
A recent review [4] focused on the existing evidence base regarding adherence
interventions in adolescents with CF. Among potential strategies to improve
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adherence, it was suggested to identify social media tools for online support; some
preliminary positive experiences have been reported with online educational video.
The German Airway League made available video clips about “Correct Inhalation
Therapy for Patients with Cystic Fibrosis.” This gives the opportunity to CF ado-
lescents to obtain, independently of time and location, autonomously, and in a
time-saving manner, information on correct inhalation treatment [5].
An educational video was recently made available to parents of babies who
resulted positive at the newborn screening program for cystic fibrosis [6], as an
adjunct to help with genetic counseling. This study demonstrated the effectiveness
of an educational video in improving parents’ knowledge.
We employed a novel face-to-facemonitoring of home inhalation therapy (IT) and
airway clearance technique (ACT), with a video call survey and educational program,
with the aim of assessing awareness of CF adolescents and helping them to improve
their knowledge and adherence. Here we present our preliminary experience.
2. Methods and patients
CF adolescents, regularly followed up at our CF Centre, were invited to
participate in a 6-month program designed to offer online support during home IT
and ACT. All patients in the age range 12–18 years were offered enrollment in the
project.
The primary endpoint of the study was the feasibility of the online video call
program and its acceptability. Feasibility was determined by percentage of adherence
(more than 75% of eligible patients), acceptability by the number of contacts for
planned calls (more than 50%), and dropout of enrolled patients (less than 20%).
A secondary endpoint was to assess its efficacy in improving patients’ knowl-
edge of therapies (preparation, sequences of IT/ACT) and autonomy in performing
respiratory therapies and in cleaning devices, by means of score assigned during
video monitoring.
Approval for conducting the study was received by the local ethics committee.
Informed consent was obtained from subjects who agreed to participate and from
their parents. All patients completed a Q1 questionnaire (see Appendix) to investi-
gate their expectations toward the project.
Six touch screen tablets and internet connections were provided to adolescents
who did not have access to one.
At the start, all subjects underwent their routine complete functional evaluation
(spirometry, 6-minute walking test, MIP/MEP (muscle inspiratory and expiratory
pressures)). All have their personalized therapeutic plan (IT and ACT), and during
the 6-month program, they received a supervision of their physiotherapy program
every 2 months at scheduled clinical visits.
A respiratory physiotherapist, via online video call, monitored, in the early
afternoon, the adolescents’ home program performances two times a week for
6 months, following each personal therapeutic plan. The scheduled time for each
connection was 30–45 minutes; this time was available to monitor both IT and ACT,
to answer questions and correct errors.
At the start and end of the study, the physiotherapist filled in a form for each
subject, evaluating their independence and awareness during a session. Three issues
were assessed, with a total of different items: (a) Does the patient know why, when,
and with which drugs to perform IT (3 items)? (b) Does the patient know how to
properly prepare the devices (9 items)? (c) Does the patient know to clean and
disinfect used devices (2 items)? For each item, a score between 0 and 5 was
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assigned (0, severely insufficient; 5, excellent). The scores (maximum, sufficient)
for each issue were (a) 15, 9; (b) 45, 27; and (c) 10, 6 (see Appendix).
With regard to the question “How do you perform ACT?,” the physiotherapist,
after evaluation of each performance, gave a personalized educational intervention
based on deficiencies identified during the video call, giving suggestions and advice
and answering questions.
At the end of the study, a Q2 satisfaction questionnaire (see Appendix) was filled
in by subjects, to evaluate agreement and acceptability of the project and to give
their suggestions.
A descriptive analysis of the data collected was performed. A Student’s t-test for
paired data was performed to assess improvement in scores at the end of the study.
3. Results
Thirty CF patients aged 12–18 years, regularly followed at our CF Centre, were
eligible. Participation in the study was offered to all. All but one accepted to partic-
ipate (97%), and 11 subjects (5 M) on a first arrived basis were enrolled.
The baseline characteristics of the study population are summarized in Table 1.
Patients Sex Genotype Respiratory
microbiology




1 M F508 del/
G542X
Staphylococcus aureus 13 72 54 58 690




15 51 86 72 720
3 M 1717-1G > A/
N1303K
Staphylococcus aureus 13 104 66 63 720
4 F F508 del/F508
del
Staphylococcus aureus 11 94 91 98 605
5 M F508del/F508
del






16 94 108 83 660
7 F W1282X/
R785X





16 69 151 149 570









13 61 167 95 557
11 F F508del/
W1282X
Staphylococcus aureus 12 79 118 96 695
Mean 13.82 77.00 107.55 88.09 649.80
SD 2.04 18.11 36.01 27.52 62.96
Table 1.
Clinical characteristics of the study population at the baseline visit.
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Six touch screen tablets and internet connections were provided to adolescents
who did not have access to one.
At the start, all subjects underwent their routine complete functional evaluation
(spirometry, 6-minute walking test, MIP/MEP (muscle inspiratory and expiratory
pressures)). All have their personalized therapeutic plan (IT and ACT), and during
the 6-month program, they received a supervision of their physiotherapy program
every 2 months at scheduled clinical visits.
A respiratory physiotherapist, via online video call, monitored, in the early
afternoon, the adolescents’ home program performances two times a week for
6 months, following each personal therapeutic plan. The scheduled time for each
connection was 30–45 minutes; this time was available to monitor both IT and ACT,
to answer questions and correct errors.
At the start and end of the study, the physiotherapist filled in a form for each
subject, evaluating their independence and awareness during a session. Three issues
were assessed, with a total of different items: (a) Does the patient know why, when,
and with which drugs to perform IT (3 items)? (b) Does the patient know how to
properly prepare the devices (9 items)? (c) Does the patient know to clean and
disinfect used devices (2 items)? For each item, a score between 0 and 5 was
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With regard to the question “How do you perform ACT?,” the physiotherapist,
after evaluation of each performance, gave a personalized educational intervention
based on deficiencies identified during the video call, giving suggestions and advice
and answering questions.
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in by subjects, to evaluate agreement and acceptability of the project and to give
their suggestions.
A descriptive analysis of the data collected was performed. A Student’s t-test for
paired data was performed to assess improvement in scores at the end of the study.
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All subjects have a confirmed CF, and all presented pancreatic insufficiency, age
ranged between 11 and 16 years. Seven subjects had moderate respiratory disease
(FEV1pp: 51–79%); four had normal function (FEV1pp: 94–104%). Chronic Pseudo-
monas infection was present in three. All presented a 6-minute walking test within
the normal limits (range 557–720 meters).
Airway clearance technique consisted of the use of PEP Mask in all of them.
In the 6-month program, 301 educational video calls were performed, which is
75% of the scheduled calls.
Their mean duration was 45 min (range 30–60 min). Each subject received a
video call at least twice a week.
During the study period, two subjects dropped out (n°9 and 10; 18%), because
of school commitments in the afternoon.
Regarding questionnaires filled in by subjects at the start (Q1) and at the
end (Q2) of the project, Q1 (filled by 11 subjects) shows that eight adolescents
were pleased to participate in the project, considering it an opportunity to
maintain frequent contact with physiotherapists (in four cases) and a way to
monitor their home program (in five). Nine subjects adhered spontaneously,
but four did it for pleasing parents, and only one boy was forced by them. All
subjects considered ACT very important to maintain their health, and their
main expectations were to improve technique and receive helpful advice (six
subjects) and have the opportunity to demonstrate their independence (two of
them).
The Q2 questionnaire (filled in by nine subjects) shows that ACT was
considered important in spite of the effort it requires. All of them were pleased to
be enrolled in the study as it was a good opportunity to monitor the way they
perform ACT; they have received helpful advice (reported by five of them) or
have maintained contact with physiotherapists (by four). Four of them felt
emotionally supported.
3.1 Results from forms filled by the physiotherapist
Issue A. Does the subject know why, when, and with which drugs to perform IT and
ACT (possible score for each patient: 0–15)? At the start, 4 out of 11 adolescents did
not know the reason for which they must perform the IT/ACT, and they did not
perform both the IT and the ACT correctly. At the end, the final scores showed a
greater awareness of why airway clearance is important and have shown a better
understanding of IT in all subjects but one (mean score at start 6.5 (range 2–13),
mean score at end 9.6 (range 5–14), (P < 0.01)).
Issue B. Does the subject properly prepare his/her IT and device (possible score for
each patient: 0–45)? At the first evaluation, almost all were already able to prepare
and assemble the devices; at the final one, all subjects were able to prepare and
assemble the devices (mean score at start 29.5 (range 13–43), mean score at end 35.8
(range 25–43), (P < 0.01)).
Issue C. Does the subject clean and disinfect his/her devices after therapy (possible
score 0–10)? None but one subject was autonomous in device cleaning and disin-
fection, leaving this duty to parents, both at the start and end (mean score 2.2 in
both evaluations, NS).
The initial assessment of appropriateness in the execution of IT/ACT shows that
seven subjects kept a right posture during IT/ACT and respected the correct
sequence of drugs, but after the educational intervention, all of them performed the
entire sequence IT / ACT appropriately.
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4. Discussion
Our preliminary experience on a limited number of CF adolescents shows the
possibility to perform an educational program by means of online video call. This
program was designed to offer online support during home IT and ACT by a
respiratory physiotherapist, with the aim of improving knowledge and adherence to
respiratory physiotherapy in CF adolescents.
Recent reported experiences on an educational program on inhalation therapy
[5] or newborn screening [6] with online video clips do not provide any kind of
personal relationship between those who produced the media available online and
the CF patient, differently by our program.
New technologies such as video call using smartphones or tablets are used on a
daily basis by adolescents; thus we hypothesized that introducing educational pro-
grams in their life using these technologies might result in better outcomes. To the
best of our knowledge, our study is the first educational program to use online video
calls provided by an experienced physiotherapist to monitor IT/ACT. This program
gave the opportunity to CF teenagers to develop personal contact with the respira-
tory therapist in their own homes, beyond the scheduled visits at the specialist
center. Our work proved the feasibility of an educational video call program, where
adolescents accepted online supervision for their daily IT/ACT and attended 75% of
the planned calls.
The main problem we faced was the timing of the video calls, scheduled in the
afternoon. In fact, 2 out of 11 patients had to abandon the project because of the
video call time coinciding with commitments to school.
ACT monitoring and individualized educational interventions in the short term
seem to lead to positive results, such as increased knowledge and better adherence
to prescribed therapies by the end of the project.
Patients agreed to receive video calls and maintain frequent contact with the
physiotherapist, and the program seemed to improve their autonomy in the man-
agement of IT and ACT.
With this study, we have also verified how an aspect of daily care, cleaning, and
disinfection of IT/ACT devices is not taken into account as a personal task by
teenagers but is constantly referred to one of the parents (usually the mother). An
explanation could be also the desire of parents to be sure of the adequacy of cleaning
or to be still present in the care of their teenage children.
Since the acquisition of personal autonomy also involves care (cleaning and
disinfection) of the tools necessary for the execution of airway clearance, we will
implement educational programs on this aspect of care.
The main positive effects of this project were the CF care team showed both the
willingness and capability of using modern technologies to communicate with
young people and improvement in knowledge, self-management, and autonomy in
CF patients.
After the study ended, as a result of the project and in response to our patients’
requests, video calls were made available during intravenous home therapy for
pulmonary exacerbations, as patients recognized its usefulness in improving
adherence.
Making additional resources available to patients outside the CF clinics, at their
own home, resulted to be beneficial in reducing the feeling of loneliness during ACT
daily performance and may, therefore, promote motivation and ameliorate adher-
ence.
This pilot study has some limitations, including the low number of patients and
its short duration. It is well known that educational interventions must be repeated
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respiratory physiotherapy in CF adolescents.
Recent reported experiences on an educational program on inhalation therapy
[5] or newborn screening [6] with online video clips do not provide any kind of
personal relationship between those who produced the media available online and
the CF patient, differently by our program.
New technologies such as video call using smartphones or tablets are used on a
daily basis by adolescents; thus we hypothesized that introducing educational pro-
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afternoon. In fact, 2 out of 11 patients had to abandon the project because of the
video call time coinciding with commitments to school.
ACT monitoring and individualized educational interventions in the short term
seem to lead to positive results, such as increased knowledge and better adherence
to prescribed therapies by the end of the project.
Patients agreed to receive video calls and maintain frequent contact with the
physiotherapist, and the program seemed to improve their autonomy in the man-
agement of IT and ACT.
With this study, we have also verified how an aspect of daily care, cleaning, and
disinfection of IT/ACT devices is not taken into account as a personal task by
teenagers but is constantly referred to one of the parents (usually the mother). An
explanation could be also the desire of parents to be sure of the adequacy of cleaning
or to be still present in the care of their teenage children.
Since the acquisition of personal autonomy also involves care (cleaning and
disinfection) of the tools necessary for the execution of airway clearance, we will
implement educational programs on this aspect of care.
The main positive effects of this project were the CF care team showed both the
willingness and capability of using modern technologies to communicate with
young people and improvement in knowledge, self-management, and autonomy in
CF patients.
After the study ended, as a result of the project and in response to our patients’
requests, video calls were made available during intravenous home therapy for
pulmonary exacerbations, as patients recognized its usefulness in improving
adherence.
Making additional resources available to patients outside the CF clinics, at their
own home, resulted to be beneficial in reducing the feeling of loneliness during ACT
daily performance and may, therefore, promote motivation and ameliorate adher-
ence.
This pilot study has some limitations, including the low number of patients and
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in time, with scheduled follow-up calls to maintain their efficacy. However, the
primary outcome was to test the feasibility of an educational program via video
calls, and this has been achieved, thanks to a rethinking of the CF health services
model, which was delivered to patients’ homes via online video calls.
The bias of the study is the very small number of patients.
In the future, further studies are needed to explore feasibility/acceptability with
a larger number of subjects and clarify the duration needed to maintain positive
results in the long term and its usefulness during home therapy for pulmonary
exacerbations.
In conclusion, our pilot experience verified the feasibility and acceptability of an
online video call educational program designed to improve knowledge and self-
management of CF adolescents.
ACT monitoring and educational interventions, performed by video call, signif-
icantly improved our patients’ ability and knowledge, promoting their adherence to
ACT/IT and awareness of the need for greater adherence to the therapeutic pro-
gram. Their independence has also been promoted. Video call educational programs
could be a helpful therapeutic tool in the CF scenario.
4.1 Psychological comment
The design of this study also arises from the deep consideration of the psycho-
logical aspects related to the adolescent world of our age and in particular to the
portion of the adolescent world that must live with a chronic disease caused by the
presence of cystic fibrosis.
This is particularly true and relevant in a perspective that strongly supports the
goodness and efficacy of the treatment being facilitated by the personalization of
the therapeutic plan, modulated according to the characteristics and specific
resources of the patient it is addressed to.
The current adolescent generation is embodied by the so-called “digital natives,”
namely, children and teenagers who have grown up hand in hand with the increas-
ingly intensive use of the Internet, in an age where the use of technology breaks
deep into everyday life, with a dramatic surge in virtual relationships that change
and significantly influence the profile of contemporary adolescents.
Adolescence is a complex age with difficult specific-phase tasks to perform, even
more so for the chronically ill adolescent, whose emotional world is permeated by
difficult balances.
Girls and boys dealing with the disease are progressively confronted with
aspects of themselves and of their pathology that binds them to a condition of
dependence and fragility. This condition acquires anti-evolutionary meaning, in
stark contrast with the increasing search for emancipation, autonomy, and self-
affirmation.
Parents, in turn, are mainly concerned about their children’s health and survival
and often tend to limit their autonomy, with an excessive overprotection and
control over the care and daily life of their children, thus possibly producing results
that are quite opposite to their expectations, i.e., poor adherence to the prescribed
therapy and onset of risk behaviors.
Therefore, respiratory physiotherapy represents an extremely delicate and
meaningful moment for adolescents with cystic fibrosis, as it is a constant reminder
of their chronic condition: they are chronically ill individuals who depend on a
treatment they would most like to avoid. Physiotherapy inevitably turns into a
battlefield where parents and children fight every day, causing distress and strain
on both sides.
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In light of these considerations, the project aiming at promoting the improve-
ment of physiotherapy through video calls is even more relevant because it pursues
multiple objectives.
On the one hand, it allows a personalized educational intervention aimed at
supporting the improvement of techniques and skills by adolescent patients, taking
advantage of technology and the Internet, which directly provide a familiar com-
mon language, appreciated by the youth and able to abolish distance.
On the other hand, the operator has the opportunity to walk into the homes of
children and parents, albeit virtually, reducing the sense of loneliness and
supporting the fatigue that adhering to such demanding regimens involves, espe-
cially during adolescence, thus encouraging a gradual autonomy, which is a funda-
mental objective both for the treatment and for the adherence to the therapies as
well as for the growth and for the psychological well-being of our patients.
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○ I like the idea to receive support by the physiotherapist.
○ I want to receive a tablet.
○ I think that this project improves my adherence to the treatment.
○ Other, please explain…………………………………………………………………
1b. If you answered “no,” please explain why:
○ Hospital visits are enough, I do not want to be checked at home.
○ These scheduled calls limit my freedom.
○ I do not like using computer.
○ I think to do physiotherapy correctly so I do not need help.
○ I think that physiotherapy is not such important for my health.
○ Other, please explain.………………………………………………
1c. If you answered “indifferent,”explain why:
○ I do not know if this project could be useful for me.
○ I do not understand what the project consists in.
○ Other, please explain………………………………………………
2. I have agreed to participate in the project:
○ Deciding by myself without any advice.
○ Because my parents forced me.
○ I decide alone with the awareness that this choice is the best for my
parents.
3. To maintain your health, do you think that physiotherapy is:
○ Very important.
○ Not so important.
○ Not important at all.
○ I know that it’s very important for my health but I do not want to perform it.
○ Other, please explain………………………………………………
4. Why do physician and physiotherapists involve you in this project? What
do you think?
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○ Because they do not believe that I perform my daily physiotherapy
○ Because they believe that I do not correctly perform it
○ Because they want to help me to feel good
○ Because they want to control me
○ To make my parents happy
○ To help me to become autonomous and responsible for my therapy
5. What do you expect from this project?
○ Being able to perform physiotherapy better than before.
○ To receive advice and useful information.
○ To receive support during my therapy.
○ To prove that I am able to do things well.
○ To please my parents, so that they “stress” me less for physiotherapy.
○ To feel supported even emotionally.
○ To waste time that I could use to do something else.
○ To “earn” a tablet.
○ I do not expect anything in particular.
○ Other, please explain.………………………………………………………………






A.2 Video Call Educational Program (Evaluation Form)
Evaluation Date:……………..
Patient’s first and last name: …………………………………………………………
Sex of the patient: ♂ Male ♀ Female Age of the patient ……………years.
The following assessment is:
○ Initial
○ Intermediate (3 months)
○ Final
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A. Knowledge of therapy
Legend:
5 = Excellent; 4 = Good; 3 = Discrete; 2 = Sufficient; 1 = Insufficient;
0 = Severely insufficient.
Educational notes (e.g., acknowledgment of need for education in a given area





B. Execution of respiratory physiotherapy session
Legend:
5 = Excellent; 4 = Good; 3 = Discrete; 2 = Sufficient; 1 = Insufficient;
0 = Severely insufficient.
0 1 2 3 4 5
1. Does the patient know why he/she had to do respiratory physiotherapy?
2. Does the patient know the correct sequence of respiratory physiotherapy
(nasal lavage-bronchodilators-hypertonic/Pulmozyme/mucolytic-
physiotherapy-antibiotic therapy)?
3. Does the patient know the drugs he/she takes by aerosol (short-acting
bronchodilators, bronchodilators and long-acting corticosteroids, oral
steroids, antibiotics, Pulmozyme/hypertonic/mucolytic, etc.)?
0 1 2 3 4 5
1. Is the patient able to prepare the necessary material for the execution of the
physiotherapy session (Lavonase, compressor, nebulizer ampoule, PEP Mask,
or other devices)?
2. Is the material clean and in good condition before the session?
3. When performing the aerosol, does the patient choose the correct interface?
4. If the patient uses the PEP Mask, is he/she able to fit the various components
(mask, resistor, valve) in the correct way?
5. If the patient uses the PEP Mask, does he/she employ the correct resistor?
6. Does the patient respect the correct timing during the airway clearance
technique?
7. Does the patient perform FET or cough?
8. Is the patient able to produce sputum?
9. Is the patient’s posture correct during the session of respiratory
physiotherapy?
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Educational notes (e.g., acknowledgment of need for education in a given area








5 = Excellent; 4 = Good; 3 = Discrete; 2 = Sufficient; 1 = Insufficient;
0 = Severely insufficient.
Educational notes (e.g., acknowledgment of need for education in a given area






Signature of the physiotherapist.
………………………………….
A.3 Questionnaire #2
Dear boys and girls, this short questionnaire follows the project “Monitoring of
Respiratory Physiotherapy Through Video Call in Adolescents.” The aim is to know
what you think about the project and its utility and receive suggestion from you.
The questionnaire is anonymous; fill only your age and gender.
Thanks for your collaboration!
Dr. Padoan and physiotherapist.




1a. If you answered “yes,” please explain why:
○ It was a way to monitor my physiotherapy.
○ I love the technology.
0 1 2 3 4 5
1. Does the patient clean the devices?
2. Does the patient disinfect the devices?
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○ I was happy to receive support in my home treatment.
○ I liked the idea to receive support by the physiotherapist.
○ I wanted to receive a tablet.
○ I thought that this project would improve my adherence to the treatment.
○ Other, please explain.
1b. If you answered “no,” please explain why:
○ Hospital visits were enough, I did not want to be checked at home.
○ These scheduled calls limited my freedom.
○ I do not like using computer.
○ I thought to perform physiotherapy correctly so I did not need help.
○ I thought that physiotherapy is not such important for my health.
○ Other, please explain.…………………………………………………………………………
…………………………………………………………………………………………………………
1c. If you answered “indifferent,”please explain why:
……………………………………………………………………………………………………………………
………………………………………………
2. What do you think about your respiratory physiotherapy?
○ It is very important.
○ It is not so important.
○ It is not important at all.
○ It is very important to feel better but I do not want to perform it.
○ Other, please explain……………………………………………………………………………
……………………………………………………………………………………………………………
3. What do you think about your involvement in this project by the physio-
therapist?
○ Physiotherapists did not believe that I perform my daily physiotherapy.
○ Physiotherapists believed I do not perform correctly my daily
physiotherapy.
○ Physiotherapists wanted to make me feel better.
○ Physiotherapists wanted to control me.
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○ Physiotherapists wanted to make my parents happy.
○ Physiotherapists wanted to help me to become autonomous and
responsible for my therapy.
4. What do you think at the end of this project?
○ I’m able to better perform physiotherapy.
○ I received advice and useful information.
○ I proved my ability to perform physiotherapy.
○ I pleased my parents.
○ I felt supported even emotionally.
○ I wasted time that I could use to do something else.
○ I did not learn anything.
○ Other, please tell us………………………………………………………………………………
…………………………………………………………………………………………………………
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○ Physiotherapists wanted to make my parents happy.
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○ I’m able to better perform physiotherapy.
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Chapter 7
Designing Heterogeneous-mHealth
Apps for Cystic Fibrosis Adults
Tamara Vagg, Cathy Shortt, Claire Fleming,
Mairead McCarthy, Sabin Tabirca and Barry J. Plant
Abstract
In this chapter, we will discuss the design and development of a patient passport
mHealth application for Cystic Fibrosis adults from ideation to app-store release. By
allowing the patients access to their own unique data, it is anticipated that it will be
of benefit when travelling abroad and between CF centres. The design process
followed a pipeline we developed that is informed by patient and healthcare pro-
fessional input. The app structure resembles an Irish patient file and is divided into
three categories: “My CF Info”, “My Medical History”, and “My Clinical Appoint-
ments”. My CF Info allows the patient to store personal information such genotype,
medical team contact information, physiotherapy, allergies, and medications. My
Medical History allows the user to record information such as CF renal disease, CF
diabetes, and the insertion/removal of a portacath/gastrostomy tube. My Clinical
Appointments allows the user to record the type of appointment (annual assess-
ment, clinic, other) and all information that would ordinarily be inserted into a
patient file such as weight, height, spirometry and other comments. Weight and
lung function are also displayed in a plot graph. The app has undergone pilot testing
with five CF adults before being rolled out onto the Google Play Store.
Keywords: cystic fibrosis, patient passport, mHealth, digital health,
self-management
1. Introduction
Cystic Fibrosis (CF) is the most common life limiting genetic disease affecting
Caucasians. Patients must adhere to rigorous therapies in order to manage their
condition. Such therapies include airway clearance physiotherapy, medications,
diet, and exercise.
Ireland has the highest prevalence of CF worldwide, with 1 in 19 people being
carriers for the CF gene [1]. Despite this, the life expectancy of patients with CF is
rising. A child born with CF in 2009 is now predicted to live into their 50s [2, 3],
compared to children born in 1950, of which half would live to the age of 16 and
only 3% to 25 years old [4, 5]. However, this increase in life expectancy comes with
an increase in patient population. There are now more adult CF patients than
pediatric patients in Ireland [6]. It is projected that the pediatric service will need to
grow by 25% and the adult service by 75% by 2025 [7]. This growth in adult
population and the advent of ICT technologies in the medical space has led to
mobile health applications (mHealth apps) being identified as potential powerful
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1. Introduction
Cystic Fibrosis (CF) is the most common life limiting genetic disease affecting
Caucasians. Patients must adhere to rigorous therapies in order to manage their
condition. Such therapies include airway clearance physiotherapy, medications,
diet, and exercise.
Ireland has the highest prevalence of CF worldwide, with 1 in 19 people being
carriers for the CF gene [1]. Despite this, the life expectancy of patients with CF is
rising. A child born with CF in 2009 is now predicted to live into their 50s [2, 3],
compared to children born in 1950, of which half would live to the age of 16 and
only 3% to 25 years old [4, 5]. However, this increase in life expectancy comes with
an increase in patient population. There are now more adult CF patients than
pediatric patients in Ireland [6]. It is projected that the pediatric service will need to
grow by 25% and the adult service by 75% by 2025 [7]. This growth in adult
population and the advent of ICT technologies in the medical space has led to
mobile health applications (mHealth apps) being identified as potential powerful
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tools to assist the growing and ageing CF population in the management of their
condition. However, any mHealth app developed in this way must be fully
personalisable in order to fit the heterogeneous nature of the treatment and man-
agement of CF.
In this chapter we will discuss the design and development of a patient passport
mHealth app for CF adults; from ideation to app-store release. This chapter will
first begin by introducing the CF unit responsible for its development, before
discussing patient passports. Following this, the chapter will introduce the
development of this mHealth app which follows the mHealth Design Pipeline as
presented by Vagg et al. [8].
1.1 Cork CF multidisciplinary team
CF clinical care is driven by a multidisciplinary team approach. The CF
Multidisciplinary Team (MDT) comprises of a mixture of healthcare professionals
with varied skill sets to support this multisystem condition. This includes a CF nurse
specialist (designated and working full time in CF care), CF physiotherapist (des-
ignated and working full time in CF care), and CF dietician (designated and
working full time in CF care). The team is supported by a respiratory technician
(with a commitment to CF) and psychologist. The MDT is medically-lead by a
respiratory specialist with an interest in CF. The respiratory physician/specialist is
also supported by a lung-disease research/specialist registrar [9].
The CF MDT at the Cork University Hospital includes: three CF nurse specialists
(>30 years collective full time experience in CF care), one dietician (>10 years full
time experience in adult and pediatric CF care) one senior physiotherapist (>5 years
full time experience CF care), one respiratory technician (>20 years full time
experience), and one CF consultant with 10 years as the director of the Cork
unit and 10 years’ experience in other leading centers both nationally and
internationally.
This multidisciplinary team supports the second largest CF center in Ireland
with over 180 adult CF patients. The Cork CF multidisciplinary team also lead
CFMATTERS; an international multicenter consortium exploring antibiotic thera-
pies in CF [10]. In addition to this, the research team includes a dedicated
medical-multimedia research specialist who works directly with the MDT.
1.2 Patient passports definition and review
A patient passport is described by the National Quality Forum (NQF) and
Health Service Executive (HSE) as a paper-based system which provides immediate
and important information regarding a patient’s health or condition to medical pro-
fessionals [11, 12]. This passport system is implemented for a number of reasons,
such as improved patient experience, improving the speed that care is delivered,
and as a solution for those patients with learning disabilities [11, 12].
An example of such a passport can be seen for asthma management in the
research conducted by Newell et al. [13]. The paper-based passport as presented in
this research is developed to store pertinent medical information that an asthmatic
would require to receive care on entering an emergency room. Newell et al. found
that patients would often experience more fear and stress in this situation as
responding medical professionals may ask the patient to repeatedly speak to gain an
understanding of this patient’s condition, or leave the patient alone so that they can
source the information. The paper passport solution is designed to be small and
convenient to carry (the size of a credit card) and can provide medical professionals
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the medical data needed to treat the patient immediately [13]. Another example
of these paper-based passports can be seen in the research carried out by Barber
et al. [14]. This passport was developed as a medication aid and allowed geriatric
patients to record and review their medications and dosages. The researchers
found that this system empowered patients to be more in control of their
medication and also acted as a mechanism for the patient to communicate and
discuss their medications more confidently with their medical team [14].
Patient passports have also been created for other long-term conditions, such as
diabetes. Similar to other chronic conditions, diabetic patients must meet with
various members of the multidisciplinary healthcare team. For diabetic patients,
passports can be beneficial as they allow the patient to record medical data received
from each member of the diabetes multidisciplinary team [15]. In this way, pass-
ports bridge a communication gap between patients and these various multidis-
ciplinary members [15].
When researching “CF Patient Passports”, only two bodies of work were found.
The first was a book titled “The Cystic Fibrosis Passport” by Fitzgerald, which aims
to aid family members in understanding the needs of children with cystic fibrosis,
and to serve as a practical guide to those who care for these children [16]. The
second was a quality improvement initiative taken by the Stanford CF Center,
which presented a paper-based system that used a passport-sized document
containing instructions on how to care for a patient with CF [17]. The document
could be presented by a CF patient to a hospital or clinic to ensure the correct
measures are taken to avoid potential issues with infection and cross-
contamination. Although both passports are important for the care of CF, they do
not include features common to long term condition passports as they do not
facilitate self-reported medical data that is accessible to patients at all times.
In addition to paper-based CF passports, a search was performed for digital CF
patient passports on both the Google Play and iOS mobile App Stores. From this
search, only one app was found that allows CF patients to record their medical data,
similar to a passport; “CF View” [18]. CFView is an app which was created by “CF
Ireland”, a CF charity in the Republic of Ireland. The app allows patients to view
medical data that has been collected regarding their condition; however, it does
not allow patients to enter or save data. In addition to this, CF patients can only use
this app if they are part of a CF registry in Ireland, Denmark or Slovenia, and
have been issued with an account by that registry. From the findings of the paper
based and digital based search, it would appear that there is no freely or publicly
available CF patient passport system that allows patients to record basic medical
data. Considering the benefits of a patient passport, it can be stipulated that
such a tool would be beneficial to adult CF patients.
1.3 Possible issues with patient passports
The previous section outlines cases where patient passports have been used
advantageously for patients; asthma patient information, diabetic patient informa-
tion, medication aid. However, patient passports can also present other challenges
which may lead to low adoption rates and minimal impact on patient experience. To
investigate this further, Dijkstra et al. interviewed diabetic patients and medical
professionals to understand their experience of implementing the passport into
their current care system [19]. Concerns expressed by the patients were predomi-
nantly focused on security, forgetting the passport, being over encumbered, and
need for additional time to enter information into the passport. For security,
patients were concerned of the ramifications of losing the passport and the threat
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tools to assist the growing and ageing CF population in the management of their
condition. However, any mHealth app developed in this way must be fully
personalisable in order to fit the heterogeneous nature of the treatment and man-
agement of CF.
In this chapter we will discuss the design and development of a patient passport
mHealth app for CF adults; from ideation to app-store release. This chapter will
first begin by introducing the CF unit responsible for its development, before
discussing patient passports. Following this, the chapter will introduce the
development of this mHealth app which follows the mHealth Design Pipeline as
presented by Vagg et al. [8].
1.1 Cork CF multidisciplinary team
CF clinical care is driven by a multidisciplinary team approach. The CF
Multidisciplinary Team (MDT) comprises of a mixture of healthcare professionals
with varied skill sets to support this multisystem condition. This includes a CF nurse
specialist (designated and working full time in CF care), CF physiotherapist (des-
ignated and working full time in CF care), and CF dietician (designated and
working full time in CF care). The team is supported by a respiratory technician
(with a commitment to CF) and psychologist. The MDT is medically-lead by a
respiratory specialist with an interest in CF. The respiratory physician/specialist is
also supported by a lung-disease research/specialist registrar [9].
The CF MDT at the Cork University Hospital includes: three CF nurse specialists
(>30 years collective full time experience in CF care), one dietician (>10 years full
time experience in adult and pediatric CF care) one senior physiotherapist (>5 years
full time experience CF care), one respiratory technician (>20 years full time
experience), and one CF consultant with 10 years as the director of the Cork
unit and 10 years’ experience in other leading centers both nationally and
internationally.
This multidisciplinary team supports the second largest CF center in Ireland
with over 180 adult CF patients. The Cork CF multidisciplinary team also lead
CFMATTERS; an international multicenter consortium exploring antibiotic thera-
pies in CF [10]. In addition to this, the research team includes a dedicated
medical-multimedia research specialist who works directly with the MDT.
1.2 Patient passports definition and review
A patient passport is described by the National Quality Forum (NQF) and
Health Service Executive (HSE) as a paper-based system which provides immediate
and important information regarding a patient’s health or condition to medical pro-
fessionals [11, 12]. This passport system is implemented for a number of reasons,
such as improved patient experience, improving the speed that care is delivered,
and as a solution for those patients with learning disabilities [11, 12].
An example of such a passport can be seen for asthma management in the
research conducted by Newell et al. [13]. The paper-based passport as presented in
this research is developed to store pertinent medical information that an asthmatic
would require to receive care on entering an emergency room. Newell et al. found
that patients would often experience more fear and stress in this situation as
responding medical professionals may ask the patient to repeatedly speak to gain an
understanding of this patient’s condition, or leave the patient alone so that they can
source the information. The paper passport solution is designed to be small and
convenient to carry (the size of a credit card) and can provide medical professionals
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the medical data needed to treat the patient immediately [13]. Another example
of these paper-based passports can be seen in the research carried out by Barber
et al. [14]. This passport was developed as a medication aid and allowed geriatric
patients to record and review their medications and dosages. The researchers
found that this system empowered patients to be more in control of their
medication and also acted as a mechanism for the patient to communicate and
discuss their medications more confidently with their medical team [14].
Patient passports have also been created for other long-term conditions, such as
diabetes. Similar to other chronic conditions, diabetic patients must meet with
various members of the multidisciplinary healthcare team. For diabetic patients,
passports can be beneficial as they allow the patient to record medical data received
from each member of the diabetes multidisciplinary team [15]. In this way, pass-
ports bridge a communication gap between patients and these various multidis-
ciplinary members [15].
When researching “CF Patient Passports”, only two bodies of work were found.
The first was a book titled “The Cystic Fibrosis Passport” by Fitzgerald, which aims
to aid family members in understanding the needs of children with cystic fibrosis,
and to serve as a practical guide to those who care for these children [16]. The
second was a quality improvement initiative taken by the Stanford CF Center,
which presented a paper-based system that used a passport-sized document
containing instructions on how to care for a patient with CF [17]. The document
could be presented by a CF patient to a hospital or clinic to ensure the correct
measures are taken to avoid potential issues with infection and cross-
contamination. Although both passports are important for the care of CF, they do
not include features common to long term condition passports as they do not
facilitate self-reported medical data that is accessible to patients at all times.
In addition to paper-based CF passports, a search was performed for digital CF
patient passports on both the Google Play and iOS mobile App Stores. From this
search, only one app was found that allows CF patients to record their medical data,
similar to a passport; “CF View” [18]. CFView is an app which was created by “CF
Ireland”, a CF charity in the Republic of Ireland. The app allows patients to view
medical data that has been collected regarding their condition; however, it does
not allow patients to enter or save data. In addition to this, CF patients can only use
this app if they are part of a CF registry in Ireland, Denmark or Slovenia, and
have been issued with an account by that registry. From the findings of the paper
based and digital based search, it would appear that there is no freely or publicly
available CF patient passport system that allows patients to record basic medical
data. Considering the benefits of a patient passport, it can be stipulated that
such a tool would be beneficial to adult CF patients.
1.3 Possible issues with patient passports
The previous section outlines cases where patient passports have been used
advantageously for patients; asthma patient information, diabetic patient informa-
tion, medication aid. However, patient passports can also present other challenges
which may lead to low adoption rates and minimal impact on patient experience. To
investigate this further, Dijkstra et al. interviewed diabetic patients and medical
professionals to understand their experience of implementing the passport into
their current care system [19]. Concerns expressed by the patients were predomi-
nantly focused on security, forgetting the passport, being over encumbered, and
need for additional time to enter information into the passport. For security,
patients were concerned of the ramifications of losing the passport and the threat
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this may have on identity theft. Furthermore, some paper passports can be the size
of a small A5 copy and cannot fit into a pocket easily. For this reason, patients
expressed concerns with forgetting to bring the passport to clinical appointments
and also friends or work colleagues seeing or finding the passport. As for time,
patients felt that entering information into the passport could often take away from
the valuable time they had with their healthcare team [19].
When interviewing medical professionals Dijkstra et al. found that often there
was no clear agenda for the passport and how it would be of benefit to patient self-
management. Consequently, it was unclear at which stage a passport should be
introduced formally to a patient to ensure they know how to use it sufficiently.
Moreover, there are discrepancies over who is responsible to manage the passport,
if it is of benefit to medical professionals, and how this passport can be
implemented seamlessly to the current healthcare system [19].
2. Patient mHealth survey
The General mHealth Design Pipeline [8] first suggests gathering insights from
key stakeholders to mHealth applications (patients and medical professionals). As
such a survey is conducted with CF adult patients from the Cork University Hospi-
tal to include their insights before developing a written report with medical pro-
fessionals. To evaluate if CF adults would find an mHealth app beneficial and to
determine what aspect of patient education and patient management that is of
interest to CF adult patients, an 18-part multiple choice survey was created and
validated over a series of three formal meetings with the Cork CF multidisciplinary
(see appendix). Participation in this survey was voluntary, and the inclusion criteria
for this survey were that participants were 18 years old or older and owned a
smartphone. Surveys were offered to all patients attending their designated outpa-
tient appointment over a 4 week period at the CF Day Ward in Cork University
Hospital. Ethical approval for this survey is obtained via the Clinical Research Ethics
Committee in University College Cork. During the study period, 49 eligible patients
completed the survey; no patients opted-not to complete the survey. The collected
survey data was anonymized, and the only clinical information collected in this
survey was that the participants have CF and are attending the Cork CF center.
2.1 Survey results
A total of 49 completed surveys were analyzed. Of the 49 participants, 55% of
respondents use an Android smartphone and 40% use an iPhone. It was reported
that 38% of participants have a mHealth app installed on their smartphone device
such as exercise trackers or calorie counters; however, only 10% (n = 5) know of
or are aware of an app which targets CF. Those CF focused mHealth apps identified
by the participants are “CF MedCare”, “MyFitnessPal”, “CFMATTERS STUDY
INFO”, and “CF View”. Two of the five participants reported having a CF app
installed on their phone (CF View and CF MedCare). The remaining 44 participants
who do not know of any CF apps or have a CF app installed were then asked to
explain their answer. Of the 44 participants, 20 patients reported being unaware
of the existence of CF apps; “I don’t think there is one”, and three advised that they
are not interested in a CF app; “Not Interested”.
The participants are also given the option to choose multiple aspects of their
CF that they would like targeted by a CF mHealth app. To note, the participants
could choose as many of these options as applicable. It was found that
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“New Research Developments” (55%), “Medication” (55%), and “Physiotherapy”
(47.5%) are the areas of most interest to the participants, followed by “Diet”
(42.50%), “Monitoring” (40%), “Social Networks” (40%), “Self-Psychological
Help” (37.50%), “News” (32.50%), “Education” (27.50%), and “Management”
(20%). One patient reported “None” for this question.
Further questions were presented regarding specific features within mHealth
applications. 85% of participants agreed that they would like to receive notifications
from the app, such as reminders to take medication or next clinical appointment.
When asked would the participant play a game to support their CF, the results were
more dispersed; 32.65% agreed they would play a game, 34.69% reported they
would not and 30.61% were unsure. Ten of the 49 participants reported as being
part of a clinical trial currently or in the past. Six of these 10 participants reported
that an mHealth application would have been of use to this trial for data collection
or self-reporting.
A series of questions regarding the collection of personal medical data was then
presented. When asked if their CF medical information, such as genotype and
medical history, is difficult to remember, 32.65% of participants regarded this
information as difficult and 42% regarded this information as easy to remember.
26.5% of participants agreed they would record their medical information in a
mHealth app. 46.9% agreed they would store this information if the mHealth app is
password protected and 16% (n = 8) agreed they would if the mHealth app is
password protected and does not have access to the internet. One participant
reported being unsure to recording their medical data. Each participant was then
given the option to further explain their reasoning for choosing their security
preference. These results are listed below.
• Yes: If password protected
◦ “Security is priority”
◦ “Only available to me and no online servers”
◦ “Privacy Matters”
◦ “As long as it is stored on a secure database”
• Yes: If password protected and does not connect to the internet
◦ “It would be very helpful/useful to store the data for myself but I would be
cautious about who else could access it”
◦ “It is personal information and so it would need to be very secure”
◦ “It is personal and private info”
• Unsure
◦ “Security Issue”
To note, two additional answers were submitted for “Yes: If password
protected”; however, these answers were specific to the perceived usefulness of such
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this may have on identity theft. Furthermore, some paper passports can be the size
of a small A5 copy and cannot fit into a pocket easily. For this reason, patients
expressed concerns with forgetting to bring the passport to clinical appointments
and also friends or work colleagues seeing or finding the passport. As for time,
patients felt that entering information into the passport could often take away from
the valuable time they had with their healthcare team [19].
When interviewing medical professionals Dijkstra et al. found that often there
was no clear agenda for the passport and how it would be of benefit to patient self-
management. Consequently, it was unclear at which stage a passport should be
introduced formally to a patient to ensure they know how to use it sufficiently.
Moreover, there are discrepancies over who is responsible to manage the passport,
if it is of benefit to medical professionals, and how this passport can be
implemented seamlessly to the current healthcare system [19].
2. Patient mHealth survey
The General mHealth Design Pipeline [8] first suggests gathering insights from
key stakeholders to mHealth applications (patients and medical professionals). As
such a survey is conducted with CF adult patients from the Cork University Hospi-
tal to include their insights before developing a written report with medical pro-
fessionals. To evaluate if CF adults would find an mHealth app beneficial and to
determine what aspect of patient education and patient management that is of
interest to CF adult patients, an 18-part multiple choice survey was created and
validated over a series of three formal meetings with the Cork CF multidisciplinary
(see appendix). Participation in this survey was voluntary, and the inclusion criteria
for this survey were that participants were 18 years old or older and owned a
smartphone. Surveys were offered to all patients attending their designated outpa-
tient appointment over a 4 week period at the CF Day Ward in Cork University
Hospital. Ethical approval for this survey is obtained via the Clinical Research Ethics
Committee in University College Cork. During the study period, 49 eligible patients
completed the survey; no patients opted-not to complete the survey. The collected
survey data was anonymized, and the only clinical information collected in this
survey was that the participants have CF and are attending the Cork CF center.
2.1 Survey results
A total of 49 completed surveys were analyzed. Of the 49 participants, 55% of
respondents use an Android smartphone and 40% use an iPhone. It was reported
that 38% of participants have a mHealth app installed on their smartphone device
such as exercise trackers or calorie counters; however, only 10% (n = 5) know of
or are aware of an app which targets CF. Those CF focused mHealth apps identified
by the participants are “CF MedCare”, “MyFitnessPal”, “CFMATTERS STUDY
INFO”, and “CF View”. Two of the five participants reported having a CF app
installed on their phone (CF View and CF MedCare). The remaining 44 participants
who do not know of any CF apps or have a CF app installed were then asked to
explain their answer. Of the 44 participants, 20 patients reported being unaware
of the existence of CF apps; “I don’t think there is one”, and three advised that they
are not interested in a CF app; “Not Interested”.
The participants are also given the option to choose multiple aspects of their
CF that they would like targeted by a CF mHealth app. To note, the participants
could choose as many of these options as applicable. It was found that
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“New Research Developments” (55%), “Medication” (55%), and “Physiotherapy”
(47.5%) are the areas of most interest to the participants, followed by “Diet”
(42.50%), “Monitoring” (40%), “Social Networks” (40%), “Self-Psychological
Help” (37.50%), “News” (32.50%), “Education” (27.50%), and “Management”
(20%). One patient reported “None” for this question.
Further questions were presented regarding specific features within mHealth
applications. 85% of participants agreed that they would like to receive notifications
from the app, such as reminders to take medication or next clinical appointment.
When asked would the participant play a game to support their CF, the results were
more dispersed; 32.65% agreed they would play a game, 34.69% reported they
would not and 30.61% were unsure. Ten of the 49 participants reported as being
part of a clinical trial currently or in the past. Six of these 10 participants reported
that an mHealth application would have been of use to this trial for data collection
or self-reporting.
A series of questions regarding the collection of personal medical data was then
presented. When asked if their CF medical information, such as genotype and
medical history, is difficult to remember, 32.65% of participants regarded this
information as difficult and 42% regarded this information as easy to remember.
26.5% of participants agreed they would record their medical information in a
mHealth app. 46.9% agreed they would store this information if the mHealth app is
password protected and 16% (n = 8) agreed they would if the mHealth app is
password protected and does not have access to the internet. One participant
reported being unsure to recording their medical data. Each participant was then
given the option to further explain their reasoning for choosing their security
preference. These results are listed below.
• Yes: If password protected
◦ “Security is priority”
◦ “Only available to me and no online servers”
◦ “Privacy Matters”
◦ “As long as it is stored on a secure database”
• Yes: If password protected and does not connect to the internet
◦ “It would be very helpful/useful to store the data for myself but I would be
cautious about who else could access it”
◦ “It is personal information and so it would need to be very secure”
◦ “It is personal and private info”
• Unsure
◦ “Security Issue”
To note, two additional answers were submitted for “Yes: If password
protected”; however, these answers were specific to the perceived usefulness of such
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an mHealth application and not their rationale for their security preference and
hence negated from the above list. The two submitted answers include: “Handy if
required when travelling/emergencies” and “It would help to track what might have been
working at the time to maintain lung function (e.g. meds/physio)”. In a follow up
question specific to the usefulness of such an application, 87.5% of participants
reported that they would find it beneficial to have access to their medical data
through an mHealth app. Of the 49 participants 67.35% agreed that an mHealth
app that recorded their medical data would be useful and 61.22% confirmed they
would use an app to record this data.
Two questions were also posed regarding travel and admission to the accident
and emergency department in a hospital to determine scenarios in which the
recording of medical information would be of benefit (similar to other passports as
discussed earlier). 75.5% of participants reported having gone travelling outside of
Ireland and only 12 participants have had to visit a hospital emergency room due
their CF. When the participants were asked if they would use a CF mHealth app if
created, 67.5% said yes; however, 27.5% were unsure.
Lastly, the participants were given the option to share what they felt a CF
mHealth app should target. Twenty three participants suggested mHealth apps
which can be categorized under three headings; Management, Support, and Infor-
mation. Sixteen participants suggested management apps to track and store their
medical information to aid in self-management of the condition. Examples of this
category include “Medication taken/taking” and “Medical Info i.e weight lung fx exer-
cise + diet plans”. Six participants suggested apps that can access medical informa-
tion such as drug names and new treatments or research. An example of this
category includes “Proper medical names of meds” and “New treatments”. Lastly, five
participants suggest apps which can allow for support among CF patients, similar to
social networks; “Experience/Information sharing between other patients”.
2.2 Survey discussion
It is noted that slightly more patients own an Android device; however, the
number of iPhone owners was still high. The first observation to note from the
survey results is the paucity in awareness of CF apps. Only five patients reported
being aware of CF mHealth apps, and only two patients have these apps installed.
To note one of the apps, “MyFitnessPal”, which was regarded as a CF specific
mHealth app, is not. This app does not target any specific cohort and includes
personalisable goal setting, such as weight gain, weight loss, weight maintenance.
When questioned further this seemed to be primarily due to being unaware of such
apps; “I don’t think there is any”. However, despite this lack of awareness, the CF
adult participants still demonstrated interest and expectations on what a CF app
should focus on. New Research Developments, Medication, and Physiotherapy
focused apps were of the most interest to these participants. Additionally, tracking
medical data and receiving alerts or reminders were the most popular features.
It is important to note that the participants demonstrated concerns regarding
data security and as such any mHealth app created for these patients will need to be
fully transparent i.e full disclosure on what data is being collected, who is it being
used/viewed by, and the security measures in place.
Personalizing educational content in this way is synonymous with patient man-
agement mechanisms and interventions, as the multimedia is educating the patient
on their medical condition data or personal symptoms. Examples of patient man-
agement interventions include: audio tapes, booklets, patient credit card/patient
passports, counseling, exercise sessions, individual plan/goal setting, manuals,
videos, and lectures/talks [20].
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3. App design
3.1 Considerations from similar passports
The issues with patient passports, as listed in the Section 1.3, pertain to diabetes
passports only; however, these problems are transferable. As such, they have been
considered in the design of the adult cystic fibrosis passport. Firstly, by deploying
the CF passport as a mobile app a number of these pitfalls may be resolved. When
considering the concerns the patients expressed for security and the possibility of
identity theft, an mHealth passport can be secured via a username and password.
Furthermore, if the phone was lost or stolen, all passport data will be encrypted and
not easily accessible. As the passport will be in a digital form on a smartphone,
issues regarding the patient being over encumbered or finding it difficult to carry
the passport on their person are removed. Furthermore, as the data entered into the
mHealth passport is minimal, there will be no smartphone memory usage issues.
Finally, as the passport will be in an mHealth form, it is unlikely that a patient will
forget their smartphone and subsequently reduces the risk of forgetting the pass-
port at clinical appointments.
3.2 Considerations from MDT meeting
The remaining issues, as highlighted by members of the diabetes healthcare
team, were discussed with cystic fibrosis nurse specialists at the Cork University
Hospital. The below discussed solutions were work shopped and agreed upon by
consensus before being implemented into the app design. Firstly, identifying the
point of care the app should be introduced was considered. In the current healthcare
model, the passport shall be introduced to patients who have just transferred from
pediatric to the adult orientated facility. However, the app can also be introduced to
existing adult patients. During this introduction, a CF nurse specialist will explain
the aim of this app and why it will be of use to the patient, the data that can be
entered into the passport, and when/how to use this app when meeting members of
their healthcare team. The nurse will then assist the patient in entering data that can
help set up their profile in the app (e.g. contact information for their healthcare
team, genotype). The patient will then be made aware that all data entered into the
app is voluntary and cannot be viewed outside the app. The nurse will also explain
to the patient that the patient is responsible for entering data into the app.
Finally, concerns surrounding time to enter information into the passport was
discussed. In Ireland, An adult CF clinic appointment can last approximately 1 hour
and 15 minutes. During this clinic, patients meet each member of the MDT. The
first member of this team is a CF nurse specialist who will encourage the patient to
enter the data into their passport while the nurse enters the data into their patient
file. Between meeting each member of the MDT there is approximately 15 minutes
of free time. Therefore, if similar to the diabetic patients, the CF patients feel as
though they would prefer to spend the time with the medical team member, they
can enter the information during this free time instead.
Considering the benefits of a patient passport and the patient insight provided
by the Patient mHealth Survey, it can be stipulated that such a tool would be
beneficial to adult CF patients. Hence, this research will develop and evaluate a
patient passport targeted at adults with cystic fibrosis. However, unlike the afore-
mentioned passports, the proposed passport will be developed as a mobile applica-
tion. The agenda for this app is to provide CF adults with their basic medical
information and also to allow them to record their medications, along with medical
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an mHealth application and not their rationale for their security preference and
hence negated from the above list. The two submitted answers include: “Handy if
required when travelling/emergencies” and “It would help to track what might have been
working at the time to maintain lung function (e.g. meds/physio)”. In a follow up
question specific to the usefulness of such an application, 87.5% of participants
reported that they would find it beneficial to have access to their medical data
through an mHealth app. Of the 49 participants 67.35% agreed that an mHealth
app that recorded their medical data would be useful and 61.22% confirmed they
would use an app to record this data.
Two questions were also posed regarding travel and admission to the accident
and emergency department in a hospital to determine scenarios in which the
recording of medical information would be of benefit (similar to other passports as
discussed earlier). 75.5% of participants reported having gone travelling outside of
Ireland and only 12 participants have had to visit a hospital emergency room due
their CF. When the participants were asked if they would use a CF mHealth app if
created, 67.5% said yes; however, 27.5% were unsure.
Lastly, the participants were given the option to share what they felt a CF
mHealth app should target. Twenty three participants suggested mHealth apps
which can be categorized under three headings; Management, Support, and Infor-
mation. Sixteen participants suggested management apps to track and store their
medical information to aid in self-management of the condition. Examples of this
category include “Medication taken/taking” and “Medical Info i.e weight lung fx exer-
cise + diet plans”. Six participants suggested apps that can access medical informa-
tion such as drug names and new treatments or research. An example of this
category includes “Proper medical names of meds” and “New treatments”. Lastly, five
participants suggest apps which can allow for support among CF patients, similar to
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being aware of CF mHealth apps, and only two patients have these apps installed.
To note one of the apps, “MyFitnessPal”, which was regarded as a CF specific
mHealth app, is not. This app does not target any specific cohort and includes
personalisable goal setting, such as weight gain, weight loss, weight maintenance.
When questioned further this seemed to be primarily due to being unaware of such
apps; “I don’t think there is any”. However, despite this lack of awareness, the CF
adult participants still demonstrated interest and expectations on what a CF app
should focus on. New Research Developments, Medication, and Physiotherapy
focused apps were of the most interest to these participants. Additionally, tracking
medical data and receiving alerts or reminders were the most popular features.
It is important to note that the participants demonstrated concerns regarding
data security and as such any mHealth app created for these patients will need to be
fully transparent i.e full disclosure on what data is being collected, who is it being
used/viewed by, and the security measures in place.
Personalizing educational content in this way is synonymous with patient man-
agement mechanisms and interventions, as the multimedia is educating the patient
on their medical condition data or personal symptoms. Examples of patient man-
agement interventions include: audio tapes, booklets, patient credit card/patient
passports, counseling, exercise sessions, individual plan/goal setting, manuals,
videos, and lectures/talks [20].
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3. App design
3.1 Considerations from similar passports
The issues with patient passports, as listed in the Section 1.3, pertain to diabetes
passports only; however, these problems are transferable. As such, they have been
considered in the design of the adult cystic fibrosis passport. Firstly, by deploying
the CF passport as a mobile app a number of these pitfalls may be resolved. When
considering the concerns the patients expressed for security and the possibility of
identity theft, an mHealth passport can be secured via a username and password.
Furthermore, if the phone was lost or stolen, all passport data will be encrypted and
not easily accessible. As the passport will be in a digital form on a smartphone,
issues regarding the patient being over encumbered or finding it difficult to carry
the passport on their person are removed. Furthermore, as the data entered into the
mHealth passport is minimal, there will be no smartphone memory usage issues.
Finally, as the passport will be in an mHealth form, it is unlikely that a patient will
forget their smartphone and subsequently reduces the risk of forgetting the pass-
port at clinical appointments.
3.2 Considerations from MDT meeting
The remaining issues, as highlighted by members of the diabetes healthcare
team, were discussed with cystic fibrosis nurse specialists at the Cork University
Hospital. The below discussed solutions were work shopped and agreed upon by
consensus before being implemented into the app design. Firstly, identifying the
point of care the app should be introduced was considered. In the current healthcare
model, the passport shall be introduced to patients who have just transferred from
pediatric to the adult orientated facility. However, the app can also be introduced to
existing adult patients. During this introduction, a CF nurse specialist will explain
the aim of this app and why it will be of use to the patient, the data that can be
entered into the passport, and when/how to use this app when meeting members of
their healthcare team. The nurse will then assist the patient in entering data that can
help set up their profile in the app (e.g. contact information for their healthcare
team, genotype). The patient will then be made aware that all data entered into the
app is voluntary and cannot be viewed outside the app. The nurse will also explain
to the patient that the patient is responsible for entering data into the app.
Finally, concerns surrounding time to enter information into the passport was
discussed. In Ireland, An adult CF clinic appointment can last approximately 1 hour
and 15 minutes. During this clinic, patients meet each member of the MDT. The
first member of this team is a CF nurse specialist who will encourage the patient to
enter the data into their passport while the nurse enters the data into their patient
file. Between meeting each member of the MDT there is approximately 15 minutes
of free time. Therefore, if similar to the diabetic patients, the CF patients feel as
though they would prefer to spend the time with the medical team member, they
can enter the information during this free time instead.
Considering the benefits of a patient passport and the patient insight provided
by the Patient mHealth Survey, it can be stipulated that such a tool would be
beneficial to adult CF patients. Hence, this research will develop and evaluate a
patient passport targeted at adults with cystic fibrosis. However, unlike the afore-
mentioned passports, the proposed passport will be developed as a mobile applica-
tion. The agenda for this app is to provide CF adults with their basic medical
information and also to allow them to record their medications, along with medical
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data from clinical appointments. In doing this, adult CF patients may become more
aware of their condition and symptoms. Additionally, three scenarios have been
identified in which the proposed app may be of use to a CF adult. Firstly, it can
allow a patient to receive immediate care when travelling abroad. Secondly, it will
allow patients to receive care if travelling between adult CF centers. Lastly, it can be
used to communicate between healthcare team members. These scenarios and the
design of the passport app with reference to the General mHealth Design Pipeline
will be discussed further in the following section.
4. General mHealth design pipeline overview
This section will discuss the design and development of the app under the
headings Preparation, Back-End, Front-End, and Deployment, in accordance to the
mHealth Design Pipeline described by Vagg et al. [8]. To note, a series of informal
scoping meetings was held with the CF nurse specialists from the Cork adult CF unit
(>10). Post initial development a further formal meeting with the entire CF
multidisciplinary team was held to sign off on the CF passport app.
4.1 Preparation
Before developing or designing the CF Patient Passport, the app’s purpose, app
type, ethics, and regulations are defined. These considerations are discussed and
outlined in the proceeding sub-sections.
4.1.1 Purpose
This section will discuss the components necessary to create a written report
before developing the app. Firstly and agenda for the mHealth passport is outlined,
so that the app can be implemented into the current health care model and have a
positive impact on the patient. Identifying the proposed agenda of the app was
discussed with members to serve the patient were identified and are listed below.
Scenario 1 Traveling between CF centers: In Ireland, there are five CF focused
centers. Patients can transfer between these centers for varying medical or personal
reasons. However, as patient data is stored as a hardcopy, there may be a delay
between the patient arriving at the center and the medical professional accessing
their clinical data. In this scenario, the mHealth passport can ensure that the patient
can provide their basic medical data when arriving to the new unit. Such informa-
tion can include recent lung function history, medications, allergies, genotypes.
Scenario 2 Travelling abroad: As quality of life and survival rates increase, more
and more CF patients are travelling abroad. In this scenario if the patient would
require any medical care when travelling abroad, the mHealth passport would
ensure that the patient could provide their basic medical data (and contact infor-
mation for their healthcare team) to the attending medical professional.
Scenario 3 Bridging Gaps between the healthcare team: In Ireland, it can be
approximately 3–4 months between clinical appointments in the adult unit.
Between appointments, patients may visit a General Practitioner (GP) and begin an
antibiotic treatment and this data must be entered into their patient file at their next
clinical appointment. The details of the new antibiotics can be either forgotten, or
only partially remembered. In this scenario the app can record any interaction with
any member of their health care team as well as new prescriptions or changes to
care to provide a broader view of their care.
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It is anticipated that the app will be first offered to CF adolescents transferring to
adult care. However, it can also be suggested to any CF adult. The app will be made
available on both iOS app store and Google Play store, in addition to being made
available on the Cork Hospital CF Centre web page. Patients will be given time
during clinical appointments to enter the data with the CF nurse specialists, or they
can enter the data during non-contact time.
All data collected through the app will be stored locally on the device. It shall not
be transmitted or viewed by any other personnel. The data recorded will not be
analyzed; however, some data shall be visualized in two interactive graphs. The first
graph will display Weight over time, and the second will display lung function as
FVC% and FEV1%. An example of this graph can be seen in Figure 1. The graph is
interactive and can allow users to touch different points on the plot to view its
corresponding information. The user can also save reminders for clinical appoint-
ments or take medications through the app.
4.1.2 Application type
The proposed CF Patient Passport can be considered as both an In Vitro app and
a Wellbeing/Lifestyle app. The passport is intended to record a patient’s basic
medical information and simultaneously plot data on a graph; as such, it is consid-
ered an In Vitro app. It is not considered a Medical Device, as this data is not being
used to perform a diagnostic or any immediate decision making for the patient.
Figure 1.
Lung function (FEV1, FVC) in “My Clinic Appointments”.
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can provide their basic medical data when arriving to the new unit. Such informa-
tion can include recent lung function history, medications, allergies, genotypes.
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and more CF patients are travelling abroad. In this scenario if the patient would
require any medical care when travelling abroad, the mHealth passport would
ensure that the patient could provide their basic medical data (and contact infor-
mation for their healthcare team) to the attending medical professional.
Scenario 3 Bridging Gaps between the healthcare team: In Ireland, it can be
approximately 3–4 months between clinical appointments in the adult unit.
Between appointments, patients may visit a General Practitioner (GP) and begin an
antibiotic treatment and this data must be entered into their patient file at their next
clinical appointment. The details of the new antibiotics can be either forgotten, or
only partially remembered. In this scenario the app can record any interaction with
any member of their health care team as well as new prescriptions or changes to
care to provide a broader view of their care.
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It is anticipated that the app will be first offered to CF adolescents transferring to
adult care. However, it can also be suggested to any CF adult. The app will be made
available on both iOS app store and Google Play store, in addition to being made
available on the Cork Hospital CF Centre web page. Patients will be given time
during clinical appointments to enter the data with the CF nurse specialists, or they
can enter the data during non-contact time.
All data collected through the app will be stored locally on the device. It shall not
be transmitted or viewed by any other personnel. The data recorded will not be
analyzed; however, some data shall be visualized in two interactive graphs. The first
graph will display Weight over time, and the second will display lung function as
FVC% and FEV1%. An example of this graph can be seen in Figure 1. The graph is
interactive and can allow users to touch different points on the plot to view its
corresponding information. The user can also save reminders for clinical appoint-
ments or take medications through the app.
4.1.2 Application type
The proposed CF Patient Passport can be considered as both an In Vitro app and
a Wellbeing/Lifestyle app. The passport is intended to record a patient’s basic
medical information and simultaneously plot data on a graph; as such, it is consid-
ered an In Vitro app. It is not considered a Medical Device, as this data is not being
used to perform a diagnostic or any immediate decision making for the patient.
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However, it can also be considered as a Wellbeing/Lifestyle app as it may improve
health behaviors among this cohort as they become more aware of their own
medical data/symptoms.
4.1.3 Ethics and regulations
All evaluations performed with patients received ethical approval from the
Clinical Research Ethics Committee in Cork. The app is currently available on the
Google Play store in Ireland and is GDPR compliant.
4.2 Back-end
To ensure that the app can be deployed to both Android and iOS, Cordova
PhoneGap [21] was used to develop the mHealth passport. PhoneGap uses web
technologies such as HTML, CSS, and JavaScript in addition to Frameworks for
navigations and layouts. For this passport, Framework 7 [22] is incorporated into
the app to ensure a consistent layout/style across both Android and iOS. The lan-
guage and dialogue used in the app is simple so that it can be understood by non-
medical persons. All graphs are developed using the Highcharts.js framework [23].
This section will discuss the validation of content and dialogue within the applica-
tion before discussing the data that can be recorded via the passport app.
4.2.1 Content and dialogue validation
As CF is a genetic disease, patients have grown up listening to and using medical
terminology to aid in the management of their condition. Therefore, the medical
data that can be recorded in the app is familiar to this cohort; however, the manner
in which the data is requested may be new to these patients, and subsequently may
require validation. A meeting was held with CF nurse specialists to discuss the
instructions on how to enter data in the app. The CF Nurse specialists were enlisted
for this task due to their extensible knowledge in communicating with this cohort.
There is no imagery used within the app, however, there are two proposed graphs.
The graphs and app instruction were modified until validation from the nurse
specialists was given.
4.2.2 Data information requirements
As the data are not being transferred and viewed by other personnel, an
opt-out service and DPA policy was not required in the app. As the CF Patient
Passport was developed as part of a pilot study, information pertaining to all inten-
tions of what data was to be collected and how it was then stored was provided to
patients in a participant information sheet. It was anticipated that once the app
was made available via app stores and over the web, these intentions would also
need to be listed.
4.2.3 Data and data analysis
Focusing on the outlined scenarios (travelling between centers, traveling
abroad, and bridging the gap between the healthcare team) a meeting was held with
the CF MDT to discuss which data should be recorded in the app to fulfill these
objectives. From this meeting it was found that the mHealth passport should follow
the same architecture as a patient file. In Ireland, a patient file can include infor-
mation stored once (genotype, date of birth, genotype etc.), information that can
sometimes be recorded (such as new medical conditions or procedures), and
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lastly data that is recorded at every clinical appointment (lung function, weight,
height etc.). Therefore the mHealth passport is separated into three core sections
and described below. To note, all data entered into the passport can be edited or
deleted if desired. These sections can be seen in Figure 2 (right).
Section 1 My CF Information: This section is targeted at the information in the
patient file that are only recorded once. This data generally describes a patient
profile such as date of diagnosis, genotype, sweat test results, allergies, contact
numbers for the healthcare team, and allergies. This can be seen in Figure 3 (left).
Section 2 My Medical History: This section is dedicated to the occasional data and
is divided into two sections. “My Medical Procedures” and “My Medical Condi-
tions”. The first section is targeted towards procedures a CF patients may have
undergone such as the insertion of a gastrostomy tube, or the removal of a
portacath. The second section focuses on new conditions or diseases which may
have developed, such as diabetes.
Section 3 My Clinic Appointments: The final section records data that are entered
into a patient file at each clinical appointment. This data can include Blood Pressure
(BP), weight, height, date, lung function (FEV1% and FVC%), bugs in mucus, new
treatments. This section can also be used for phone calls with the healthcare team,
GP Visits, and annual assessment.
4.2.4 Security operations
As the data is being stored on the smartphone, security precautions are put in
place for local storage. First, the mHealth app is password protected (as seen in
Figure 2 left). In the event of a forgotten password, a randomly generated password
is created within the app and emailed to the user. All data stored in the CF Patient
Passport is optional. Any data that is recorded is encrypted using the Advanced
Encryption Standard (AES) algorithm and stored in a local SQLite database. If the
app is uninstalled from the device, the databases will also be deleted.
Figure 2.
Login screen (left) and main menu in the passport (right).
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undergone such as the insertion of a gastrostomy tube, or the removal of a
portacath. The second section focuses on new conditions or diseases which may
have developed, such as diabetes.
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(BP), weight, height, date, lung function (FEV1% and FVC%), bugs in mucus, new
treatments. This section can also be used for phone calls with the healthcare team,
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As the data is being stored on the smartphone, security precautions are put in
place for local storage. First, the mHealth app is password protected (as seen in
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4.3 Front-end
In keeping with the mHealth pipeline discussed previously, the User Interface
(UI) and User Experience (UX) of the app are discussed.
4.3.1 User interface (UI)
A meeting was held with CF nurse specialists and physiotherapists to discuss the
plausibility of an Adaptive UI. From this meeting it was determined that a UI model
was not required. It was considered that perhaps an Adaptive Navigation model
may be beneficial for the use cases as described in 6.5.1 under Preparation; however,
this was later dismissed as data recorded and shown in the app is at the patient’s
discretion.
Informal discussions between the CF nurse specialists and the CF adults attend-
ing clinic found that this cohort would prefer the UI to be designed so that it does
not appear to be a mHealth app. As such, the icon that was to appear on the main
screen of the user’s smartphone does not contain any indications that the app is for
CF; hence this icon is named “My Passport”. Furthermore, the style and UI ele-
ments in the app were designed so that they do not appear to be “medical” or
“clinical”. Similarly, all menus and buttons were created to reflect the data col-
lected.
4.3.2 User experience (UX)
On reviewing diabetic patient passports, a number of issues which could prevent
the use of such of an intervention was found. Of interest to the UX aspects of this
mHealth app is outlining how the app should be implemented into the current care
system. A solution for this is discussed in Section 3.2. It is agreed by CF nurse
Figure 3.
Menu from the “My CF Info” section (left) and list of saved clinical appointments in “My Clinic Appointments”
(right).
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specialists that the app will be offered to CF adolescents transferring to CF adult
care and CF adults already registered in the hospital. If the patients are interested in
using the app a workshop will be given by nurses on how to use the app and the data
that can be recorded. The nurses will then assist the patient in entering any histor-
ical and profile data. Time is then allocated during clinical visits for patients to enter
this data with a CF nurse or during non-contact time.
4.4 Deployment
In this section, further testing and reviews conducted on the app are discussed.
Following on from the results of the reviews and testing, future plans for the
deployment of this mHealth app are outlined.
4.4.1 Stress test
The purpose of this test was to evaluate the performance of this app and its
design. Seven participants without CF were enlisted who all owned Android
devices. The decision to recruit non-CF participants was intended to identify per-
formance and design issues and to remedy them. For the stress test, participants
from a similar age range to the target CF adult cohort were chosen. Five participants
(three females and two males) between 19 and 51 were recruited. The technical
capability of this participants varied, some participants were novices at using tech-
nology, while others were ICT professionals.
The participants were asked to download the mHealth passport onto their
smartphones and test for 3 months. During this time participants were required to
enter, edit, and delete data to “My CF Information” and “My Medical History” a
minimum of once a month. However, they were requested perform the same tasks
in the “My Clinic Appointments” more frequently (once a week). Each month the
participants sent a report of any issues they encountered using the app (such as
performance, usability, or general feedback) via email.
At the end of this stress test it was found that there were no major performance
issues and the users did not find the mHealth passport difficult to use. The primary
issue reported on was a style issue that occurred on different phone screen resolu-
tions whereby the submit button to enter data would remain behind the keyboard
(users must close the keyboard before being able to submit). Another issue reported
was the lack of clarity or structure when entering dates into the mHealth app. The
final issue reported on was that the default “Go” button on the smartphone key-
board did not move to the next text field as expected. Following this feedback, the
styling was adjusted and retested on different devices to ensure the submit button
was no longer hidden, a calendar was implemented to enter in the date, and finally
functionality was created and bound to the “Go” button to ensure users could
navigate through the form items. The above solutions were implemented in prepa-
ration for pilot testing with CF adult patients.
4.4.2 Peer review
The CF Patient Passport was then presented to CF nurse specialists, CF physio-
therapists and respiratory consultants for review. During this review, the app pur-
pose, aesthetics, dialogue, content, and functionality was reviewed. Slight
modifications are recommended by the reviewers to improve the quality of data
entered and prevent errors. Examples of this feedback included the incorporation of
a drop-down menu which contains all possible bugs that can be growing in mucus as
opposed to the patient manually entering this data. Similarly, in places where
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final issue reported on was that the default “Go” button on the smartphone key-
board did not move to the next text field as expected. Following this feedback, the
styling was adjusted and retested on different devices to ensure the submit button
was no longer hidden, a calendar was implemented to enter in the date, and finally
functionality was created and bound to the “Go” button to ensure users could
navigate through the form items. The above solutions were implemented in prepa-
ration for pilot testing with CF adult patients.
4.4.2 Peer review
The CF Patient Passport was then presented to CF nurse specialists, CF physio-
therapists and respiratory consultants for review. During this review, the app pur-
pose, aesthetics, dialogue, content, and functionality was reviewed. Slight
modifications are recommended by the reviewers to improve the quality of data
entered and prevent errors. Examples of this feedback included the incorporation of
a drop-down menu which contains all possible bugs that can be growing in mucus as
opposed to the patient manually entering this data. Similarly, in places where
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patients must enter a date range (e.g. start date and end date) it should be possible
for the user to enter just a month and year as opposed to date, month, and year.
Overall it is agreed that the CF patient passport can be of benefit to CF adult
patients as it will allow for this cohort to always have access to their basic medical
data and become more aware of their own condition and symptoms.
4.4.3 Patient review
Following on from the stress test and peer review, ethical approval was granted
by the Clinical Research Ethics Committee in the University College Cork for pilot
testing with CF adults from the Cork University Hospital. The inclusion criteria for
this study was that patients must be 18 years old or older and own an Android
smartphone. Participation in this study was voluntary and was offered to patients
during clinical appointments over two consecutive days. Five eligible patients were
identified and recruited by the CF nurse specialists. All five patients agreed to
partake in the study; one participant was female and the remaining four were male.
Each participant was provided with an information sheet outlining the purpose of
the app, the data collected, intentions for the data, and security measures. After the
app was installed on their devices, the participants partook in a short workshop
with the CF nurse specialists, who demonstrated how to use the app. The CF nurse
specialists also assisted the participants in entering any of their historical or patient
file data into the passport app. The patients were then asked to test the app over
3 months before completing a feedback questionnaire, which was provided to them
at their next closest clinical appointment.
5. Results
During the three-month study period, one male participant lost his smartphone
and as such was unable to complete the feedback questionnaire. Of the remaining
four participants, three reported their smartphone models: a Oneplus 5, Sony Xperia
M5, and Samsung Galaxy. All four participants agreed that they were provided with
sufficient information to use the app. The participants were then asked to rate the
appearance of the app from 1 to 5 (1 being Do not Like It, 3 being Neutral, and 5
being Like It), with two participants rating the app a 3 and the remaining partici-
pants rating the appearance a 4.
During the study period all participants reported inserting data into the app.
Two participants confirmed they used the app to share their medical information.
When asked to explain this further, one participant reported using the app in a
clinical appointment. When asked to rate the difficulty of the app from 1 to 5
(1 being Difficult, 3 being Moderate, and 5 being Easy), one participant rated the
app a 5, two participants rated the app a 4, and the remaining participant rated the
app a 3. When asked which parts of the app was difficult, the participant who rated
the app a 3 reported difficulty in inputting “some information”. One other partici-
pant also advised that the built-in back button on their device caused the app to
close instead of returning to the previous page and was therefore reliant on the
built-in navigation bar. When asked which features the participant would like to
remove from the app, three participants reported none. When asked what features
the participant would like to add to the app, one participant advised they would like
for their doctor to be able to access the data or input new data remotely.
The participants were next asked to rate the helpfulness of the app from 1 to 5
(1 being Not Helpful, 3 Indifferent, and 5 being Helpful). One participant reported
a 5 for this question, two reported a 4, and one participant reported a 3. When
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asked to explain their answer, the participant who reported a 3 did not elaborate
further. However, two other participants remarked that the app is helpful as it
allows them access to their medical information:
“It’s useful to have this information in an easily accessible place”
“It’s handy for me to have my information so readily accessible”
This is further enforced in Question 10, where all participants agreed that it
was beneficial to have access to their basic medical information through the app.
When asked who the participants believe is responsible for inputting data into the
app, three participants reported that the responsibility is theirs, while one
participant believed it was the shared responsibility of the participant and their CF
treatment team. The users were then asked to explain their answer. It was found
from these answers that users believe it is their responsibility as entering data
should be at their discretion. However, one participant welcomes guidance from
their healthcare team.
“I put what I think is necessary”
“Personal info on a personal device should only be entered by the owner unless
explicit permission is given. I think I am ultimately responsible for knowing about
my condition and recording the information but I might not always know the most
important information to be recorded which is why my nurses and doctors should
also have input.”
“It’s my app and on my phone, so it’s my own responsibility to keep it updated”
One participant reported a barrier which prevented the editing of data. This
participant found that some saved data in the My CF Info section of the app could
not be edited, and instead needed to be deleted and inputted again, which they
regarded as frustrating. The participants were then asked to rate the regularity of
using the app from 1 to 5 (1 being Not Regularly, 3 being Sometimes, and 5
being Regularly). Two participants rated this question a 1, one participant reported
a 3, and the remaining participant reported a 4. When asked to list scenarios in
which they felt the app maybe useful, the participants reported the following
scenarios:
“If I got sick on holidays could show what I’m on”
“Listing medication/medical details at clinics etc”
“Sharing information with my GP or if I’m traveling and need to share information
with a doctor. Going abroad or another hospital/GP”
It can be seen from the above scenarios that participants felt that the app
maybe of most benefit when travelling abroad or sharing information with medical
and healthcare professionals. Lastly, the participants were asked to rate how ade-
quate the security precautions within the app are from 1 to 5 (1 being not adequate
and 5 being adequate), to which two participants rated a 5, and the remaining two
rated a 4.
5.1 Initial observations
It is acknowledged that some limitations of this study are the small number of
participants and the disproportionate ratio of male to female participants, which
could present a potential gender bias. There was a notable difference in the partic-
ipants reported regularity of the apps use. Patients were asked about how often they
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patients must enter a date range (e.g. start date and end date) it should be possible
for the user to enter just a month and year as opposed to date, month, and year.
Overall it is agreed that the CF patient passport can be of benefit to CF adult
patients as it will allow for this cohort to always have access to their basic medical
data and become more aware of their own condition and symptoms.
4.4.3 Patient review
Following on from the stress test and peer review, ethical approval was granted
by the Clinical Research Ethics Committee in the University College Cork for pilot
testing with CF adults from the Cork University Hospital. The inclusion criteria for
this study was that patients must be 18 years old or older and own an Android
smartphone. Participation in this study was voluntary and was offered to patients
during clinical appointments over two consecutive days. Five eligible patients were
identified and recruited by the CF nurse specialists. All five patients agreed to
partake in the study; one participant was female and the remaining four were male.
Each participant was provided with an information sheet outlining the purpose of
the app, the data collected, intentions for the data, and security measures. After the
app was installed on their devices, the participants partook in a short workshop
with the CF nurse specialists, who demonstrated how to use the app. The CF nurse
specialists also assisted the participants in entering any of their historical or patient
file data into the passport app. The patients were then asked to test the app over
3 months before completing a feedback questionnaire, which was provided to them
at their next closest clinical appointment.
5. Results
During the three-month study period, one male participant lost his smartphone
and as such was unable to complete the feedback questionnaire. Of the remaining
four participants, three reported their smartphone models: a Oneplus 5, Sony Xperia
M5, and Samsung Galaxy. All four participants agreed that they were provided with
sufficient information to use the app. The participants were then asked to rate the
appearance of the app from 1 to 5 (1 being Do not Like It, 3 being Neutral, and 5
being Like It), with two participants rating the app a 3 and the remaining partici-
pants rating the appearance a 4.
During the study period all participants reported inserting data into the app.
Two participants confirmed they used the app to share their medical information.
When asked to explain this further, one participant reported using the app in a
clinical appointment. When asked to rate the difficulty of the app from 1 to 5
(1 being Difficult, 3 being Moderate, and 5 being Easy), one participant rated the
app a 5, two participants rated the app a 4, and the remaining participant rated the
app a 3. When asked which parts of the app was difficult, the participant who rated
the app a 3 reported difficulty in inputting “some information”. One other partici-
pant also advised that the built-in back button on their device caused the app to
close instead of returning to the previous page and was therefore reliant on the
built-in navigation bar. When asked which features the participant would like to
remove from the app, three participants reported none. When asked what features
the participant would like to add to the app, one participant advised they would like
for their doctor to be able to access the data or input new data remotely.
The participants were next asked to rate the helpfulness of the app from 1 to 5
(1 being Not Helpful, 3 Indifferent, and 5 being Helpful). One participant reported
a 5 for this question, two reported a 4, and one participant reported a 3. When
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asked to explain their answer, the participant who reported a 3 did not elaborate
further. However, two other participants remarked that the app is helpful as it
allows them access to their medical information:
“It’s useful to have this information in an easily accessible place”
“It’s handy for me to have my information so readily accessible”
This is further enforced in Question 10, where all participants agreed that it
was beneficial to have access to their basic medical information through the app.
When asked who the participants believe is responsible for inputting data into the
app, three participants reported that the responsibility is theirs, while one
participant believed it was the shared responsibility of the participant and their CF
treatment team. The users were then asked to explain their answer. It was found
from these answers that users believe it is their responsibility as entering data
should be at their discretion. However, one participant welcomes guidance from
their healthcare team.
“I put what I think is necessary”
“Personal info on a personal device should only be entered by the owner unless
explicit permission is given. I think I am ultimately responsible for knowing about
my condition and recording the information but I might not always know the most
important information to be recorded which is why my nurses and doctors should
also have input.”
“It’s my app and on my phone, so it’s my own responsibility to keep it updated”
One participant reported a barrier which prevented the editing of data. This
participant found that some saved data in the My CF Info section of the app could
not be edited, and instead needed to be deleted and inputted again, which they
regarded as frustrating. The participants were then asked to rate the regularity of
using the app from 1 to 5 (1 being Not Regularly, 3 being Sometimes, and 5
being Regularly). Two participants rated this question a 1, one participant reported
a 3, and the remaining participant reported a 4. When asked to list scenarios in
which they felt the app maybe useful, the participants reported the following
scenarios:
“If I got sick on holidays could show what I’m on”
“Listing medication/medical details at clinics etc”
“Sharing information with my GP or if I’m traveling and need to share information
with a doctor. Going abroad or another hospital/GP”
It can be seen from the above scenarios that participants felt that the app
maybe of most benefit when travelling abroad or sharing information with medical
and healthcare professionals. Lastly, the participants were asked to rate how ade-
quate the security precautions within the app are from 1 to 5 (1 being not adequate
and 5 being adequate), to which two participants rated a 5, and the remaining two
rated a 4.
5.1 Initial observations
It is acknowledged that some limitations of this study are the small number of
participants and the disproportionate ratio of male to female participants, which
could present a potential gender bias. There was a notable difference in the partic-
ipants reported regularity of the apps use. Patients were asked about how often they
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would use the app. At face value, not regularly could be perceived as concerning;
however, CF patients attend CF clinic appointments quarterly, and entering data is
at the patient’s discretion. In addition to this, minor issues in device functionality
were reported by this cohort, which have since been addressed and resolved.
Interestingly, unlike the findings of the paper-based patient passport, partici-
pants of this study identified themselves as the sole or major inputter of data. This is
perhaps a clear advantage to paper-based passports, which reported uncertainties in
this responsibility, as discussed previously. This may be attributed to the passport
being based on a patient’s personal device, as opposed being provided to them in a
hospital branded booklet.
Moreover, the app in its current form was received positively by the participants
of this study. All participants agreed that having access to their basic medical
information is of benefit to them. Furthermore, these patients envision practical
scenarios in which this app may be of benefit to them in the future.
6. Conclusion and future works
The app is currently available for free on the Google Play Irish store. Future
works would include deploying the app to iOS app store and being linked to the
Cork CF Centre website. Information pertaining to data usage intentions and stor-
age will is made available on the app store description page. The results of the
patient survey conducted found that this cohort showed interest in the recording
and viewing of their medical data in a convenient and manageable way. To this end,
it was found that the concept of a patient passport could prove to be a suitable
solution. Patient passports have been proven to help patients with self-management
as it facilitates the ability to closely monitor their own condition. Hence a passport
application was developed so that CF adults could record their medications and
basic CF information. It is also anticipated that this will allow these patients to
receive care when travelling between centers and abroad. A pilot study with four
participants demonstrates that CF adults perceive this passport app to be beneficial
as it allows them access to their basic medical information. It was also found
through the pilot study that participants would not use this mHealth app frequently.
This is a similar finding to paper-based passports, as patients only enter the data
into the app during clinical appointments (quarterly) and share data in specific
scenarios such as with a GP, or when travelling abroad. As the app is password
protected, the user must be able to enter in their correct credentials and navigate
through the app to share data. However, in situations such as needing to attend the
accident and emergency room, this may cause further frustration to the patient,
whereas a paper-based passport can be handed to medical professional who can
locate all data needed in order to provide care. This is perhaps one advantage of the
paper-based system over the digital mHealth app. To contend with this, future
iterations of the app may include a Generate PDF button on the main menu which
will compile all the most pertinent medical data into an A4 PDF which can be
shown to medical professionals via the device or emailed to them directly. This
suggestion can also be applied to mHealth patient passports for other conditions. It
is also noted that the data from the app is stored locally only. For this reason if the
phone became lost or stolen, it would not be possible to restore a profile onto a new
phone, in this case the user would have to re-input all their data. This design choice
was made based on the feedback from the mHealth survey regarding security and
the app connecting to other online sources. However, future iterations of this app
will implement the ability to migrate data from one smartphone to another in the
event the user purchases a new phone. Once the data has been migrated, data stored
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on the old smartphone device will be deleted. In conclusion, an mHealth
patient passport is desirable among the adult CF cohort and we believe it can have
significant impact on how patients can manage their condition and have access
to their data.
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would use the app. At face value, not regularly could be perceived as concerning;
however, CF patients attend CF clinic appointments quarterly, and entering data is
at the patient’s discretion. In addition to this, minor issues in device functionality
were reported by this cohort, which have since been addressed and resolved.
Interestingly, unlike the findings of the paper-based patient passport, partici-
pants of this study identified themselves as the sole or major inputter of data. This is
perhaps a clear advantage to paper-based passports, which reported uncertainties in
this responsibility, as discussed previously. This may be attributed to the passport
being based on a patient’s personal device, as opposed being provided to them in a
hospital branded booklet.
Moreover, the app in its current form was received positively by the participants
of this study. All participants agreed that having access to their basic medical
information is of benefit to them. Furthermore, these patients envision practical
scenarios in which this app may be of benefit to them in the future.
6. Conclusion and future works
The app is currently available for free on the Google Play Irish store. Future
works would include deploying the app to iOS app store and being linked to the
Cork CF Centre website. Information pertaining to data usage intentions and stor-
age will is made available on the app store description page. The results of the
patient survey conducted found that this cohort showed interest in the recording
and viewing of their medical data in a convenient and manageable way. To this end,
it was found that the concept of a patient passport could prove to be a suitable
solution. Patient passports have been proven to help patients with self-management
as it facilitates the ability to closely monitor their own condition. Hence a passport
application was developed so that CF adults could record their medications and
basic CF information. It is also anticipated that this will allow these patients to
receive care when travelling between centers and abroad. A pilot study with four
participants demonstrates that CF adults perceive this passport app to be beneficial
as it allows them access to their basic medical information. It was also found
through the pilot study that participants would not use this mHealth app frequently.
This is a similar finding to paper-based passports, as patients only enter the data
into the app during clinical appointments (quarterly) and share data in specific
scenarios such as with a GP, or when travelling abroad. As the app is password
protected, the user must be able to enter in their correct credentials and navigate
through the app to share data. However, in situations such as needing to attend the
accident and emergency room, this may cause further frustration to the patient,
whereas a paper-based passport can be handed to medical professional who can
locate all data needed in order to provide care. This is perhaps one advantage of the
paper-based system over the digital mHealth app. To contend with this, future
iterations of the app may include a Generate PDF button on the main menu which
will compile all the most pertinent medical data into an A4 PDF which can be
shown to medical professionals via the device or emailed to them directly. This
suggestion can also be applied to mHealth patient passports for other conditions. It
is also noted that the data from the app is stored locally only. For this reason if the
phone became lost or stolen, it would not be possible to restore a profile onto a new
phone, in this case the user would have to re-input all their data. This design choice
was made based on the feedback from the mHealth survey regarding security and
the app connecting to other online sources. However, future iterations of this app
will implement the ability to migrate data from one smartphone to another in the
event the user purchases a new phone. Once the data has been migrated, data stored
120
Cystic Fibrosis - Heterogeneity and Personalized Treatment
on the old smartphone device will be deleted. In conclusion, an mHealth
patient passport is desirable among the adult CF cohort and we believe it can have
significant impact on how patients can manage their condition and have access
to their data.
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